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B R E A S T C A N C E R
Over the past years cancer has become a major public health issue being the most 
common cause of death in the Netherlands (1). In The Netherlands, the incidence rises 
with 3% per year and comparing incidences of 1989 (56,000) to 2011 (100,600) leads to 
the conclusion that the incidence has been doubled over the past 20 years (www.iknl.
nl). For 2020, it is expected that 123,000 new cases of cancer will be diagnosed. Opposite 
to the increase in incidence, a decrease in mortality has been observed with half of the 
patients being alive at 5 years after establishing the diagnosis. This decrease is, amongst 
others, due to early detection but also to the availability of more, and more effective, 
treatment options (www.iknl.nl). However, mortality rates and the extent of possible 
therapies is still very different between the various types of cancer.
From all types of cancer, breast cancer is the most common cancer in females. Yearly, 
14,000 new cases are diagnosed in The Netherlands. Of these women, 25% is younger 
than 50 years, 58% between 50 and 75 and 19% older than 75 years. Most of the cases 
are low stage breast cancer with favorable prognosis. Overall, 97% of the patients is still 
alive one year after diagnosis and the 10-year survival rate is currently 76% (www.iknl.
nl). These relatively favorable statistics compared to other types of cancer is presumably 
partly due to the extensive screening program although the exact advantages of this 
program are still under debate.
P R I M A RY B R E A S T C A N C E R
The prognosis of primary breast cancer is dependent on stage at presentation, which 
encompasses tumor size, lymph node status and presence or absence of distant 
metastases. Besides staging and grading, the molecular classification of tumors is an 
important prognostic and predictive factor. The most known molecular factors are the 
hormonal receptor molecules estrogen receptor (ER) and progesterone receptor (PR). 
The majority of breast tumors is positive for one or both of these receptors. 
PR depends on progesterone stimulation and ER on estrogen for their growth. This way, 
ER is involved in (ab)normal cell growth and therefore forms an attractive and effective 
treatment target. The expression of ER and PR can be determined by multiple techniques, 
of which immunohistochemistry (IHC) is currently being used in the clinic. The presence 
of these receptors is inversely related with stage and histological grade since ER/PR-
positive tumors are most commonly of low grade and well-differentiated (2).
Over the past years, many therapies have been developed that target the ER and have 
dramatically improved the prognosis of breast cancer. Tamoxifen, a selective estrogen 
receptor modulator, competes with estradiol for the binding to ER and represses the 
transcriptional activity of ER by inducing a conformational change of the receptor (3). 
For more than 30 years, tamoxifen forms the mainstay of treatment for premenopausal 
women and has been shown to safely reduce risks of breast cancer recurrence and death 
when used in the adjuvant setting (4). 
G E N E R A L I N T RO D U C T I O N A N D O U T L I N E O F T H E T H E S I S
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An alternative strategy in treating ER-positive breast cancer was provided by the 
development of inhibitors of aromatase (AI). AI therapy depletes serum estradiol levels by 
inhibiting the aromatase enzyme that is involved in the synthesis of estradiol. It is mostly 
effective in postmenopausal women or in premenopausal women in whom ovarian 
function has been suppressed or the ovaries have been removed (5). The development 
of AI therapy led to a change in the endocrine therapy of postmenopausal women since 
several randomized controlled trials had shown that AI therapy compared to tamoxifen 
significantly improved disease-free survival (DFS). Nowadays, the use of AI therapy in a 
sequential manner with tamoxifen is the standard of care in postmenopausal ER-positive 
breast cancer patients (5).
Next to ER and PR, the human epidermal growth factor receptor 2 (HER2) is nowadays 
routinely measured in the clinic by using IHC and in-situ hybdrization (ISH) techniques. 
The ERBB2 oncogene that encodes for the HER2 protein is amplified in 15% of the breast 
cancers and is associated with increased tumor aggressiveness and higher recurrence 
rates. It serves as a molecular target for specific therapies such as trastuzumab (6).
Additionally to ER, PR and HER2 characterization, over the years, large-scale genomic 
studies have been performed, which showed that breast cancer can be classified into 
several subtypes that demand to be treated differently due to their specific features and 
major differences in prognosis (7-9). The vast majority of all breast tumors (75%) are of 
the luminal subtype in which tumor cell proliferation is thought to depend on activity of 
the ER.  
Breast cancer subtypes also differ by the pattern of metastatic disease. The most common 
metastatic site is bone, except for basal-like tumors which are more likely to metastasize 
to brain, lung and distant nodes. The most common metastatic sites in luminal HER2-
positive and HER2-positive/ER-negative tumors are, next to bone, brain, liver and lung 
metastases (10).
M E TA S TAT I C B R E A S T C A N C E R
Approximately 5-10% of the patients present with distant metastases at the initial 
diagnosis. Additionally, approximately 30% of the patients initially diagnosed and treated 
for non-metastatic disease, depending on stage, develop distant metastases during 
follow-up despite prior intensive treatment (11). Metastatic breast cancer (MBC) is a 
highly heterogeneous disease for which many therapies have been developed over the 
years. Also here, treatment is highly dependent on the ER/PR/HER2 status of the tumor.
For most patients with ER/PR-positive disease, endocrine therapy is still the mainstay of 
treatment because of the favorable toxicity profile. In postmenopausal women, tamoxifen 
used to be the standard of care but clinical data have shown that AI therapy provides 
more benefit in terms of progression-free survival (PFS) and toxicity profile compared 
to tamoxifen (12, 13). For premenopausal women with ER-positive breast cancer, 
tamoxifen is still, after all those years, one of the standards of care. Key in treatment of 
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premenopausal women with metastatic ER/PR-positive disease is suppression of ovarian 
function for which luteinizing hormone-releasing hormone (LHRH) agonists are used. 
The combination of an LHRH agonist with tamoxifen has shown to significantly improve 
both PFS and overall survival (OS) compared to LHRH agonists alone (14).
For previously untreated ER-positive MBC, objective response rates of 32-44% and 
time to progression (TTP) of 8-10 months are observed when treated with endocrine 
therapy (15). In patients with ER/PR-positive disease without wide-spread metastatic 
disease, liver metastases, or lymphangitis pneumonia requiring a rapid tumor response, 
it is common practice to use multiple different hormonal agents in sequence as disease 
progresses. In postmenopausal women, when disease has progressed after non-steroidal 
AI therapy (anastrozole, letrozole) a steroidal aromatase inactivator (exemestane) can be 
used, nowadays combined with everolimus (see below) (16, 17). Another active agent 
is fulvestrant, an antiestrogen that binds to the ER and thus destabilizes the receptor 
resulting in its degradation. It has only estrogen antagonistic activity (18). Notably, the 
optimal sequence of the different endocrine therapy agents remains yet unknown. 
Currently, the treatment of choice for HER2-positive tumors consists of a combination of 
blocking the function of HER2 together with chemotherapy. Treatment with trastuzumab, 
a humanized recombinant monoclonal antibody that blocks HER2-mediated signaling 
pathways results in a significantly longer TTP and survival compared to chemotherapy 
alone (19). Recently, it was found that the combination of antibodies against HER2, 
trastuzumab and pertuzumab, added to docetaxel resulted in a significantly improved 
OS compared to the combination of trastuzumab and docetaxel alone (20). This effect 
is caused by a more efficient signaling blockade since both antibodies target different 
extracellular regions of the HER2 protein (21). As a result, this triple therapy has now 
become the first-line standard approach for HER2-positive MBC. 
Additionally, combined with HER2-targeting agents in HER2-positive MBC, chemotherapy 
is also required when there is extensive visceral organ involvement and there is a high 
need for a rapid response at diagnosis of ER+ MBC or when endocrine therapy has 
failed. Also for the subset of MBC patients where the tumor does not display ER/PR/
HER2 expression, so called triple negative disease, chemotherapy is indicated. Taxanes 
and anthracyclines are mostly used but there are many chemotherapeutic agents with 
different mechanisms of actions and side-effects available for MBC, including capecitabine 
(antimetabolite, fluorouracil pro-drug), vinorelbine (vinca alkaloid), cis- and carboplatin 
(platinum analogs),  mitomycin, eribulin, and  etoposide (topoisomerase inhibitor) (15).
Despite of all the developments and enormous progress in the understanding of the 
biological behavior, MBC is still an incurable disease due to occurrence of resistance to 
therapy.
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E N D O C R I N E T H E R A P Y R E S I S TA N C E 
As mentioned, endocrine treatment is one of the most important treatments used for 
MBC patients. Although many patients greatly benefit from endocrine therapies, a major 
limitation is that approximately 30% of the MBC patients never respond due to de novo 
resistance while all initial responders eventually relapse and develop progressive disease 
due to acquired resistance (22). 
Resistance to single-agent cancer therapeutics is frequently the result of reactivation of 
the signaling pathway that is being targeted, indicating the impossibility of fully blocking 
the cancer-relevant signaling pathway. Already numerous factors accounting for 
resistance to endocrine therapy have been revealed and have led to the development of 
new drugs and new combinations. Loss of ER expression due to clonal selection of ER-
negative cells or transcriptional repression of ER gene expression are some of the most 
known causes of resistance (23-25). It has been shown that demethylating agents or 
histone deacetylase inhibitors can reactivate ER expression when its promotor has been 
methylated leading to renewed sensitivity to endocrine therapies (26). 
Another possible mechanism of acquired endocrine therapy resistance is the occurrence 
of mutations in ESR1, the gene coding for ER, during endocrine therapy. It has been 
shown that activating ESR1 mutations are frequently present in ER-positive metastases 
that have become (AI) resistant but are absent in the corresponding primary tumors 
(27-30).
Next, in vitro experiments showed that overexpression of the HER2 receptor leads to 
activation of MAPK and inhibition of ER expression (31, 32), offering a rationale for dual 
blockade of HER2 and ER in order to overcome resistance (33). Furthermore, some 
tumors that are originally negative for HER2 show HER2 amplification after tumor 
progression during tamoxifen therapy (34).
The PI3K/AKT/mTOR pathway is the most frequently activated signaling pathway in 
breast cancer and emerging evidence points to hyperactivation of this pathway as a 
key mechanism of endocrine therapy resistance (35, 36). The combination of an mTOR 
inhibitor (everolimus) and AI therapy (exemestane) has already been extensively studied 
and set as golden standard in the treatment of MBC patients who failed previous 
treatment with a non-steriodal AI due to its prolonged PFS compared to exemestane 
alone (17). Although the combination therapy of everolimus and exemestane resulted in 
a clinically meaningful improvement in PFS, it has recently been shown that OS was not 
significantly improved (37). Several other agents that target this pathway are currently 
under investigation and have shown promising results (38).
Importantly, although much is already known, there is still a high need to get more 
insight into the factors causing resistance to endocrine therapy in order to develop 
methods to overcome resistance and to identify biomarkers that can contribute to a 
more personalized treatment approach of individual patients.  
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EZH2
One of the more recent discovered factors that might contribute to endocrine therapy 
resistance is Enhancer of Zeste Homolog 2 (EZH2). After a genome-wide profiling study 
in MBC patients, the Enhancer of Zeste family was revealed as one of the involved factors 
(39).
EZH2 is one of the Polycomb group (PcG) proteins and forms the catalytic subunit of 
the Polycomb repressive complex 2 (PRC2). It acts as a histone methyltransferase that 
mediates trimethylation of lysine residue 27 on histone 3 (H3K27) in order to control 
transcriptional processes. The H3K27me3 activity is dependent on post-translational 
modifications. For example, phosphorylation at serine 21 of EZH2 by Akt1 reduces 
its activity while phosphorylation at threonine 350 by CDK1 and CDK2 is required to 
maintain the H3K27me3 repressive marks on its target genes (40, 41). By repressing 
certain genes, EZH2 plays a pivotal role in embryonic development, cell differentiation, 
and carcinogenesis (42-44). Evidence has been provided that EZH2 might play a role in 
the development of many types of cancers including prostate cancer (45), lymphomas 
(46, 47), urogenital tract tumors (48-50), and breast cancer (51).
Increased expression of EZH2 has been associated with increased tumor cell proliferation 
and therefore worse survival (48, 51-53). The association between EZH2 and tumor 
aggressiveness has been confirmed in several tumor types (54-56) and resulted in the 
consideration of EZH2 as an important therapeutic target. Two microRNAs (miRs) able 
to regulate EZH2 expression in different tissues have been discovered, i.e. miR26a and 
miR-101 (57, 58). 
Since the great impact EZH2 inhibition might have in the treatment of multiple types 
of tumors, synthetic inhibitors are of more interest. 3-deazaneplanocin A (DZNep) can 
inhibit H3K27me3 and is an effective method to revert epithelial-to-mesenchymal 
transition (EMT), making it an interesting agent to prevent metastatic disease (59). 
However, this agent is a global histone methyltransferase inhibitor and not specific for 
EZH2 (60). Fortunately, small-molecule inhibitors of EZH2 have been developed and have 
shown to be able to decrease the histone methyltransferase activity of EZH2 resulting 
in reactivation of silenced target genes, especially in lymphomas with EZH2-activating 
mutations (61, 62). However, direct EZH2 inhibition by these small molecules may have 
an unfavorable effect on global methylation patterns in non-cancerous cells. Affecting 
the EZH2 phosphorylation pattern through inhibitors of CDK1/2 can diminish the EZH2 
activity in tumor cells and may be of more interest since it less affects the global EZH2 
mediated gene silencing (41).
More knowledge is however needed to identify the exact role of EZH2 in endocrine 
therapy resistance in breast cancer and to what extent. 
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C I R C U L AT I N G T U M O R C E L L S
Another reason underlying resistance in MBC is the constantly changing molecular 
make-up of tumor cells. Currently, the determination of predictive factors for treatment 
decision making is most commonly done in the primary tumor tissue while differences in 
clinically relevant molecular characteristics between the primary tumor and metastases 
are increasingly recognized. Characteristics of metastatic cells rather than of the primary 
tumor are therefore likely to be more important since the ultimate outcome of cancer 
patients is determined by the behavior of metastases. With respect to the expression of 
ER, tumor status differs in 20% when comparing the primary tumor with its metastases, 
which would lead to a relevant treatment change in a substantial number of patients 
(25, 63, 64). This change in tumor status can be partly explained by the fact that tumors 
consist of different subclones with differential gene expression and diverse abilities 
to metastasize. Moreover, over the course of tumor development and exposure to 
treatment, genomic instability leads to different genomic landscapes that can cause 
differences in response to treatment over time (65). As also mentioned above, one 
of the key mechanisms in acquired endocrine therapy resistance is the occurrence of 
activating mutations in ESR1 in metastatic tumors during treatment causing proliferation 
in the absence of hormone (28, 29).
Therefore, repetitive analyses of metastatic tissue could probably lead to more 
appropriate information for response prediction. However, metastatic tissue is often 
hard to obtain and only possible through invasive procedures, which limits its use in 
clinical practice. Hence, the characterization of circulating tumor cells (CTCs) poses an 
attractive alternative. CTCs are tumor cells found in the peripheral blood and are thought 
to originate from either the primary tumor or metastases. They can be obtained through 
venipunctures and can serve as a ‘liquid biopsy’.
The detection of CTCs is challenging with a median CTC count of 3 - 5 per 7.5 mL of blood 
in MBC patients (66). Detection methods therefore require extreme sensitivity and 
specificity. Over the years, many different CTC detection methods have been developed 
based on different properties of CTCs that distinguish them from normal blood cells 
(67). Some techniques isolate CTCs on physical properties (size, density, electric charges) 
but most of them use their biological properties by using surface protein expression, 
which is mostly the epithelial marker EpCAM. Amongst these methods, the CellSearch 
system is the only FDA-cleared system. Major drawback with epithelial marker based 
techniques however is that cells that have undergone EMT, thereby potentially losing 
EpCAM expression, possibly remain undetected whilst these cells are thought to 
underlie haematogenous metastases and therefore associate with poor prognosis (68-
71). Methods using expression of mesenchymal markers like N-Cadherin and Vimentin 
that are not repressed during EMT are under development to overcome the problem 
of missing this putatively most aggressive CTC subpopulation (72, 73). However, it has 
recently been demonstrated that the CellSearch system is able to detect CTCs in patients 
with triple negative breast cancer although the sensitivity is slightly lower than in non-
triple negative disease (74). 
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Despite the technical advancements in CTC detection, CTC enumeration is not yet ready 
to be implemented as a cancer screening tool or to be used for diagnosis. However, 
enumeration of CTCs has repeatedly proven to have prognostic value in multiple tumor 
types where the presence of CTCs in breast cancer has shown to be associated with a 
worse survival (75-79).
Besides detection of CTCs a major clinical challenge encompasses characterizing CTCs 
in order to base clinical decision making more on the characteristics of metastatic cells. 
However, since the isolation of pure fractions of CTCs is a major technological challenge, 
molecular characterization of CTCs is difficult to achieve since its low frequency and 
presence amongst a substantial number of leukocytes. It is however worthwhile to 
strive to since it holds great promise in improving knowledge on mechanisms underlying 
resistance to endocrine therapy. Nowadays, several techniques have been developed 
to molecularly characterize CTCs for drug target expression (77, 80, 81), mutations (82), 
and gene expression (83-85) and has, amongst others, revealed the high frequency of 
PIK3CA mutations in CTCs, which offers rationale for exploring PI3K-inhibitors in these 
patients (86).
Several clinical studies are now being conducted in order to better understand the 
possible use of both the count and characteristics of CTCs in the clinic. Most of them 
are focusing on the possibility to use CTC counts to test for early chemoresistance or to 
assess new treatment strategies using anti-HER2 agents (87).
Concerning the use of CTCs in better understanding endocrine therapy resistance not 
much is yet known. It has been demonstrated that CTCs of MBC patients with ER-
positive primary tumors frequently lack ER expression, which is a possible explanation 
for endocrine therapy resistance. In these CTCs, ESR1 mutations were not found (88). 
Currently, the clinical implication of a CTC-Endocrine Therapy Index (CTC-ETI), in which 
the protein expression of markers that play a role in endocrine therapy response (e.g. 
ER, B-cell lymphoma 2 (BCL-2), HER2, and Ki67) are stained in CTCs, is evaluated in a 
prospective trial (89). But more research is needed to fully understand whether or not 
CTC characterization can explain endocrine therapy resistance and can provide new 
guidance to overcome resistance. 
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A I M S  A N D  O U T L I N E  O F  T H E  T H E S I S
This thesis is aimed at exploring putative factors that are involved in endocrine therapy 
resistance by using cell line models and both primary tumors and CTCs of patients. The 
contribution of EZH2 expression in the behavior and drug response of tumors has been 
investigated on multiple levels of expression and the importance of characterization of 
CTCs has been explored.
In Chapter 2 we evaluate the association between different mRNA expression levels of 
EZH2 and PFS for ER-positive breast cancer patients who received first-line tamoxifen for 
advanced disease. In this chapter we propose the inverse relation between EZH2 and ER 
and suggest EZH2 as a potential treatment target to increase the anti-tumor activity of 
anti-estrogen therapies in breast cancer.
In order to obtain more understanding about the molecular pathway of EZH2, we 
performed pathway analysis on microarray data of 65 ER-positive tumors as being 
described in Chapter 3. By using expression levels of miR-26a and miR-101, both having 
EZH2 as common target, the goal was to discover a pathway that explains the association 
between high levels of miR-26a and low levels of EZH2 in order to define more factors 
that are related with a favorable outcome to tamoxifen therapy.  
In Chapter 4 we further explore the association between EZH2 and response to 
tamoxifen therapy by using a tissue microarray (TMA) created of ER-positive primary 
breast tumor tissues of 250 MBC patients who received tamoxifen as first-line therapy. 
EZH2 expression can be scored by IHC for intensity and quantity, and can be related to 
PFS.
Since nowadays AIs form the major first-line treatments for MBC, the next chapters 
contain studies on resistance against this type of therapy. In Chapter 5 we combine both 
ER and EZH2 by investigating the epigenetic modification H3K27me3 as a result of EZH2 
activity on ER and check for its consequences on treatment outcome for first-line AI 
treatment. 
In addition to the results obtained in cell line models and primary tumors of patients, 
we performed studies on CTCs of patients with advanced breast cancer. In Chapter 6 we 
use CTC characterization of MBC patients treated with endocrine therapy to investigate 
genes that predict response to AI therapy to guide clinical decision making in a more 
valuable way since the decision would be based on recent tumor events by using CTCs 
instead of the primary tumor that has been removed years before.
In conclusion, this thesis entitled ‘Changing the horizon of endocrine therapy resistance’ 
explores the factors involved in endocrine therapy resistance aiming to come to a more 
personalized and targeted anti-cancer treatment.
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CHAPTER 2
Decreased expression of EZH2 is associated with upregulation of ER 
and favorable outcome to tamoxifen in advanced breast cancer
E.A. Reijm*, M.P.H.M. Jansen*, K. Ruigrok-Ritstier, I.L. van Staveren, M.P. Look, M.E. Meijer-van Gelder, 
A.M. Sieuwerts, S. Sleijfer, J.A. Foekens, E.M.J.J. Berns
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A B S T R A C T
The purpose of this study is to investigate EZH2 in a large series of breast cancer 
patients for its prognostic and predictive value, and to evaluate its functional role in 
treatment response in vitro. EZH2 levels were measured using quantitative Real-Time 
Polymerase Chain Reaction (qRT-PCR) in primary breast cancer specimens and related 
to clinicopathologic factors and disease outcome. EZH2 expression was downregulated 
with siRNAs in MCF7, to assess expression alterations of putative EZH2 downstream 
genes and to determine cell numbers after treatment with the anti-estrogen ICI 164384. 
In 688 lymph node-negative patients who did not receive adjuvant systemic therapy, 
EZH2 was not significantly correlated with metastasis-free survival (MFS). In 278 patients 
with advanced disease treated with first-line tamoxifen monotherapy, the tertile with 
highest EZH2 levels was associated with the lowest clinical benefit (OR = 0.48; P = 0.02) 
and with a shorter progression-free survival (PFS) in both univariate (HR = 1.80; P < 0.001) 
and multivariate analysis, including traditional factors (HR = 1.61; P = 0.004). In vitro, 
EZH2 silencing in MCF7 caused a 38% decrease in cell numbers (P < 0.001) whereas 
ICI 164384 treatment resulted in a 25% decrease (P < 0.001) compared to controls. 
Combining EZH2 silencing with ICI treatment reduced cell numbers with 67% (P < 0.001) 
compared to control conditions. EZH2 downregulation was associated with an almost 
two-fold upregulation of the estrogen receptor alpha (ER) (P = 0.001). In conclusion, 
EZH2 has no prognostic value in breast cancer. High levels of EZH2 are associated with 
poor outcome to tamoxifen therapy in advanced breast cancer. Downregulated EZH2 
leads to upregulation of the ER and better response to anti-estrogens.
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I N T R O D U C T I O N
 
The anti-estrogen tamoxifen has been used for treatment of estrogen receptor alpha 
(ER) positive breast cancer for more than 20 years both in the adjuvant and advanced 
setting. Although the majority of breast tumors express the ER, approximately half of 
the patients with ER-positive advanced disease do not respond to endocrine therapy or 
will eventually develop resistance. As a consequence, there is a high need for markers 
to identify patients likely to benefit from tamoxifen and to get a better insight into 
mechanisms conferring resistance. 
In a previous genome-wide profiling study in breast cancer patients with advanced 
disease, we revealed an 81-gene signature for resistance to first-line tamoxifen 
treatment (1). One of the gene families from this profile is Enhancer of Zeste, consisting 
of Enhancer of Zeste Homolog 1 (EZH1, OMIM 601674) and Enhancer of Zeste Homolog 
2 (EZH2, OMIM 601573). Both EZ homologs belong to Polycomb group (PcG) proteins, 
and are involved in transcriptional control and epigenetic memory maintenance for 
preservation of cellular characteristics (2). EZH2 comprises the core of the Polycomb 
Repressor Complex 2 (PRC2) (3-5), has histone lysine methyltransferase activity, and 
mediates di- and trimethylation on histone 3 lysine residue 27 (H3K27) (2). EZH1 can also 
be a part of PRC2, although with low histone lysine methyltransferase activity (6). We 
previously explored EZH1 with qRT-PCR, but did not observe a significant correlation 
with clinical outcome in 229 ER-positive tumors of patients with advanced disease 
treated with first-line tamoxifen monotherapy (7).
In contrast to EZH1, EZH2 has been extensively studied in malignancies. Increased 
expression of EZH2 in breast, prostate, and bladder cancer has been associated with a 
high histological grade and increased tumor cell proliferation (8-10). In addition, EZH2 
was identified as an adverse prognostic marker for breast and prostate cancer, but these 
studies included only small series of patients (11, 12). Its predictive value for outcome to 
tamoxifen in advanced breast cancer has, however, not been studied yet.
The aims of this study were [1] to assess the prognostic value of EZH2 in a large series 
of patients, [2] to study its predictive value for outcome to tamoxifen treatment in 
advanced breast cancer, and [3] to explore its functional role in endocrine therapy 
resistance.
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P A T I E N T S  A N D  M E T H O D S
PAT I E N T S
This retrospective study, in which coded tumor tissues were used, has been approved 
by the medical ethics committee of the Erasmus MC Rotterdam, The Netherlands (MEC 
02.953), was performed in accordance with the Code of Conduct of the Federation of 
Medical Scientific Societies in the Netherlands (http://www.fmwv.nl), and reported 
following the REMARK recommendations (13), wherever possible. Frozen breast 
tumor tissue specimens of female patients with primary operable breast cancer who 
entered the clinic between 1979 and 1996 were analyzed. Follow-up, tumor staging, 
and response to therapy were defined by standard International Union Against Cancer 
(Geneva, Switzerland) classification criteria (14). 
Tumor protein expression levels of ER and progesterone receptor (PgR) were determined 
(15), and 10 fmol/mg cytosolic protein was used as cut-off point to classify tumors as 
ER and/or PgR-positive. The following criteria were applied to include tumor specimens 
from final analysis: [1] sufficient frozen tumor material, [2] more than 30% epithelial 
tumor cells in hematoxylin and eosin stained sections, [3] breast tumor tissue specimen 
of good RNA quality according to predefined criteria (16), and [4] EZH2 mRNA expression 
levels were measured and reference mRNA levels were detectable. After applying the 
inclusion criteria, tumor specimens and clinical data of 1,318 patients were available for 
analysis. From these 1,318 patients (for clinicopathologic details, see Supplementary 
Table S1), 580 patients (44%) underwent breast conserving lumpectomy and 738 
patients modified mastectomy (56%). The median follow-up time of patients alive was 
90 months, range 4–231 months. Eight hundred and eighty-nine patients did not receive 
adjuvant systemic therapy, while 429 patients (33%; all lymph node-positive) did; 198 
(15%) were treated with hormonal therapy, 216 (16%) with chemotherapy (70 patients 
anthracycline-based (FAC/FEC) and 146 patients non-anthracycline-based (CMF)) and 
15 patients received both hormonal and chemotherapy.
H O R M O N A L T H E R A P Y O F A DVA N C E D D I S E A S E
ER-positive tumors of 249 patients (out of the 1,318 M0 patients) who developed 
advanced disease after treatment for primary breast cancer and who received first-line 
tamoxifen therapy were included in this study. This set was completed with 29 tumors 
of patients with distant metastases at initial diagnosis (M1 patients). These 278 patients 
were divided according to response to tamoxifen. Clinical benefit from tamoxifen, 
defined as a complete or partial response according to standard International Union 
Against Cancer (Geneva, Switzerland) classification criteria (14) or no change longer 
than 6 months after treatment initiation (stable disease), was observed in 173 patients 
(62%); 11 patients showed complete response, 38 a partial response and 124 patients 
had stable disease. No clinical benefit occurred in 105 patients (38%).
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R N A I S O L AT I O N A N D Q UA N T I TAT I V E R E A L-T I M E P C R
Tissue processing, RNA isolation, cDNA synthesis, quantitative real-time polymerase 
chain reaction (qRT-PCR) and expression data generation were performed as described 
previously (16). The qRT-PCR assays were carried out on an ABI Prism 7700 Sequence 
Detection System (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands) or a 
MX3000P Real-time PCR system (Stratagene, Amsterdam, The Netherlands). Assay-
on-Demand kits (Applied Biosystems) were used to measure mRNA levels of EZH2 
(Hs00544830_m1) and ER (Hs00174860_m1; measures ESR1). Primer sequences 
of the reference genes PGBD, HPRT, B2M have been described (16). Forty rounds of 
amplification were performed and fluorescent signals of Taqman probes were used to 
generate Cycle threshold (Ct) values to calculate mRNA expression levels. Expression 
levels of EZH2 and ER were normalized against average expression levels of three 
reference genes in tumor samples and against HPRT levels in cell lines (16). 
B R E A S T C A N C E R C E L L  L I N E A N D R N A I N T E R F E R E N C E
MCF7, an estrogen sensitive ER-positive breast cancer cell line, was cultured in 
RPMI 1640 containing phenol red and 10% heat-inactivated fetal calf serum (Sigma–
Aldrich Chemie). To perform EZH2 knockdown experiments, small interfering RNA 
(siRNA) targeting EZH2 mRNA (Qiagen, Venlo, The Netherlands) was used according 
recommendations and described previously (17). Two different siRNA duplexes 
for EZH2 were pooled with target sequences: r(CCAUGUUUACAACUAUCAA)dTdT 
(sense) and r(UUGAUAGUUGUAAACAUGG)dTdT (antisense) for the first duplex and 
r(GCAAAUUCUCGGUGUCAAA)dTdT (sense) and r(UUUGACACCGAGAAUUUGC)dTdT 
(antisense) for the second duplex. As control, MCF7 cells were transfected with non-
specific silencing pool of siRNAs (Qiagen). siRNAs (5 nM) were introduced via inverse 
transfection into MCF7, using HiPerfect transfection reagent (Qiagen). Six experiments 
were independently performed at different time points in 24 (N = 1) or 96 wells plates 
(N = 5). The 24 and 96 wells plate contained 330,000 cells and 6,000 cells per well, 
respectively, and two and eight wells per condition was used and pooled for further 
analyses. Within three experiments in 96 wells plates, part of the cells was harvested 
after 96 h for mRNA and protein analysis. The remaining part was transfected with siRNAs 
again, and subsequently grown for 96 h in standard culture medium supplemented with 
the pure ER antagonist ICI 164384 (100 nM) or with ethanol vehicle alone as control. 
The pure ER antagonist ICI was used to exclude the agonistic effects of tamoxifen. To 
assess the effect of EZH2 silencing, cell numbers were counted with a coulter counter 
at day 4 and 8. To determine response to 96 h of ICI 164384 treatment cell numbers 
were counted at day 8. Throughout an experiment, culture medium was renewed every 
3 days and at the end cells were lysed and RNA and protein isolated using the MirVana 
Paris kit (Ambion, Foster City, CA, USA).
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I M M U N O C Y T O C H E M I S T RY A N D W E S T E R N B L O T T I N G
Cytospins were prepared from MCF7 cells of above experiments, fixed with 1% 
formaldehyde and incubated with a monoclonal antibody against EZH2 (BD Biosciences, 
San Jose, CA, (1:2000)) and a secondary peroxidase conjugated rabbit anti-mouse 
antibody. EZH2 protein expression was visualized with a diaminobenzidine staining 
reaction. Western blotting of protein samples were performed as described previously 
(17). Antibodies against EZH2 (monoclonal (1:2000), BD Biosciences, 1:2000), H3K27 
(polyclonal (1:5000), ABCAM, Cambridge, MA, USA) and GAPDH (monoclonal (1:500), 
Chemicon Inc., Temecula, CA, USA) were used and detected with horseradish peroxidase 
(HRP)-conjugated or HRP-polymer (DAKO Real Envision, DAKO, Diagnostica GmbH, 
Hamburg, Germany) labeled secondary antibodies and chemiluminescent reagents 
(ECL-kit, Pierce, Rockford, IL). The Scanalytics One-D program (Alpha Innotech Ltd., 
Cannock, UK) was used for quantification.
DATA A N A LY S I S  A N D S TAT I S T I C S
The relationship of EZH2 expression levels with patient and tumor characteristics 
was investigated using non-parametric methods, i.e., Spearman rank correlations 
for continuous variables and Wilcoxon rank-sum or Kruskal–Wallis test for ordered 
variables. For the analyses with continuous variables, mRNA levels of EZH2 were log 
transformed and of ER and PgR were box-cox transformed to reduce skewness of the 
distribution. Logistic regression analysis was used to calculate the odds ratio (OR) that 
defines the relation between expression levels and clinical benefit from therapy. The 
Cox proportional hazards model was used to compute the hazard ratio (HR) in the 
analysis of metastasis-free survival (MFS), overall survival (OS) and progression-free 
survival (PFS). MFS and OS were previously described (18). PFS was defined as the time 
elapsed between initiation of tamoxifen therapy and the first detection of disease 
progression. In multivariate analysis, logistic and Cox regression analysis was applied 
to determine whether EZH2 had predictive value and was independent when added 
to the base model of traditional factors. The Cox proportional hazard assumption 
was not violated as verified by a test based on Schoenfeld residuals. Both HR and OR 
were represented with their 95% confidence intervals (95% CI). Survival curves were 
generated using the Kaplan and Meier method and a log rank test was used to test for 
differences. Computations were done with the STATA statistical package, release 10.1 
(STATA Corp., College Station, TX). In the in vitro studies, a student t-test was performed 
to test for significance for differences in cell counts and RNA levels. All P-values were 
two-sided and P < 0.05 was considered statistically significant.
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R E S U L T S
A S S O C I AT I O N S O F E Z H2 M R N A E X P R E S S I O N L E V E L S W I T H 
C L I N I C O PAT H O L O G I C A L FAC T O R S
In this study, we determined the mRNA expression levels in 1,318 primary breast 
carcinomas. Median expression levels of EZH2, its interquartile range, and its 
association with patient and tumor characteristics are summarized in Supplementary 
Table 1. Briefly, high EZH2 mRNA levels were significantly associated with younger age, 
premenopausal status, poor histologic grade, larger tumor size, and status of ER, PgR, 
ERBB2, and EGFR. An inverse correlation between EZH2 and ER was observed (P < 0.001, 
r
s
 = −0.33). Expression of EZH2 was higher in ERBB2 positive samples compared with 
ERBB2 negative samples (P < 0.001).
E Z H2 L E V E L S A N D C L I N I C A L O U T C O M E
The prognostic value of EZH2 was assessed in 688 lymph node-negative (LNN) patients 
who did not receive any adjuvant systemic therapy. EZH2 levels, as continuous variable, 
were not significantly correlated with MFS (HR = 1.14, 95% CI: 0.98–1.32; P = 0.10). 
Considering OS, EZH2 was significantly associated in LNN patients (HR = 1.25, 95% CI: 
1.07–1.46; P = 0.006).
A S S O C I AT I O N O F E Z H2 L E V E L S W I T H C L I N I C A L B E N E F I T  A N D P F S 
In univariate analysis, increasing EZH2 expression levels as continuous variable were 
significantly associated with a lower clinical benefit in patients with advanced breast 
cancer treated with first-line tamoxifen monotherapy (N = 278) (OR = 0.68, 95% CI: 0.47–
0.98; P = 0.04) (Supplementary Table S2). In analogy, after categorizing EZH2 expression 
levels into tertiles, the highest tertile was significantly associated with a lower clinical 
benefit to tamoxifen therapy (OR = 0.48, 95% CI: 0.26–0.89; P = 0.02). In multivariate 
analysis, however, when corrected for traditional predictive factors including age, 
menopausal status, DSR, DFS, ER and PgR levels, no significant association with clinical 
benefit was observed (Supplementary Table S2). In univariate analysis, increasing EZH2 
expression levels analyzed as continuous variable were significantly associated with 
shorter PFS (HR = 1.28, 95% CI: 1.08–1.51; P = 0.004) (Table 1). In univariate analysis, 
compared with tumors in the lowest tertile of EZH2 expression, those with the highest 
EZH2 levels were associated with a poor PFS (HR = 1.80, 95% CI: 1.32–2.46; P < 0.001) 
(Table 1; Figure 1). Remarkably, the intermediate and highest expression groups have a 
similar PFS during the first 12 months while the curves diverge thereafter. In multivariate 
analysis, compared with tumors with EZH2 levels in the lowest tertile, those with highest 
EZH2 levels were significantly associated with poor PFS (HR = 1.61, 95% CI: 1.16–2.24; 
P = 0.004). Moreover, ER levels were not significantly (P = 0.21) different between the 3 
different tertiles of EZH2 (Supplemental Figure S1).
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TA B L E 1. Cox uni- and multivariate analysis for PFS of EZH2, continuous and categorized, in estrogen 
receptor-positive tumors from 278 patients whose recurrence was treated with first-line tamoxifen 
monotherapy.
Factor of base model Univariate analysis Multivariate analysis*
    N HR 95% CI P HR 95% CI P
Age (y)
    ≤ 55 104 (37.4%) 1.00 1.00
    56-70 102 (36.7%) 0.83 0.62-1.10 0.19 0.68 0.45-1.03 0.07
    >70  72 (25.9%) 0.68 0.50-0.94 0.02 0.60 0.38-0.93 0.02
Menopausal status
    Premenopausal  68 (24.5%) 1.00
    Postmenopausal 210 (75.5%) 0.90 0.67-1.19 0.45
Disease-free survival
    ≤ 1 year  72 (25.9%) 1.00 1.00
    1-3 years 124 (44.6%) 0.69 0.51-0.92 0.01 0.67 0.49-0.90 0.009
    >3 years  82 (29.5%) 0.51 0.36-0.71  <0.001 0.50 0.36-0.71  <0.001
Dominant site of relapse
    Soft tissue  29 (10.4%) 1.00 1.00
    Bone  145 (52.2%) 1.29 0.85-1.96 0.23 1.29 0.81-2.01 0.26
    Viscera 104 (37.4%) 1.18 0.76-1.83 0.45 1.39 0.87-2.21 0.17
ER mRNA 278 (100%) 0.90 0.86-0.96  <0.001 0.91 0.86-0.97 0.004
PgR mRNA 278 (100%) 0.90 0.85-0.96 0.001 0.92 0.86-0.98 0.01
Factors analyzed Additions to the base model
EZH2 mRNA
Continuous variable 278 (100%) 1.28 1.08-1.51 0.004 1.26 1.05-1.52 0.015
Categorized variable
    t1  93 (33.5%) 1.00 1.00
    t2  93 (33.5%) 1.40 1.04-1.89 0.03 1.48 1.08-2.02 0.02
    t3  92 (33.0%) 1.80 1.32-2.46  <0.001 1.61 1.16-2.24 0.004
* Stratified for postmenopausal status
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E Z H2 A N D R N A I N T E R F E R E N C E
To investigate how EZH2 is functionally involved in response to anti-estrogens, we 
performed in vitro studies in the ER-positive human breast cancer cell line MCF7. To 
this end MCF7 cells were treated with ICI 164384 combined with non-silencing (NS) or 
EZH2 silencing. When cells transfected with siNS were exposed to 100 nM ICI 164384 
a decrease in cell numbers of 25% (range 12–30%, N = 3, P < 0.001) after 96 h was 
observed, confirming that MCF7 is an anti-estrogen sensitive cell line. Knockdown 
experiments showed an average silencing level of EZH2 of 79% (range 64–93%, N = 6, 
P < 0.001) after 96 h (Figure 2). EZH2 silencing caused a significant decrease in cell 
numbers of 38% (range 17–53%, N = 3, P < 0.001) compared with controls (Figure 3). 
When EZH2 silencing and ICI-treatment were combined, cell numbers were reduced 
with 67% (range 54–75%, N = 3, P < 0.001) compared to non-silenced MCF7 cells. Both 
immunocytochemistry of cytospins and western blotting confirm knockdown of EZH2 
on the protein level after 96 h of EZH2 silencing (Figure 4). To validate EZH2 silencing 
functionally we demonstrated (Figure 4) that methylation of lysine residue 27 of histone 
3 diminishes when silencing EZH2.
Trend P < 0.001
t1
t2
t3
93
93
92
47
34
32
25
16
6
18
11
1
At risk:
F I G U R E 1. Kaplan-Meier curves of PFS as a function of EZH2 mRNA expression levels. Patients were 
evenly divided into three groups according to EZH2 mRNA levels. Patients at risk at different time points 
are indicated.
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F I G U R E 2.    EZH2 and ER mRNA expression levels 
after EZH2 silencing (siEZH2) in MCF7 cells. Average 
level of siEZH2 was 79% after 96 hours of culturing. 
Downregulation of EZH2 was associated with an av-
erage upregulation of ER of almost two-fold. Bars 
represent mean ± SD of triplicate measurements 
expressed as fold-difference compared with non-si-
lenced MCF7 cells. Data shown are of six time-point 
independent cell culture experiments.
F I G U R E 3. EZH2 silencing (siEZH2) in MCF7 and 
response to ICI 164384 treatment. MCF7 cells were 
cultured for 8 days in RPMI containing 10% FCS and 
transfected with siRNAs at day 0 and again at day 4. 
Culture medium was supplemented with ICI 164384 
after 96 hours. Cell numbers were measured in 
siEZH2 and/or ICI 164384 at day 8. Bars represent 
mean ± SD of triplicate measurements expressed 
as fold-difference compared with untreated and 
non-silenced MCF7 cells. Results were obtained 
from 3 time-point independent cell culture exper-
iments.
ICI164,384 - - + +
siEZH2 - + - +
EZH2 and response to the selective estrogen 
receptor modulator ICI 164,384 in MCF7
Relative cell numbers 
0.00
0.20
0.40
0.60
0.80
1.00
1.20
F I G U R E 4. Immunocytochemistry of cytospins 
and western blotting. EZH2 protein expression after 
96 h EZH2 silencing (siEZH2) compared with non-si-
lenced MCF7 cells (siNS) is shown by immunocyto-
chemistry (top). Western blotting (bottom) shows 
histone 3 lysine 27 trimethylation (H3K27me3).
s i E Z H 2 s i N S
E Z H 2
G A P D H 
H 3 K 2 7 m e 3
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A S S O C I AT I O N B E T W E E N E Z H2 L E V E L S A N D E R E X P R E S S I O N
In view of the inverse correlation between EZH2 and ER mRNA expression levels 
observed in our 1,318 breast cancer tumor specimens, we next studied the effect of 
EZH2 silencing on ER expression in vitro. Downregulation of EZH2 in MCF7 cells (79% 
after 96 h, range 64–93%, N = 6) was associated with an average two-fold upregulation 
of ER (N = 6, range 1.5–2.3, P = 0.001) (Figure 2), which is concordant with the observed 
inverse correlation between EZH2 and ER mRNA expression in clinical samples.
D I S C U S S I O N
We demonstrate here for the first time that a significant association exists between 
high levels of EZH2 with outcome in terms of PFS for ER-positive breast cancer patients 
treated with first-line tamoxifen for advanced disease. Additionally, it was shown 
that EZH2 expression impacts response to tamoxifen rather than reflecting tumor 
aggressiveness since no prognostic value for EZH2 was revealed in LNN primary breast 
cancer who did not receive adjuvant systemic therapy.
In contrast to our findings, EZH2 has previously been suggested to bear prognostic 
value in breast cancer. Based on in silico analysis, on a relatively small set of 78 tumors 
of young LNN patients (<55 years) with low grade tumors (19), Kleer et al. reported 
that mRNA expression of EZH2 was significantly higher in invasive carcinomas that 
metastasize within 5 years of primary diagnosis compared with invasive carcinomas 
that did not (11). In another study immunohistochemistry was used to demonstrate 
an association between EZH2 expression and increased tumor cell proliferation in 
melanoma, prostate, endometrial, and breast cancer (9). Association of high EZH2 
expression with unfavorable prognosis was revealed in all investigated tumor types 
with the exception of breast cancer as survival data were not available. We observed 
that EZH2 associates significantly with OS; however, OS is not only dependent on tumor 
aggressiveness but also on treatment and response of the patient in the adjuvant and/
or advanced disease setting. That EZH2 in our study predicts poor OS in LNN patients 
who did not obtain adjuvant systemic therapy suggests an association with treatment 
response in the advanced disease setting, as for example shown for first-line tamoxifen 
monotherapy in this study. Collett et al. also used immunohistochemistry to assess the 
prognostic value of EZH2 in breast cancer (8). In 190 tumors (100 EZH2-negative and 
90 EZH2-positive), they demonstrated a significant correlation between EZH2 positivity 
and high disease stage at time of diagnosis in terms of locally advanced disease or 
metastatic disease. However, this group comprises only six patients with metastatic 
disease at initial diagnosis. Additionally, this set was heterogeneous with both LNN and 
LN-positive tumors. And though treatment status was not discussed, it is reasonable 
to assume that LNP patients have received systemic treatment thereby impacting 
outcome and obscuring EZH2’s true prognostic value. However, in our study population 
comprising the largest series of patients studied so far, 688 LNN patients, who did not 
receive any adjuvant systemic therapy enabling to assess the true prognostic value of 
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EZH2, we could not confirm its prognostic value. This discrepancy in findings remains to 
be clarified but might be due to the methodology applied and the cohorts of patients 
studied.
Furthermore, we found an association between EZH2 and the type of response to 
therapy in advanced disease with the highest EZH2 levels related to poor outcome. 
In order to elucidate the potential underlying mechanisms for this association, we 
explored the association between EZH2 expression and ER expression. In our 1,318 
breast cancer tumor specimens, we observed an inverse association between EZH2 
and ER mRNA expression levels. Accordingly, in silico analysis of 15 independent breast 
cancer datasets of the Oncomine database (Supplementary Figure S2), with in total 
2,437 samples (713 ER-negative, 1724 ER-positive), confirmed this finding. In addition, 
we performed functional studies in which EZH2 expression was silenced with siRNAs 
in the human estrogen sensitive breast cancer cell line MCF7. The decrease in cell 
numbers following downregulating EZH2 expression in MCF7 suggests that EZH2 has 
an effect on cell proliferation, in agreement with previously performed studies showing 
an association between EZH2 and cell proliferation (8, 11). We have shown that growth 
inhibition in the experiment with ICI + siEZH2 (67% inhibition) adds up the effect of 
EZH2 silencing and ICI 164384 treatment on MCF7 growth (38 and 25% inhibition, 
respectively). These combined ICI + siEZH2 experiments demonstrate no overlap in 
growth inhibition and indicates that the effect of EZH2 silencing on MCF7 growth is 
independent of the effect of ER inhibition by ICI. Our observed upregulation of ER by 
silencing of EZH2 and the inverse correlation between EZH2 and ER status (ER-negative 
versus ER-positive) in breast cancer specimens (Supplemental Figure S2), however, 
suggest an EZH2 and ER interaction which may also result in enhanced sensitivity to ICI 
164384. Although the observed two-fold upregulation of ER does not seem impressive 
at first glance, it is already observed after 96 h of culturing. Moreover, MCF7 is a cell 
line with already one of the highest ER expression levels in our panel of 39 breast cancer 
cell lines (data not shown). In that perspective, an almost two-fold upregulation can be 
regarded substantial. Furthermore, the extent of ER upregulation by silencing EZH2 is 
in the range of what has been described for other downstream factors. For example, Yu 
et al. published a 1.6-fold upregulation of the Adrenergic Receptor when silencing EZH2 
(20). We hypothesize that the promoter region of ER lacks DNA methylation in MCF7 
and that the observed upregulation of ER is predominantly due to decreased histone 
H3K27 trimethylation caused by EZH2 knockdown. Further studies are needed to verify 
this hypothesis.
Given the presumed role of EZH2 in the regulation of ER expression, EZH2 might be 
an interesting target for therapy. Recently, Varambally et al. discovered a physiological 
EZH2-inhibitor, miRNA-101, which inhibits the expression and function of EZH2 in cancer 
cell lines (21). It has been shown that miRNA-101 expression diminishes during cancer 
progression, resulting in an increased EZH2 expression and concomitant dysregulation 
of epigenetic pathways. This cascade is thought to underlie progression of several 
types of cancers, e.g., prostate, brain, and lung cancer (21). In addition, also miRNA-
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26a has been reported to post-transcriptionally repress EZH2 (22). Recently, Kota et al. 
demonstrated the capacity of miRNA-26a as an anti-tumor therapy in a mouse model 
of hepatocellular carcinomas, where it resulted in inhibition of cancer cell proliferation 
and induction of tumor-specific apoptosis (23). As a result, it would be interesting to 
further investigate EZH2 as a potential target for therapy, and include miRNA-101 and 
miRNA-26a as “in vivo” inhibitors.
In conclusion, EZH2 has no prognostic value in our large set of LNN adjuvant untreated 
breast cancer patients. However, high EZH2 levels are associated with unfavorable 
outcome to tamoxifen treatment in breast cancer patients with advanced disease, which 
suggests that EZH2 can be used as a predictive marker. Moreover, downregulation of 
EZH2 caused additional growth inhibition next to anti-estrogen therapy in vitro and 
resulted in ER upregulation. If validated, EZH2 may be considered to serve as a potential 
target to increase the anti-tumor activity of anti-estrogen therapies in breast cancer. 
Furthermore, its assessment may contribute to a more appropriate selection of patients 
for tamoxifen therapy and thereby a more tailored management of patients with breast 
cancer.
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CHAPTER 3
High miR-26a and low CDC2 levels associate with decreased EZH2 expression 
and with favorable outcome on tamoxifen in metastatic breast cancer 
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A B S T R A C T
For patients with metastatic breast cancer, we previously described that increased 
EZH2 expression levels were associated with an adverse outcome to tamoxifen therapy. 
Main objective of the present study is to investigate miR-26a and miR-101 levels, which 
both target EZH2, for their association with molecular pathways and with efficacy of 
tamoxifen as first-line monotherapy for metastatic breast cancer. Expression levels 
were measured using quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) in 
primary breast cancer specimens of 235 estrogen receptor-α (ER)-positive patients. 
Pathway analysis was performed on microarray data available for 65 of these tumors. 
Logistic regression and Cox uni- and multivariate analysis were performed to relate 
expression levels with clinical benefit and time to progression (TTP). Increasing levels 
of miR-26a were significantly (P < 0.005) associated with both clinical benefit and 
prolonged TTP, whereas miR-101 was not. Cell cycle regulation and CCNE1 and CDC2 
were the only significant overlapping pathway and genes differentially expressed 
between tumors with high and low levels of miR-26a and EZH2, respectively. In addition, 
increasing mRNA levels of CCNE1 (P < 0.05) and CDC2 (P < 0.001) were related to poor 
outcome. Multivariate analysis revealed miR-26a and CDC2 as an optimal set of markers 
associated with outcome on tamoxifen therapy, independently of traditional predictive 
factors. To summarize, only miR-26a levels are related with treatment outcome. Cell 
cycle regulation is the only overlapping pathway linked to miR-26a and EZH2 levels. Low 
mRNA levels of EZH2, CCNE1, and CDC2, and high levels of miR-26a are associated with 
favorable outcome on tamoxifen.
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I N T R O D U C T I O N
The anti-estrogen tamoxifen has been used for more than three decades for the 
treatment of estrogen receptor-α (ER)-positive breast cancer in both adjuvant and 
metastatic settings. The majority of breast tumors express ER, however, half of the 
patients with metastatic disease initially fail to respond to endocrine therapy, while 
the remaining patients will develop resistance during therapy. More insight into factors 
underlying tamoxifen resistance as well biomarkers to identify patients likely to benefit 
from tamoxifen is therefore needed. 
We identified and validated an 81-gene signature that predicts tamoxifen resistance in 
patients with metastatic breast cancer (1, 2). This signature included a member of the 
Enhancer of Zeste Homolog (EZH) family, which consists of EZH1 (OMIM 601674) and 
EZH2 (OMIM 601573). EZH2 is one of the polycomb proteins, a highly conserved group 
of chromatin modifiers known for their role in epigenetic memory and preservation 
of cellular characteristics (3). Our in vitro studies showed that knockdown of EZH2 
upregulates ER as a consequence of which sensitivity to anti-estrogen therapy increases 
(4). In line with this, we have validated the predictive value of EZH2 and showed that low 
EZH2 levels were associated with favorable outcome on tamoxifen treatment in breast 
cancer patients with metastatic disease (4).
MicroRNAs (miRs) consist of a family of endogenously expressed small noncoding 
RNAs that target coding mRNAs to repress translation or induce degradation of their 
target mRNAs (5). There is accumulating evidence that misregulation of miRs plays 
an important role in cancer. In breast cancer, miRs have been related with metastatic 
behavior, clinical outcome and ER status (6, 7). Expression of several miRs in ER-positive 
breast cancer have also been associated with response to tamoxifen in cell lines 
(miR-221 and -222) (8), and in patients with metastatic disease treated with first-line 
tamoxifen (miR-30a, -30c, and -182) (9).
With respect to EZH2, miR target prediction tools have indicated that several miRs can 
target EZH2, but only two miRs, i.e., miR-26a and miR-101, have actually been shown to 
regulate EZH2 expression in different tissues (10, 11). In the present study, we examined 
whether miR-26a and miR-101 were associated with EZH2 mRNA levels in breast cancer 
and with outcome on first-line tamoxifen therapy. In addition, using available whole 
genome mRNA data from a subset of tumors, the global testing approach (GTA) was 
performed to identify molecular pathways correlated with expression levels of miR-
26a, miR-101, and EZH2 and to reveal genes, within these pathways, that associate with 
outcome on tamoxifen.
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P A T I E N T S  A N D  M E T H O D S
PAT I E N T S
Frozen breast tumor tissue specimens from female patients with primary operable 
breast cancer, who entered the clinic between 1981 and 1996 were analyzed. Follow-
up, tumor staging, and response to therapy were performed as defined by standard 
International Union Against Cancer (Geneva, Switzerland) classification criteria (12). 
This retrospective study was performed in accordance with the Code of Conduct of the 
Federation of Medical Scientific Societies in the Netherlands (http://www.fmwv.nl), and 
reported following the REMARK recommendations (13), wherever possible. The study 
has been approved by the medical ethics committee of the Erasmus MC Rotterdam, The 
Netherlands (MEC 02.953).
Tumor protein expression levels of ER and progesterone receptor (PgR) were determined 
and used to classify tumors as ER- and/or PgR-positive as described previously (4, 14). 
The following criteria were applied to include breast tumor specimens for final analysis 
in this study: [1] sufficient frozen tumor material, [2] more than 30% epithelial tumor cell 
nuclei in haematoxylin/eosin-stained sections, and [3] specimen of good RNA quality 
according to predefined criteria (15). After applying these criteria, 235 patients with ER-
positive tumors, who had metastatic disease treated with tamoxifen as first-line therapy, 
were included in this study. From these 235 patients, 89 patients (38%) underwent 
breast-conserving lumpectomy and 146 patients modified mastectomy (62%). The 
median follow-up time of patients alive was 89 months, range 10–165 months. Hundred 
and sixty five patients (70%) did not receive prior adjuvant systemic therapy, while 42 
patients (18%) were previously treated with adjuvant chemotherapy [25 patients (11%) 
with non-anthracycline-based (CMF) and 17 patients (7%) with anthracycline-based 
(FAC/FEC) regimens].
Twenty eight patients (12%) presented with distant metastases at initial diagnosis (M1 
patients). Clinical benefit on first-line tamoxifen monotherapy, defined as a complete 
or partial response according to standard International Union Against Cancer (Geneva, 
Switzerland) classification criteria (12) or no change longer than 6 months after treatment 
initiation (stable disease), was observed in 148 patients (63%). Eleven patients (5%) 
showed a complete response, 33 (14%) a partial response, and 104 patients (44%) had 
stable disease. No clinical benefit occurred in 87 patients (37%). Time to progression 
(TTP) was defined as the time elapsed between initiation of tamoxifen therapy and first 
detection of disease progression.
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M E T H O D S
Details of applied methodologies are available at Supplemental Methods. In brief, tissue 
processing, RNA isolation, cDNA synthesis, quantitative Real-Time Polymerase Chain 
Reaction (qRT-PCR), and expression data generation were performed as described 
previously (15). For pathway analysis, samples with whole genome mRNA expression 
profiles available, measured on Affymetrix HG-U133A and Plus2 chips, were selected 
(N = 65, 28%) and only reliable, i.e., quality checked, probes (N = 10,520) were evaluated. 
Samples were grouped according to median expression levels of miR-26a, miR-101 or 
EZH2. The Global Test Approach (GTA) was used to identify KEGG/BioCarta biological 
pathways in genes co-expressed with the biomarker of interest. Pathways were taken 
into account when P-values, after correction for multiple testing and resampling, were 
below 0.05 and genes with z-scores >1.96 were considered significant contributors to the 
pathways. The GTA package version 4.14.0 was run in the R version 2.9.0. Data analysis 
and statistics were performed as previously described (4). Expression levels of miR-26a, 
miR-101, and EZH2, CCNE1, CDC2, ER, and PgR mRNA levels were transformed to reduce 
distribution skewness. Logistic regression analysis was used to compute the odds ratio 
(OR) for clinical benefit and the Cox proportional hazards model to calculate the hazard 
ratio (HR) for TTP. Computations were done with the STATA statistical package, release 
11.1 (STATA Corp., College Station, TX). All P-values were two-sided, and P < 0.05 was 
considered as statistically significant.
R E S U L T S
A S S O C I AT I O N S W I T H C L I N I C O PAT H O L O G I C A L FAC T O R S
In this study, we determined the miR-26a, miR-101, and EZH2 mRNA expression levels 
in 235 primary breast carcinomas. The median and interquartile ranges of expression 
levels for miR-26a were 0.99 and 0.41, for miR-101 were 1.03 and 0.81 and for EZH2 were 
0.10 and 0.07. The miR-26a and miR-101 levels correlated with each other (r
s
 = 0.43, 
P < 0.001) and showed an inverse relation with EZH2 mRNA levels (r
s
 = −0.21 and 
r
s
 = −0.15, respectively, P < 0.05). Expression levels of both miRs were not significantly 
related with age, tumor grade, tumor size, or nodal status (Table 1). Only miR-101 levels 
were associated with postmenopausal status (P = 0.036). The ER and PgR mRNA levels 
showed a significant positive correlation with those of miR-26a (r
s
 = 0.21 and r
s
 = 0.34, 
for both P < 0.002) and miR-101 (r
s
 = 0.13, P = 0.04 and r
s
 = 0.27, P < 0.001).
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A S S O C I AT I O N S W I T H C L I N I C A L B E N E F I T  A N D T I M E T O P R O G R E S S I O N 
Expression levels of miR-26a, miR-101 and EZH2 mRNA levels were evaluated in uni- and 
multivariate analysis for their associations with clinical benefit (Supplemental Table 2) 
and TTP (Table 2) in patients with metastatic breast cancer treated with tamoxifen 
as first-line monotherapy. The miR-101 levels were not related with clinical benefit 
(OR = 0.84, P = 0.40) nor with TTP (Table 2). As continuous variable, increasing levels 
of miR-26a were significantly associated with clinical benefit (OR = 32.1, P < 0.001) 
and with favorable TTP (HR = 0.13, P < 0.001; Table 2). Increasing mRNA levels of EZH2 
were related to lower chance of clinical benefit (OR = 0.61, P = 0.02) and shorter TTP 
(HR = 1.26, P = 0.02). Analysis of miR-26a and EZH2 categorized in thirds (i.e. three 
quantiles) showed that the third with highest levels of miR-26a was related to clinical 
benefit (OR = 4.10, P < 0.001) and with prolonged TTP (HR = 0.43, P < 0.001), whereas 
the third with the highest EZH2 levels correlated with treatment failure (OR = 0.34, 
P = 0.002) and shorter TTP (HR = 1.91, P < 0.001). Kaplan–Meier curves as function of 
categorized expression levels of miR-26a and EZH2 visualize their association with TTP 
(Figure 1). The median differences in TTP were 6.5 months between patients with high 
and low expression levels for miR-26a and 5.6 months for those with high and low EZH2 
expression levels. In multivariate analysis, when added separately to the base model of 
predictive factors, miR-26a and EZH2 were significantly associated with clinical benefit 
and TTP, both as continuous and as categorized variables. Patients with high miR-26a 
levels showed clinical benefit (OR = 3.31, P = 0.005) and the longest TTP (HR = 0.52, 
P < 0.001), whereas those with high EZH2 levels had less benefit (OR = 0.39, P = 0.02) 
and shorter TTP (HR = 1.80; P = 0.001). The results of the multivariate analysis show the 
independence of miR-26a and EZH2 from traditional predictive factors included in the 
base model.
TA B L E 2.  Cox uni- and multivariate analysis for TTP in patients with metastatic disease treated with 
tamoxifen.
Univariate analysis Multivariate analysis*
Factor of base model N % HR 95% CI  P HR 95% CI  P
Age (y)
    ≤ 55 87 37 1.00 1.00
    55-70 89 38 0.82 0.60-1.11 0.19 0.71 0.45-1.11 0.13
    >70 59 25 0.66 0.47-0.94 0.02 0.58 0.36-0.94 0.03
Menopausal status
    Premenopausal 56 24 1.00
    Postmenopausal 179 76 0.86 0.63-1.17 0.33
Disease-free survival
    ≤ 1 year 62 26 1.00 1.00
    1-3 years 109 46 0.66 0.48-0.91 0.01 0.63 0.46-0.88 0.006
    >3 years 64 27 0.51 0.35-0.75  <0.001 0.52 0.36-0.77 0.001
03
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Dominant site of relapse
    Soft tissue 26 11 1.00 1.00
    Bone 127 54 1.29 0.83-2.02 0.26 1.28 0.79-2.07 0.31
    Viscera 82 35 1.12 0.70-1.79 0.64 1.29 0.77-2.15 0.33
ER mRNA 235 100 0.89 0.83-0.94  <0.001 0.90 0.84-0.96 0.002
PgR mRNA 235 100 0.90 0.84-0.96 0.002 0.91 0.85-0.98 0.02
Factors analyzed Additions to base model
miR-26a
Continuous variable 235 100 0.13 0.06-0.28   <0.001 0.18 0.07-0.44   <0.001
    Low 79 34 1.00 1.00
    Intermediate 78 33 0.93 0.68-1.29  0.68 1.18 0.83-1.66 0.35
    High 78 33 0.43 0.31-0.61   <0.001 0.52 0.36-0.76  <0.001
miR-101
Continuous variable 235 100 0.87 0.70-1.07 0.19 0.90 0.71-1.13   0.37
EZH2 mRNA
Continuous variable 235 100 1.26 1.06-1.51  0.01 1.28 1.05-1.56  0.02
    Low 79 34 1.00 1.00
    Intermediate 78 33 1.58 1.14-2.19  0.006 1.73 1.23-2.44  0.002
    High 78 33 1.91 1.37-2.68   <0.001 1.80 1.26-2.55  0.001
CCNE1 mRNA
Continuous variable 226 96 1.27 1.12-1.45  <0.001 1.24 1.06-1.44  0.007
    Low 76 34 1.00 1.00
    Intermediate 75 33 1.19 0.85-1.66  0.31 1.24 0.88-1.76 0.22
    High 75 33 1.87 1.33-2.62  <0.001 1.62 1.11-2.35 0.01
CDC2 mRNA
Continuous variable 230 98 1.53 1.29-1.81   <0.001 1.54 1.27-1.87  <0.001
    Low 77 34 1.00 1.00
    Intermediate 77 33 1.53 1.09-2.13 0.01 1.52 1.07-2.15 0.02
    High 76 33 2.07 1.47-2.90  <0.001 2.05 1.42-2.98   <0.001
miR-26a & CDC2
    miR-26a 230 98 0.22 0.09-0.52  <0.001 0.27 0.11-0.65 0.004
    CDC2 230 98 1.38 1.15-1.65 0.001 1.47 1.20-1.79  <0.001
Univariate analysis Multivariate analysis*
Factor of base model N % HR 95% CI P HR 95% CI   P
TA B L E 2. (continued)
*The multivariate analysis is stratified for menopausal status
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PAT H WAY A N A LY S I S  F O R M I R-26A A N D E Z H2
In an exploratory pathway analysis with GTA, we evaluated 109 KEGG/BioCarta 
biological pathways and 10,520 mRNAs for differentially expressed pathways and 
genes. GTA identified only two pathways which significantly correlated with miR-26a, 
and 10 pathways with EZH2 mRNA expression (Table 3). The cyclins and cell cycle 
regulation pathway, and genes CCNE1 and CDC2 were the only overlapping pathway and 
genes between miR-26a and EZH2 that contributed significantly (Figure 2). Increased 
expressions of CCNE1 and CDC2 were observed in samples with low miR-26a levels and 
in samples with high EZH2 levels.
At risk:
79
78
78
23
28
44
8
7
24
3
4
19
0
25
50
75
100
TTP in months0 12 24 36
C
um
ul
at
iv
e 
pe
rc
en
ta
ge
miR-26a
Expression Levels:
Low 
Intermediate
High 
Logrank trend P <.001
At risk:
79
78
78
43
25
27
23
12
4
17
8
1
0
25
50
75
100
TTP in months
0 12 24 36
C
um
ul
at
iv
e 
pe
rc
en
ta
ge
EZH2
Expression Levels:
Low 
Intermediate
High 
Logrank trend P <.001
Logrank P <.001
At risk:
76
75
75
40
30
24
21
14
4
15
10
1
0
25
50
75
100
TTP in months0 12 24 36
C
um
ul
at
iv
e 
pe
rc
en
ta
ge
Expression Levels:
Low 
Intermediate
High 
CCNE1
Logrank P <.001
At risk:
77
77
76
41
27
23
21
11
4
16
6
2
0
25
50
75
100
TTP in months0 12 24 36
C
um
ul
at
iv
e 
pe
rc
en
ta
ge
Expression Levels:
Low 
Intermediate
High 
CDC2
F I G U R E 1. Kaplan-Meier curves of TTP as a function of miR-26a, EZH2, CCNE1 and CDC2 expression 
levels. Patients were evenly divided into three groups according to their expression levels. Curves were 
generated as function of low, intermediate, and high miR-26a, EZH2, CCNE1 and CDC2 expression levels. 
Patients at risk at different time points are indicated.
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To confirm this exploratory analysis, the predictive value of CCNE1 and CDC2 was 
evaluated by qRT-PCR. The median and interquartile mRNA levels were 0.03 and 0.03 
for CCNE1 (N = 226), and 9.94 and 7.11 for CDC2 (N = 230), respectively. The mRNA 
levels of CCNE1 and CDC2 correlated with each other (r
s
 = 0.44, P < 0.001) and showed 
a positive association with EZH2 mRNA levels (r
s
 = 0.45 and r
s
 = 0.57, for both P < 0.001) 
and an inverse relation with miR-26a (r
s
 = −0.44 and r
s
 = −0.30, respectively, for both 
P ≤ 0.001). The ER and PgR mRNA expression levels showed an inverse correlation with 
those of CCNE1 (r
s
 = −0.14, P = 0.03 and r
s
 = −0.24, P < 0.001) and CDC2 (r
s
 = −0.07, 
P = 0.32 and r
s
 = −0.27, (P < 0.001). Expression levels of CDC2 and CCNE1 were not 
related with age, menopausal status, tumor grade, tumor size, or nodal status (Table 
1). In univariate analysis, increasing mRNA levels of CCNE1 were related to treatment 
failure (OR = 0.67, P = 0.005; Supplemental Table 2) and shorter TTP (HR = 1.27, P < 0.001; 
Table 2). In addition, increased expression of CDC2 was associated with poor clinical 
benefit (OR = 0.45, P < 0.001) and TTP (HR = 1.53, P < 0.001). In multivariate analysis, 
CCNE1 and CDC2, when added separately to the base model, were both independent 
from traditional predictive factors for their association with clinical benefit and TTP 
(Supplemental Table 2; Table 2). Categorized into thirds, Kaplan–Meier survival analysis 
showed that patients with higher mRNA levels of CCNE1 and CDC2 had a shorter TTP 
(Figure 1). Compared to the group with low tumor levels of CCNE1, those with high 
levels of CCNE1 had an OR of 0.33 (P = 0.002) and a HR of 1.87 (P < 0.001), respectively. 
Patients with high tumor levels of CDC2 had an OR of 0.28 (P < 0.001) and even a HR 
of 2.07 (P < 0.001), respectively, compared with those with low tumor CDC2 levels. 
These results indicate that an activated cell cycle regulation pathway through increased 
expressions of CCNE1 and CDC2 is significantly associated with poor outcome on 
tamoxifen therapy. Moreover, two additional cyclins and cell cycle regulation pathway 
genes (E2F1 and CCNB1) were evaluated, next to CCNE2 (not in GTA because it failed 
quality control), to confirm the involvement of the cell cycle regulation pathway in 
the response to tamoxifen. All three genes showed a significant association with TTP 
in uni- and multivariate analyses as continuous variables, i.e., E2F1 had a HR of 1.38 
(P = 0.013), CCNE2 had a HR of 1.38 (P < 0.001) and CCNB1 had a HR of 1.86 (P < 0.001) 
(Supplemental Table 3).
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Global Testing Approach - KEGG/BioCarta Pathway Analysis
Genes Tested P Genes significant (z-score >1.96)
miR-26a associated pathways
Cyclins and Cell Cycle Regulation 18 0.008 CCNE1,CDK7,CDKN2D,CDC2
TPO Signaling Pathway 18 0.018 HRAS,THPO,RASA1
EZH2 associated pathways
Cell Cycle G1 S Check Point 21 0.002
TGFB1,E2F1,ATM,SMAD4,CDC2, 
CCNE1,SKP2,ATR,ABL1
Role of BRCA1  BRCA2 and  
ATR in Cancer Susceptibility
20 0.003
FANCG,RAD51,ATM,FANCA,CHEK1, 
ATR,RAD9A,NBN,FANCC,BRCA1
Cyclins and Cell Cycle Regulation 18 0.005 CCNB1,E2F1,CDC2,CCNE1,CCND2
ATM Signaling Pathway 16 0.011
RAD51,ATM,NFKB1,CHEK1, 
GADD45A,ABL1,NBN,BRCA1
Spliceosomal Assembly 15 0.018
SNRPD1,SNRPG,SNRPF,U2AF1, 
SFRS2,U2AF2,SNRPE,SNRPA1
Cytokines and Inflammatory Response 15 0.019 TGFB1,HLA-DRA,IL15,CD4,CSF1,LTA
Cell Cycle G2 M Checkpoint 21 0.025
CCNB1,ATM,CDC2,PLK1,CHEK1, 
ATR,WEE1,GADD45A,BRCA1
ADPRibosylation Factor 15 0.029
KDELR1,ARFGAP1,DDEF2, 
PSCD4,COPA,CENTD1
Hypoxia and p53 in the  
Cardiovascular system
16 0.038 ATM,FHL2,CSNK1A1,GADD45A
p38 MAPK Signaling Pathway 32 0.044
TGFB1,CREB1,DAXX,CDC42,DDIT3, 
MAPKAPK5,HMGN1,HRAS,PLA2G4A
TA B L E 3. miR-26a and EZH2 related pathways and genes. 
In 65 breast cancer samples, for which whole-genome mRNA expression profiles were available, pathways and 
genes were identified with the GTA of 109 KEGG/BioCarta biological pathways and 10,520 mRNAs. Only those 
pathways and their genes are indicated, which show a significant relationship with miR-26a and EZH2 expression 
levels. The number of genes tested is indicated per pathway. The P-values determine the significance of the 
association after correction for multiple testing and resampling.
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M U LT I VA R I AT E A N A LY S I S  O F M I R-26A , E Z H2, C C N E1, A N D C D C2
To determine a set of predictive biomarkers, the expression of miR-26a levels and of 
EZH2, CCNE1, and CDC2 mRNA levels were added simultaneously in a multivariate 
analysis to evaluate their relationship with TTP. Both CCNE1 and EZH2 mRNA levels lost 
their predictive value when included with miR-26a and CDC2, defining miR-26a and 
CDC2 levels as the set of predictive biomarkers associated with TTP. The HRs in the 
simultaneous analysis of miR-26a and CDC2 as continuous variables were 0.22 (P < 0.001) 
and 1.38 (P = 0.001), respectively (Table 2). Their contribution to the multivariate base 
model was independent from traditional predictive factors included in the model (Table 
2). Converting miR-26a and CDC2 levels into a score followed by categorization into 
thirds resulted in a HR of 1.90 for the group with intermediate scores and a HR of 3.03 
for the group with highest scores (see Supplemental Figure 1 for Kaplan–Meier survival 
curves).
EZH2*
*
*
*
*
miR-26a
*
*
*
*
TFDP1
CCNB1
CDC2
CDKN1A
RB1
CCND1
E2F1
CDK4
CDK7
CDKN1B
CCNE1
CCNH
CCND2
CCNA1
CDKN2D
CDKN2A
CDKN2C
CCND3
F I G U R E 2. Global testing approach (GTA) result of the cyclins and cell cycle regulation pathway. This 
pathway was overlapping between miR-26a- and EZH2-related pathways. Red bars illustrate high expres-
sion levels of the pathway gene in samples with high miR-26a or EZH2 levels, whereas green bars indicate 
high expression levels in samples with low miR-26a or EZH2 levels. The number of vertical markers in a bar 
indicates the significance and the height of a bar the contribution of a gene to the pathway. The continuous 
line shows the threshold for significance; bars with more than two lines above this border are significantly 
(P < 0.05) differentially expressed genes within the pathway, which are also indicated with an asterisk. Only 
CCNE1 and CDC2 showed significant associations with both miR-26a and EZH2.
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D I S C U S S I O N
This study shows that miR-26a levels associate with outcome of metastatic disease 
on first-line tamoxifen monotherapy, whereas miR-101 does not. Patients with clinical 
benefit have high miR-26a and low EZH2 mRNA levels. Additionally, only the cell cycle 
regulation pathway with its genes CCNE1 and CDC2 overlap between miR-26a and EZH2 
linked molecular pathways. These two genes also correlate with treatment outcome. 
The miR-26a and CDC2 levels that regulate EZH2 levels and activity were identified as a 
set of predictive biomarkers for treatment outcome.
Overexpression of EZH2 was observed in prostate and breast cancer in which it was 
associated with aggressive clinical behaviour (16, 17). We demonstrated that decreased 
EZH2 mRNA levels were predictive for favorable outcome on tamoxifen in metastatic 
breast cancer (4). Both miR-26a and miR-101 repress EZH2 expression (10, 11, 18). 
Although miR-26a and miR-101 expressions correlate with EZH2 levels in our current 
study, only miR-26a had a significant association with outcome on tamoxifen. Expression 
of miR-26a is repressed by estrogens in vitro and is induced in breast cancer patients 
treated with anti-estrogen neoadjuvant therapy (19) whereas miR-101 expression is 
upregulated by androgen stimulation (18), but is not regulated by estrogens (19, 20). 
The fact that androgens stimulate miR-101 expression, whereas estrogens repress miR-
26a expression needs to be elucidated, but suggests that EZH2 repression by miR-26a 
and miR-101 might be tissue as well as hormone dependent. That only miR-26a and 
not miR-101 has a relation with treatment outcome is because these miRs target many 
other genes. Of the genes predicted to be targets of miR-26a (1,012 targets) and miR-101 
(1,198 targets), only a few (66 genes, including EZH2) are targeted by both miRs (data 
not shown). We cannot exclude another relevant gene for endocrine therapy outcome 
as specific miR-26a target which is not targeted by miR-101. This certainly needs further 
exploration but is not within the scope of the current study.
Our pathway analyses identified only the cell cycle regulation pathway to be correlated 
with miR-26a and EZH2 levels. The genes CDK7, CCNE1, CDC2, and CDKN2D for miR-26a 
and CCNB1, CCNE1, CDC2, CCND2, and E2F1 for EZH2 were differentially expressed within 
this pathway. CCNE2 and CDK2, important genes in this pathway, were not included in 
the analyses because their probes failed quality control. The association of EZH2 with 
cell cycle regulation is extensively reported (21, 22). Moreover, the Targetscan algorithm 
predicted cyclins D2, E1, and E2 (CCND2, CCNE1, and CCNE2), and cyclin dependent 
kinase 6 (CDK6), which all play a role in the G1–S transition, as miR-26a targets (23). 
Finally, estrogens that regulate G1 cyclin-dependent kinases (24) and tamoxifen has a 
cytostatic effect on breast cancer cells and arrest them in G0/G1 phase (25).
Based on our study, CCNE1 and CDC2 were the only overlapping genes for miR-26a and 
EZH2. We have shown earlier Cyclin E as prognostic marker for lymph node-negative 
breast cancer (26). Now, we show that in the metastatic disease setting, high CCNE1 
mRNA levels correlate with poor outcome on tamoxifen. In concordance, patients 
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with high CCNE protein levels had less benefit from tamoxifen in an adjuvant setting 
(27), and the overexpression of low molecular weight CCNE isoforms was associated 
with resistance to fulvestrant (28) and letrozole (29). CCNE1 is a kinase and regulatory 
subunit of CDK2 that accumulates at the G1–S phase (30).
The second gene, CDC2 [also known as cyclin-dependent kinase 1 (CDK1)], correlated 
with miR-26a and EZH2 and treatment outcome. CDC2 is a mitotic cyclin-dependent 
Ser/Thr protein kinase and the master controller of mammalian cell–cycle regulation 
which is activated by CDK7 phosphorylation (31, 32). At present, expression of CDC2 
has been linked to response to tamoxifen in cell line models (33), and we now show an 
8-month delay in disease progression in patients with the lowest CDC2 mRNA levels 
compared with those with the highest expression levels. Thus, the status of the cell 
cycle regulation pathway, specified by CCNE1 and CDC2 levels but also confirmed by 
CCNB1, CCNE2, and E2F1, seems to play a role in how the metastasis will respond to 
first-line tamoxifen therapy.
Multivariate analysis of miR-26a, EZH2, CCNE1, and CDC2 to determine their associations 
with treatment outcome showed that the predictive values of EZH2 and CCNE1 levels 
were less significant than those of miR-26a and CDC2. Interestingly, not only miR-26a 
but also CDC2 have a physical interaction with EZH2 (Figure 3), although with opposite 
effects on EZH2 functioning. As mentioned, miR-26a binds to the 3'-UTR of EZH2 and 
inhibits transcription of EZH2. On the other hand, CDC2 (CDK1) and CDK2 have been 
shown to activate EZH2 by phosphorylation of its Thr350 residue (34-36). This Thr350 
phosphorylation is necessary for EZH2 recruitment at target loci and for maintenance 
of H2K27me3 levels (34). Since EZH2 expression and activity are higher in proliferating 
rather than differentiating cells (22), both miR-26a and CDC2 may define endocrine-
responsive or -resistant phenotypes of ER-positive breast cancer cells through their 
modulation of EZH2 levels and activity. In ER-negative breast cancer cells, EZH2 
knockdown results in increased CDC2 and pCDC2 protein expressions (37), but recently 
it was suggested that EZH2 in ER-negative tumors functions as a transcriptional activator 
but acts as a repressor in ER-positive tumors (38).
Therapeutics that can modulate miR-26a, CDC2, or EZH2 activity might be an attractive 
strategy for patients resistant to tamoxifen to resensitize them for anti-estrogen 
treatment. Systemic administration of miR-26a with adeno-associated virus in mouse 
models results in decreased cancer cell proliferation and suppressed tumor progression 
(23). Preclinical evaluation of CDC2 and CDK2 inhibitors revealed G2/M arrest and cell 
death in both anti-estrogen-sensitive and resistant cells (33). Hydrolase inhibitors, such 
as DZNep, induce EZH2 depletion in breast cancer cell lines and result in cell cycle arrest 
and apoptosis (39, 40). At the end, all these treatments target EZH2 levels and activity. 
We hypothesize that patients resistant to tamoxifen with low miR-26a and high CDC2 
and EZH2 levels in their primary tumor may benefit from these treatment strategies in 
order to overcome tamoxifen resistance.
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In summary, we have shown that high miR-26a and low EZH2 mRNA levels associate 
with clinical benefit and prolonged TTP. The cell cycle regulation pathway and its genes 
CCNE1 and CDC2 correlate significantly with miR-26a and EZH2 levels and with outcome 
on tamoxifen. Multivariate analysis revealed miR-26a and CDC2 as sets of biomarkers 
to predict outcome on tamoxifen in metastatic breast cancer. Our findings might help 
one to improve the identification of individual patients resistant to tamoxifen, who may 
benefit from therapeutics that block EZH2 expression and activity.
F I G U R E 3.  The regulatory network of EZH2.  A model for the modulation of the expression and activity 
of EZH2 based on our results and available data in the literature. Binding of miR-101 and miR-26a to the 
3′-UTR blocks transcription of EZH2 (10, 11). Our data linked expression levels of miR-26a and EZH2 by the 
GTA of pathways to the cyclins and cell cycle regulation pathway with two significant genes [CCNE1 and 
CDC2 (CDK1)]. CDC2 (CDK1) and CDK2 activate EZH2 through the phosphorylation of its Thr350 residue (34-
36). Our study shows that, in breast cancer, miR-26a and CDC2 might be involved in the regulation EZH2 
expression and activity, respectively, and as a result associate with response to tamoxifen.
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CHAPTER 4
High protein expression of EZH2 is related to unfavorable 
outcome to tamoxifen in metastatic breast cancer 
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A B S T R A C T
B AC KG R O U N D 
Metastatic breast cancer (MBC) is a highly heterogeneous disease with great differences 
in outcome to both chemo- and endocrine therapy. Better insight into the mechanisms 
underlying resistance is essential to better predict outcome to therapy and to obtain 
a more tailored treatment approach. We have previously described that increased 
mRNA expression levels of Enhancer of Zeste homolog (EZH2) are associated with worse 
outcome to tamoxifen therapy in MBC. Here, we explored whether this is also the case 
for EZH2 protein expression. 
PAT I E N T S A N D M E T H O D S 
A tissue microarray (TMA) was created using formalin-fixed, paraffin-embedded 
estrogen receptor (ER)-positive primary breast tumor tissues of 250 MBC patients 
treated with first-line tamoxifen. Quantity and intensity of EZH2 expression were 
determined by immunohistochemistry (IHC) and both were used to generate and group 
scores according to a previously described method for scoring EZH2. 
R E S U LT S
In total, 116 tumors (46%) were considered to be EZH2 positive. The presence of EZH2 
protein expression was significantly associated with progression-free survival (PFS) 
in both univariate [hazard ratio (HR) 1.51, 95% confidence interval (CI) 1.17–1.97, P = 
0.002] and multivariate analysis including traditional factors associated with tamoxifen 
outcome (HR 1.41, 95% CI 1.06–1.88, P = 0.017). Considering quantity irrespective of 
intensity, tumors with >50% EZH2-positive cells had the worst PFS (HR 2.15, 95% CI 
1.42–3.27, P < 0.001), whereas intensity alone did not show a significant association 
with PFS. Application of other methods of scoring EZH2 positivity resulted in a similar 
significant association between the amount of EZH2 positive cells and PFS. 
C O N C L U S I O N 
In addition to EZH2 mRNA levels, these results suggest that protein expression of EZH2 
can be used as a marker to predict outcome to tamoxifen therapy. This provides new 
rationale to explore EZH2 inhibition in the clinical setting and increases the possibilities 
for a more personalized treatment approach in MBC patients. 
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I N T R O D U C T I O N 
For already more than 30 years, both primary and metastatic breast cancer (MBC) 
patients with estrogen receptor (ER)-expressing tumors greatly benefit from endocrine 
therapies such as tamoxifen. However, outcome to tamoxifen differs considerably 
between MBC patients with ~30% not benefitting at all while virtually all patients who 
initially benefit eventually develop progressive disease due to acquired resistance. 
Consequently, there is a high need to get more insight into the factors causing resistance 
to tamoxifen in order to develop methods to overcome resistance and to identify 
biomarkers to obtain a more personalized treatment approach. Numerous factors have 
already been revealed to account for resistance to endocrine therapy including loss 
of ER expression (1-3), overexpression of the HER2 receptor (4), and hyperactivation 
of the phosphatidylinositol 3-kinase (PI3K) pathway (5), and have subsequently led to 
the development of new targeted therapies (6, 7). Additionally, we have previously 
identified overexpression of EZH2 as a potential factor involved in therapy resistance 
(8, 9). EZH2, being a histone methyltransferase that mediates di- and trimethylation of 
lysine residue 27 on histone 3 (H3K27), comprises the catalytic subunit of the Polycomb 
Repressor Complex 2 (PRC2) and belongs to the Polycomb group (PcG) proteins. These 
proteins mainly act as transcriptional repressors of multiple genes involved in embryonic 
development, cell differentiation, and carcinogenesis (10-12). EZH2 has been found to 
play a pivotal role in the tumorigenic process since its expression has been shown to be 
upregulated in several malignancies including prostate cancer (13), lymphomas (14, 15), 
urogenital tract tumors (16-18), and breast cancer (19). Concerning the latter, increased 
expression of EZH2 protein has been associated with a high histological grade and 
worse survival suggesting its promising role as a prognostic biomarker for aggressive 
breast cancer (18-21). Additionally, EZH2 has been proposed as a therapeutic target due 
to its association with tumor aggressiveness in several tumor types (18-23). Recently, 
small-molecule inhibitors of EZH2 histone methyltransferase activity have showed to 
decrease global H3K27me3 levels resulting in reactivation of silenced target genes and 
inhibition of proliferation, particularly in lymphomas with EZH2-activating mutations 
(24). In breast cancer, we have previously shown that low expression of EZH2 mRNA 
was associated with a favorable response to tamoxifen treatment in MBC patients as 
well as, using in vitro silencing techniques, in a preclinical setting, which suggests EZH2 
as a new potential therapeutic target (9). However, this study was carried out on mRNA 
expression levels of EZH2 while the predictive value of EZH2 on protein expression level 
has not yet been studied. In the current study, we explored the association between 
protein expression of EZH2 and PFS in tamoxifen-treated MBC patients.
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P A T I E N T S  A N D  M E T H O D S
 
E T H I C S S TAT E M E N T
This retrospective study, in which coded tumor tissues were used, has been approved 
by the medical ethics committee of the Erasmus MC Rotterdam, The Netherlands (MEC 
02.953). Informed consent was not required. The study was carried out in accordance 
with the Code of Conduct of the Federation of Medical Scientific Societies in The 
Netherlands (http://www.fmwv.nl) and has been reported, wherever possible, following 
the REMARK guidelines (25).
PAT I E N T S A N D T U M O R T I S S U E S
Patients with primary operable ER-positive breast cancer between 1985 and 1998 and 
from whom a formalin-fixed, paraffin-embedded primary breast tumor tissue specimen 
was available were included in the study provided that they subsequently developed 
MBC treated with first-line tamoxifen and detailed clinical follow-up data were available. 
In order to be included for final analysis, tumor specimens needed to have sufficient 
tumor material to obtain three independent cores. Central pathology review of the 
primary tumor was carried out by a breast pathologist (CvD), which included histologic 
subtype according to the World Health Organization (WHO) and histologic grade defined 
according to the modified Bloom–Richardson score based on the percentage of tubule 
formation, nuclear pleomorphism, and mitotic activity (26). After applying the inclusion 
criteria of having three independent tumor cores per patient, tumor core biopsies on a 
breast tissue microarray (TMA) (for details see supplementary materials and methods) 
for 250 of the 316 available patients were selected for further analyses. Of these 250 
patients, 106 (42%) underwent breast conserving surgery and 144 modified mastectomy 
(58%). Median follow-up time was 98 months (range 9–222 months). One hundred 
fifty-three patients (61%) did not receive adjuvant systemic therapy, while 77 (31%) 
were treated with adjuvant chemotherapy and 20 (8%) had metastatic disease upon 
diagnosis. None of the patients received adjuvant hormonal therapy. Response to first-
line tamoxifen treatment, as assessed by RECIST criteria (version 1.1; http://www.eortc.
be/recist/), was observed in 156 patients (62%) of whom 7 had complete response (CR; 
3%), 42 a partial response (PR; 17%), and 107 (43%) stable disease for more than 6 
months. Ninety-four patients (38%) did not have clinical benefit.  
PFS was used as end point with PFS defined as the time elapsed between start of 
tamoxifen therapy and the first detection of disease progression or death, whatever 
came first during treatment. Detailed clinicopathological information for these 250 
patients is provided in Supplementary Table S1. 
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I M M U N O H I S T O C H E M I C A L E VA L UAT I O N
EZH2 staining was interpreted and recorded independently by two experienced observers 
(EAR and AMT) in a blinded manner. Expression was assessed using a combination of 
both intensity (0 no staining, 1 weak, 2 moderate, and 3 strong) and proportion of cells 
stained for EZH2 (1 ≤10%, 2 11%–50%, and 3 ≥50%) according to the method described 
previously by Bachmann et al. (18). Scores were multiplied to a maximum of 9 and a 
cutoff of >3 was considered as EZH2 positive.
DATA A N A LY S I S  A N D S TAT I S T I C S
Statistical analyses were done with the STATA statistical package, release 12.0 (STATA 
Corp., College Station, TX). The relationship of EZH2 expression with patient and tumor 
characteristics was investigated using Pearson’s χ2 test or Fisher’s exact when expected 
numbers were too small. The Cox proportional hazards model was used to compute 
the hazard ratio (HR) with the 95% CI in the analysis of PFS. In multivariate analysis, 
logistic and Cox regression analysis were used to determine whether the intensity and 
quantity of EZH2 expression had predictive value and were independent when added to 
the base model of traditional factors. Survival curves were generated using the Kaplan–
Meier method and a log-rank test was used to test for differences between survival 
curves. When more than 2 curves were compared a log-rank test for trend was used for 
ordered categories. All P values were two-sided and P < 0.05 was considered statistically 
significant.
 
R E S U L T S
 
Q UA N T I T Y A N D I N T E N S I T Y O F E Z H2 P R O T E I N E X P R E S S I O N
EZH2 expression was primarily identified in the nucleus, as reported previously (14, 19, 21, 
27). Fifty-one of the 250 tumors (20%) did not show any EZH2 expression (Supplementary 
Table S2). Together with the 66 tumors (26%) that showed weak staining irrespective of 
the percentage of stained cells and the 17 tumors (7%) that showed moderate staining 
in <10% of the cells these were classified as EZH2 negative. The 116 remaining tumors 
(46%) were ranked as EZH2 positive, 93 showed moderate staining in >10% of the cells 
while 23 were strongly stained (Supplementary Table S2, Figure 1).
A S S O C I AT I O N B E T W E E N E Z H2 P R O T E I N E X P R E S S I O N W I T H 
C L I N I C O PAT H O L O G I C A L C H A R AC T E R I S T I C S
There was no significant association between EZH2 protein expression and menopausal 
status, tumor histology, progesterone receptor (PgR) status, dominant site of relapse 
(DSR), and disease-free interval (DFI) (Supplementary Table S1). A significant positive 
association was observed with age, the amount of lymph nodes involved at initial 
diagnosis, histologic grade, and HER2/neu status.
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A S S O C I AT I O N O F E Z H2 P R O T E I N E X P R E S S I O N W I T H P F S
In univariate analysis, the presence of EZH2 protein expression was significantly 
associated with PFS (HR 1.51, 95% CI 1.17–1.97, P = 0.002) (Table 1 and Figure 2A). 
When considering intensity and quantity separately, intensity showed no relation with 
PFS (Figure 2B). Quantity was associated with PFS with tumors with >50% EZH2-positive 
cells (N = 31) having the poorest PFS (HR 2.15, 95% CI 1.42–3.27, P < 0.001) (Table 1 
and Figure 2C). In multivariate analysis, when corrected for traditional predictive factors 
including age, menopausal status, adjuvant therapy, DSR, DFI, PgR, and HER2/neu status, 
tumors with EZH2 protein expression were significantly associated with poor PFS (HR 
1.41, 95% CI 1.06–1.88, P = 0.017) compared with tumors that scored negative for EZH2 
protein expression. The overall survival data showed a HR of 1.31 with 95% CI 0.99–1.73, 
P = 0.055.
F I G U R E 1. Representative tissues with IHC staining of EZH2 protein. Strong (A), moderate (B), and 
weak (C) nuclear staining in >50% of the tumor cells. (D) Strong nuclear staining in 21%-30% of the cells. (E) 
Moderate nuclear staining in 6-10% of the cells. (F) Negative staining of EZH2 protein.A, B, and D obtained a 
score of >3 and were classified as EZH2 positive; C, E and F were considered to be EZH2 negative.
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Factor of base model Univariate analysis Multivariate analysis
N HR 95% CI P HR 95% CI P
Age (years)
    ≤40 14 1.00 1.00
    41-55 76 1.12 0.62-2.02 0.710 1.13 0.61-2.11 0.699
    56-70 92 0.69 0.38-1.23 0.208 0.57 0.27-1.22 0.150
    >70 68 0.54 0.29-0.99 0.046 0.46 0.20-1.02 0.056
Menopausal status
    Premenopausal 64 1.00 1.00
    Postmenopausal 186 0.64 0.48-0.85 0.003 1.12 0.70-1.78 0.644
Adjuvant therapy
    None  173*  1.00 1.00
    Chemotherapy 77 1.38 1.04-1.82 0.023 0.97 0.69-1.37 0.853
Disease-free interval (years)
    ≤1 38 1.00 1.00
    1-3 118 0.86 0.59-1.25 0.430 0.71 0.48-1.07 0.105
    >3 94 0.71 0.48-1.06 0.092 0.60 0.39-0.93 0.023
Dominant site of relapse
    Soft tissue 25 1.00 1.00
    Bone 127 1.51 0.93-2.43 0.093 1.41 0.87-2.31 0.166
    Viscera 98 1.97 1.20-3.24 0.007 2.12 1.28-3.52 0.004
PgR†
    Negative 64 1.00 1.00
    Positive 188 0.88 0.65-1.17 0.376 0.80 0.59-1.08 0.146
HER2/neu†
    Negative 204 1.00 1.00
    Positive 46 1.09 0.78-1.53 0.620 0.94 0.66-1.35 0.739
Factors analyzed  Additions to the base model
EZH2 protein 250 1.51 1.17-1.97 0.002 1.41 1.06-1.88 0.017
    Intensity
        Negative 51 1.00
        Weak 66 0.90 0.61-1.32 0.581
        Moderate 110 1.28 0.90-1.81 0.171
        Strong 23 1.34 0.81-2.23 0.257
TA B L E 1.  Cox uni- and multivariate analysis for PFS of EZH2 protein expression levels for the product of 
intensity and quantity and separate analysis of intensity and quantity in 250 ER-positive tumors from 
patients  with MBC treated with first-line tamoxifen therapy.
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F I G U R E 2.
A. Kaplan-Meier curve of PFS as a function 
of EZH2. Patients were divided into two 
groups according to their expression 
levels of EZH2 in which EZH2 positivity was 
defined as >3 based on the scores of both 
intensity and quantity. Patients at risk at 
different time points are indicated.
Green: EZH2 negative; Blue: EZH2 positive. 
B. Kaplan-Meier curve of PFS as a function 
of intensity of EZH2. Patients were 
divided into four groups according to the 
intensity of EZH2 staining in their primary 
tumor tissue specimen. Patients at risk at 
different time points are indicated.
Green: no staining; Blue: weak; Red: 
moderate; Orange: strong. 
C. Kaplan-Meier curve of PFS as a function 
of quantity of EZH2. Patients were divided 
into three groups according to the amount 
of EZH2-positive cells in their primary 
tumor tissue specimen. Patients at risk at 
different time points are indicated.
Green: <10%; Blue: 11-50%; Red: >50%.
Quantity (%)
        <10% 110 1.00 1.00
        11-50 109 1.46 1.10-1.92 0.008 1.45 1.07-1.96 0.017
        >50 31 2.15 1.42-3.27  <0.001 2.03 1.30-3.16 0.002
* Combination of no adjuvant therapy (N = 153) and metastatic disease at diagnosis (N =20)
† As retrieved from TMA
Factor of base model Univariate analysis Multivariate analysis
N HR 95% CI P HR 95% CI P
TA B L E 1. (continued)
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D I S C U S S I O N
In the present study, we demonstrate the association between high levels of protein 
expression of EZH2 and poor outcome to endocrine therapy in ER-positive MBC patients 
treated with first-line tamoxifen. To our best knowledge, this is the first study that shows 
a relationship between EZH2 protein expression and outcome to tamoxifen therapy in 
MBC. These results are concordant with our previous study showing a similar association 
based on EZH2 mRNA levels (9). There, we also found an association between high EZH2 
mRNA expression and lower clinical benefit. In this study, we could establish similar 
results on protein level with an association between EZH2 protein expression and a 
worse response rate, defined as CR and PR after initiation of therapy (odds ratio 0.17, 
95% CI 0.10–0.29, P < 0.001; data not shown). Of the 250 patients in this study, we had 
EZH2 mRNA data available of 66 patients (26%). In this small subgroup, we observed a 
significant positive correlation between presence of EZH2 protein and EZH2 mRNA (P = 
0.04) (Supplementary Figure S1). 
EZH2 has previously been suggested to bear prognostic value in several types of cancer. 
By using the same technique of TMAs, Alford et al. reported higher EZH2 expression in 
invasive breast carcinomas that relapsed after primary diagnosis compared with those that 
did not, regardless of received systemic adjuvant therapy (27). As expected in our study 
of ER-positive tumors, most of the tumors were classified as moderately differentiated. 
The poorly differentiated tumors were more often EZH2 positive compared with the well 
and moderately differentiated. In accordance with our findings, an association between 
high EZH2 expression and high histologic grade has been demonstrated multiple times 
despite the use of different methods to classify the differentiation of tumors (18, 20, 21). 
Importantly, the assessment of scoring protein expression is semiquantitative and 
several methods exist. One of the most widely used methods to evaluate nuclear 
immunostaining is the Allred score in which quantity and intensity are also involved but 
quantity is composed of six categories (28). This complex method is convenient to use 
for commonly expressed factors as ER, EGFR, and PgR (29-31), but it is difficult to divide 
less frequently expressed factors such as EZH2 into the six different quantity categories. 
Since there is no golden standard for scoring EZH2, we used the method of Bachmann 
et al. (18) in which the product of intensity and quantity is used and a cutoff value of >3 
to quantify tumors as EZH2 positive. However, other studies on EZH2 protein expression 
in breast cancer used different criteria. Kleer et al. (19) and Alford et al. (27) only used 
quantity when scoring 194 and 480 invasive carcinomas, respectively, and classified 
tumors with >25% of nuclei staining with any intensity as EZH2 positive. Raaphorst et al. 
(21) also judged only quantity without a cutoff for positivity in 25 breast tumors ranging 
from precursor lesions to invasive tumors. In our study, adapted application of the scores 
as used by Kleer et al. (19), Alford et al. (27), and Raaphorst et al. (21) also resulted in 
an association between EZH2 protein expression and PFS despite of the difference in 
the number of tumors that were classified as EZH2 positive when applying the different 
methods (116 tumors using the method of Bachmann et al. versus 105 tumors using 
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Kleer et al. and Alford et al., respectively) (Supplementary Figure S2A and B and Tables 
S3A and B and S4). Due to lack of standardized methods and to have a validation, we have 
also applied the method of Chan et al. to validate the different methods of EZH2 scoring 
(32). This method has been used to classify the expression of the seven in absentia 
homolog 2 (SIAH2) protein in breast tumors and uses a sum of intensity and quantity 
with a cutoff value of >2 to quantify tumors as SIAH2 positive. Application of this method 
to EZH2 scoring resulted in a similar association between EZH2 protein expression and 
PFS (Supplementary Figure S2C and Tables S3C and S4). Thus, the relation seems to be 
independent of the method of scoring, as long as the amount proportion of stained 
cells is included since intensity by itself did not associate with PFS, whereas quantity did 
according to different methods. 
Considering downstream effects of EZH2, we have previously shown that silencing of 
EZH2 in the ER-positive cell line MCF7 leads to a higher expression of ER and increased 
sensitivity to antiestrogen treatment (9). The present study confirms this association 
between EZH2 and sensitivity to tamoxifen by demonstrating the association between 
high EZH2 protein expression and poor outcome to first-line tamoxifen treatment in MBC 
patients. Therefore, adding EZH2 inhibition to antiestrogen therapies is an approach 
worthwhile to explore in MBC and EZH2 expression might be the biomarker to select 
patients who benefit most. 
Recently, several EZH2 inhibitors have been developed and preclinically tested in multiple 
types of cell lines and xenografts (33, 34). Both EPZ-6438 (E7438) and GSK126 as selective 
small-molecule inhibitors of histone methyltransferase activity have shown promising 
results in both small-cell lung cancer (SCLC) cell lines and malignant rhabdoid tumors 
xenografts. The most convincing preclinical results have been obtained in lymphomas, 
which often bear EZH2-activating mutations (24). This has led to the recent start of a 
phase I/II trial in patients with EZH2-mutated B-cell lymphomas (www.clinicaltrials.gov, 
NCT01897571). EZH2 mutations have not yet been described in other types of tumors. 
In conclusion, we demonstrate that high EZH2 protein levels are associated with 
unfavorable outcome to tamoxifen treatment in MBC patients. We explored multiple 
methods for scoring EZH2 protein levels leading to a preference for the use of quantity 
or the sum or product of intensity and quantity over intensity alone due to their 
significant association with PFS. The association of EZH2 expression, both at the mRNA 
and the protein level, with outcome to tamoxifen in MBC and the previous finding that 
downregulation of EZH2 increases ER expression and subsequently, sensitivity to anti-
estrogen treatment in preclinical models renders EZH2 an attractive target to explore in 
combination with anti-estrogen treatment in ER-positive breast cancer. Furthermore, its 
assessment could be used to categorize patients according to their likelihood to benefit 
from tamoxifen and if confirmed, could allow a better selection of patients for tamoxifen 
and a more personalized treatment approach. 
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A B S T R A C T
Aromatase inhibitors are the major first-line treatment of estrogen receptor–positive 
breast cancer, but resistance to treatment is common. To date, no biomarkers have 
been validated clinically to guide subsequent therapy in these patients. In this study, 
we mapped the genome-wide chromatin-binding profiles of estrogen receptor α 
(ERα), along with the epigenetic modifications H3K4me3 and H3K27me3, that are 
responsible for determining gene transcription (N = 12). Differential binding patterns 
of ERα, H3K4me3, and H3K27me3 were enriched between patients with good or poor 
outcomes after aromatase inhibition. ERα and H3K27me3 patterns were validated in an 
additional independent set of breast cancer cases (N = 10). We coupled these patterns 
to array-based proximal gene expression and progression-free survival data derived 
from a further independent cohort of 72 aromatase inhibitor–treated patients. Through 
this approach, we determined that the ERα and H3K27me3 profiles predicted the 
treatment outcomes for first-line aromatase inhibitors. In contrast, the H3K4me3 pattern 
identified was not similarly informative. The classification potential of these genes was 
only partially preserved in a cohort of 101 patients who received first-line tamoxifen 
treatment, suggesting some treatment selectivity in patient classification.
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I N T R O D U C T I O N
Breast cancer is the most frequently diagnosed malignancy among women worldwide, 
with annually around 1.4 million new cases and half a million patients who die from the 
disease each year (1). Seventy-five percent of all breast tumors are of the luminal subtype 
and tumor cell proliferation is thought to depend on activity of the estrogen receptor α 
(ERα). Inhibition of ERα by endocrine therapy is therefore a major treatment modality 
for these tumors, either by tamoxifen or the state-of-the-art aromatase inhibitors. 
Although many studies have focused on defining predictive markers for tamoxifen 
resistance, relatively little is known about the molecular determinants of aromatase 
inhibitor response. Such knowledge is essential as intrinsic and acquired resistance 
to treatment is common (2, 3). Whole-genome sequencing analyses on breast tumor 
samples revealed a set of 18 genes to be mutated in patients with breast cancer that 
correlated with differential survival upon aromatase inhibitor treatment (4), including 
PI3K, TP53, MAP3K1, and GATA3. These data were supported by other reports, indicating 
differential gene expression pathways to be enriched in poor versus good outcome 
patients upon aromatase inhibitor treatment (5, 6).
ERα–binding profile assessment in breast cancer cell lines has greatly increased our 
knowledge of hormonal receptor action. ERα rarely binds promoters and most estrogen 
receptor/chromatin interactions occur at distal enhancers (7), which are involved in 
chromatin loop structures to regulate gene expression (8). ERα/chromatin interactions 
require the functional involvement of other proteins, including FOXA1. FOXA1 is one of 
the key luminal-defining transcription factors (9, 10) and acts as pioneer factor for ERα 
by untangling chromatin structures, which enables ERα to bind its targets as shown in 
cell lines (11) and breast tumor samples (12). Other pioneer factors have been described 
for ERα function, including AP-2γ (13) and PBX1 (14), which function in synergy with 
FOXA1 in enabling ERα/chromatin interactions and subsequent activity. These reports 
tightly link ERα action with chromatin structure.
The epigenetic regulation of chromatin structure is a highly complex interplay between 
multiple histone modifiers and their downstream histone modifications, each with their 
intrinsically distinct patterns and functions (15). Two of the best-studied histone marks 
are the repressive trimethylation on lysine 27 of histone 3 (H3K27me3) (16) and the 
activating trimethylation on lysine 4 on histone 3 (H3K4me3) (17). H3K4me3 is found 
enriched at promoter regions (18, 19), whereas H3K27me3 can be found over large 
genomic regions spanning one or more epigenetically silenced genes (20, 21), which is 
directly regulated by the EZH2-driven polycomb repressive complex PRC2 (22).
To test for a possible interplay between differential ERα binding and epigenetic regulation 
of gene activity, we determined the genome-wide chromatin-binding patterns of ERα, 
H3K4me3, and H3K27me3 in primary breast tumor samples. Following relapse, patients 
were treated with an aromatase inhibitor for metastatic disease and time to progression 
(TTP) was correlated with altered ERα/H3K4me3/H3K27me3 binding profiles to identify 
distinct patterns that could hallmark aromatase inhibitor resistance.
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M A T E R I A L S  A N D  M E T H O D S
PAT I E N T S, T U M O R S A M P L E S, A N D P R O C E S S I N G
The Erasmus University Medical Center (EMC; Rotterdam, the Netherlands), the 
Netherlands Cancer Institute (Amsterdam, the Netherlands), and the Translational 
Cancer Research Unit (Saint Augustinus Hospital, Antwerpen, Belgium) participated in 
this study. A detailed description of the tumor samples has been described previously 
(23) and can be found in the Supplementary Methods.
In addition, previously described dataseries from patients with breast cancer, receiving 
neoadjuvant letrozole treatment (6) or tamoxifen for metastatic disease (24) were 
applied.
C H R O M AT I N I M M U N O P R EC I P I TAT I O N S
Chromatin immunoprecipitations (ChIP) were performed as described before (25) with 
minor adjustments. Firstly, as input material, tumor samples were cryosectioned (30× 
30 μm sections) before further processing for ChIP-seq. For each ChIP, 10 μg of antibody 
was used, and 100 μL of Protein A magnetic beads (Invitrogen). ERα (SC-543; Santa Cruz), 
H3K4me3 (ab8580; Abcam), and H3K27me3 (07–449; Millipore) were used as antibodies. 
Primer sequences for quantitative PCR (qPCR) analyses are in Supplementary Table S5.
S O L E X A S E Q U E N C I N G A N D E N R I C H M E N T A N A LY S I S
ChIP DNA was amplified as described (25). Sequences were generated by the Illumina 
Hiseq 2000 genome analyzer (using 50 bp reads), and aligned to the Human Reference 
Genome (assembly hg19, February 2009). Enriched regions of the genome were 
identified by comparing the ChIP samples to mixed input using the MACS peak caller 
(26) version 1.3.7.1. Details on the number of reads obtained, the percentage of reads 
aligned, and the number of peaks called can be found in Supplementary Table S3. 
Bioinformatic analyses are described in the Supplementary Methods.
R N A I S O L AT I O N A N D M R N A E X P R E S S I O N A N A LY S I S
Total tumor RNA was isolated as described previously (27). mRNA quality was assessed 
by quantitative real-time PCR (qRT-PCR) and bioanalyzer. Amplification, labeling, and 
hybridization of samples to 44k mRNA oligonucleotide-arrays (Agilent Technologies) 
were performed as described (27). Samples were hybridized against a breast cancer 
reference pool consisting of RNA from 105 primary breast tumors. A detailed description 
of mRNA expression analyses and progression-free survival analyses can be found in the 
Supplementary Methods.
DATA AC C E S S
All genomic data are deposited at the NCBI GEO, with accession numbers GSE40867 
(ChIP-seq data) and GSE41994 (expression data).
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R E S U L T S
G E N O M E-W I D E B I N D I N G PAT T E R N S O F E Rα, H3K4M E3, A N D H3K 27M E3 
I N P R I M A RY B R E A S T T U M O R S P EC I M E N S
Fresh frozen primary tumor specimens from a cohort of 84 patients with breast cancer 
were tested. These patients received aromatase inhibitor treatment of metastatic 
disease, i.e., anastrozole, letrozole, or exemestane (Supplementary Table S2). TTP was 
taken as an endpoint (Figure 1A). Poor outcome patients were defined as patients with 
a TTP < 12 months, whereas good outcome patients were defined as patients with a TTP 
> 24 months (Supplementary Tables S1 and S2). To determine the differential patterns 
in the ERα/chromatin–binding landscape and the epigenetic modifications H3K4me3 
and H3K27me3 as well as their possible correlations with outcome after aromatase 
inhibitor treatment, five good outcome tumor samples and seven poor outcome tumors 
were randomly selected as “discovery set.” Remaining samples from the entire cohort 
were used as “validation sets,” as will be discussed later. The tumor cell percentage 
was consistently high (>70%), and all tumors were ERα and progesterone receptor (PR) 
positive, whereas negative for HER2. Other clinicopathologic parameters are shown in 
Supplementary Table S2.
For all 12 tumors from the discovery set, fresh frozen samples were cryosectioned, and 
chromatin was isolated for ChIP. For each tumor sample, the ChIP for ERα, H3K4me3, 
and H3K27me3 was performed and isolated DNA fragments were analyzed by high-
throughput sequencing (ChIP-seq) (25). The number of aligned reads, unique reads, 
and number of peaks for each ChIP-seq sample are shown in Supplementary Table 
S3. Clear and distinct peaks were observed for each condition, as exemplified for one 
tumor sample (good outcome tumor #5; Figure 1B). In this example specimen, 13,575 
binding events for ERα, 19,012 binding events for H3K4me3, and 33,661 binding events 
for H3K27me3 were found. Although the vast majority of binding events found from 
this tissue sample were unique among the markers, overlap was found between ERα 
and H3K4me3 as well as between H3K4me3 and H3K27me3 (Figure 1C; for all tumor 
samples, see Supplementary Figure S1). Even though the total numbers of binding events 
greatly varied among tumors, these relative distributions of the three ChIP conditions 
were consistently found for all tumor samples tested (Supplementary Figure S1). For the 
exemplified tumor sample, motif analysis was performed for each ChIP condition, Figure 
1D. As expected, ERα–binding events were enriched for ESR1 motifs, but also for its 
designated pioneer factors FOXA1 (7) and TFAP2 (13). For H3K4me3 ChIP on this tumor 
sample, enriched motifs were found for the promoter-selective transcription factors 
GTF2I (28), ZIC1 (29), and E2F1:TFDP2 (30), whereas only motifs for the mitochondrial 
transcription factor A (TFAM) were observed for H3K27me3-bound regions.
For all tested tumor samples, example binding events for ERα, H3K4me3, and H3K27me3 
are shown (Figure 1E), illustrating clear and high-quality data for all samples. For one 
tumor sample, no data could be generated for the H3K4me3 ChIP (poor outcome sample 
#2). Most ERα–binding events were found at distal enhancers and introns (Figure 1F), 
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consistent with previous reports in cell lines (7) and breast tumors (12). H3K4me3 was 
more markedly enriched at promoters, 3′-UTRs and exons, this in contrast to H3K27me3. 
These distributions were consistent in all analyzed tumors studied. The binding site 
distributions of all peaks related to the most proximal gene were found not to differ 
between good and poor outcome tumors.
F I G U R E 1. Genome-wide DNA-binding patterns of ERα, H3K4me3, and H3K27me3 in primary human 
breast tumors. 
A. Kaplan–Meier survival curve for the cohort of breast cancer patients who received aromatase inhibitors 
for metastatic disease. TTP < 12 months (red) is defined as poor outcome, whereas TTP > 24 months (green) 
is defined as good outcome.
B. Genome browser snapshot of ERα (red), H3K4me3 (blue), and H3K27me3 (green) ChIP-seq data from the 
same tumor sample. Genomic coordinates are indicated. Tag count is shown on the y-axis. 
C. Venn diagram, illustrating shared and unique chromatinbinding events between ERa, H3K4me3, and 
H3K27me3 from the same human breast tumor specimen. 
D. Enriched motifs for the ERα-, H3K4me3-, and H3K27me3–binding events, as highlighted in B and C. 
E. Genome browser snapshot examples of binding events for ERα (red), H3K4me3 (blue), and H3K27me3 
(green) for all the tested tumor samples.
F. Genomic distributions of binding events of ERα, H3K4me3, and H3K27me3 in poor (red) and good outcome 
(blue) tumors, illustrating the positioning of the binding events related to the most proximal gene. 
Bars, SD values of all tested tumor samples. 05
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DISTINCT GENOME-WIDE BINDING PATTERNS OF ERα, H3K4ME3, AND H3K27ME3 
CORRELATE WITH PATIENT SURVIVAL AFTER AROMATASE INHIBITOR TREATMENT
Next, we aimed to determine whether the chromatin-binding patterns of ERα-, 
H3K4me3-, and H3K27me3–binding events would deviate between patients with a 
good versus a poor outcome upon aromatase inhibitor treatment. This was achieved 
through differential binding analysis (DBA) (12, 31), directly comparing good outcome 
and poor outcome tumor ChIP-seq data. DBA normalizes the sequencing data for each 
run over the effective library size (reads in peaks) after input background subtraction, 
and determines relative enrichment of raw sequence reads over two distinct subgroups 
of tumor samples, in this case good versus poor outcome. Called peaks that were found 
in at least two tumor samples were considered for DBA to minimize noise, resulting 
in 14,232 peaks for ERα, 22,587 peaks for H3K4me3, and 35,602 peaks for H3K27me3 
(Supplementary Figure S2). On the basis of these peaks, the raw read counts for all 
tumor samples were checked for differential binding intensities between the two patient 
subgroups, resulting in lists of 222 (ERα), 66 (H3K4me3), and 351 (H3K27me3) peaks, 
with a false discovery rate of < 0.1 (Figure 2A). Tumors from patients with the same 
outcome clustered together for ERα and H3K27me3 and, although less pronounced, for 
the H3K4me3 signals (Figure 2B). This class separability was also observed in a principal 
component analysis (Supplementary Figure S3). The read count and peak caller score did 
not bias patient stratification (Supplementary Figure S4).
A. Example genomic regions with differential ERα (red), H3K4me3 (blue), and H3K27me3 (green) binding 
events. Genomic coordinates are indicated. Tag count is shown for each position. 
B. Cross-correlation analysis for ERα (red), H3K4me3 (blue), and H3K27me3 (green) on the basis of the 
differential-bound profiles. Heatmap intensities and counts are depicted in the top left corner for each 
factor. 
C.  Heatmap visualization of the ERα (red), H3K4me3 (blue), and H3K27me3 (green) peak intensities that were 
differentially enriched in good and poor outcome tumors. Heatmap intensities and counts are depicted in 
the top left corner for each factor. 
D. Pie chart depicting the relative number of peaks that were differentially enriched in good and poor 
outcome tumors.
E.  Genomic locations of the differentially enriched peaks of ERα, H3K4me3, and H3K27me3 in good and poor 
outcome, related to the most proximal genes. 
F. Top motif enrichment for the unique binding events in good and poor outcome tumors for all three 
markers. No enriched motifs were found for the H3K4me3 peaks that were only observed in the good 
outcome patients.
F I G U R E 2. (on the right) Distinct chromatin-binding patterns of ERα and H3K27me3 in tumor 
samples with differential aromatase inhibitor response. 
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Peak regions that were significantly differentially enriched between the poor and 
good outcome patients are shown in a heatmap for all three conditions (Figure 2C), 
with a clear distinction for ERα and H3K27me3, whereas case mixing was observed for 
H3K4me3 signals. The number of poor outcome peaks greatly outweighs the number of 
good outcome events for both histone marks, but not for ERα (Figure 2D). A list of all 
differentially bound regions between good and poor outcome for ERα, H3K4me3, and 
H3K27me3 is shown in Supplementary Table S4.
The binding events that were differentially enriched between the two patient subgroups 
were analyzed for their localization relative to the most proximal genes (Figure 2E). No 
clear differences in genomic locations of the ERα peaks were observed between good 
and poor outcome patients. H3K4me3 poor outcome peaks were found enriched at 3'-
UTR regions and downstream thereof, whereas the 3′-UTR signals for H3K27me3-binding 
events were selectively lost in poor outcome tumor samples.
The ERα-, H3K4me3-, and H3K27me3–binding events were analyzed for DNA motifs 
differentially enriched in the good and poor outcome patient subgroups (Figure 2F). 
Although only ESR1 motifs were found in good outcome patients, TFAP2A and TCF4 
motifs were enriched next to ESR1 for the poor outcome patients. For H3K27me3, good 
outcome–enriched binding events were enriched for TERF1 and PPARG:RXRA motifs, 
whereas for poor outcome–enriched binding events, motifs were found for ERG and 
SIX1/SIX3. No distinct enriched motifs were found for the good outcome–enriched 
binding event for H3K4me3, but the poor outcome sites were statistically enriched for 
LHX2/GBX2, ARID5B, PAX7, and HOXB8 motifs.
M U T UA L E XC L U S I V I T Y O F D I F F E R E N T I A L LY E N R I C H E D C H R O M AT I N -
B I N D I N G E V E N T S B E T W E E N T H E PAT I E N T S U B G R O U P S
A large variation was found in the number (Supplementary Table S2) and overlap of 
chromatin-binding events between samples as exemplified for three specimens (Figure 
3A; for all samples Supplementary Figure S2). This is consistent with a previous report 
that studied ERα ChIP-seq on breast tumor specimens (12). Because ERα/chromatin 
interactions are dictated by and have a facilitating effect on histone accessibility (11), we 
determined if altered ERα–binding patterns are accompanied by changes in the epigenetic 
profile of H3K4me3 and H3K27me3. When ERα–binding events observed in the poor 
outcome tumor sample were absent in the good outcome tumor, these alterations are 
not accompanied by a loss or gain of proximal histone marks, as exemplified in Figure 
3B. In line with these data, differences of either histone mark between good and poor 
outcome patients were virtually mutually exclusive and not shared with changed ERα–
binding patterns (Figure 3C). Consequently, a limited overlap was observed for the genes 
that were proximal to the altered ERα-, H3K4me3-, and H3K27me3–binding events 
(Figure 3D). The altered binding events were mapped over all chromosomes and no clear 
bias towards distinct regions or chromosomes was observed (Figure 3E).
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F I G U R E 3. Mutual exclusivity of altered binding events. 
A. Venn diagram, showing shared and unique binding events of ERα (red), H3K4me3 (blue), and H3K27me3 
(green) from three example tumor samples. ERα and H3K27me3–binding patterns are highly heterogeneous 
between tumors, in contrast to H3K4me3-binding events. 
B. Genome browser snapshot from a good outcome (top) and a poor outcome (bottom) tumor sample. 
Even though the ERα–binding sites between the two tumor samples were altered, no change was 
found for the present H3K4me3 (blue) and absent H3K27me3 (green) signals. 
C. Venn diagram, showing the shared and unique differentially bound binding events for ERα, H3K4me3, 
and H3K27me3, comparing good and poor outcome patients. 
D. As in C, but now analyzing the genes proximal to the altered binding events. All peaks within a gene 
body or 20 kb upstream from the transcription start site (TSS) were considered as proximal. 
E.   Visualization of the genome-wide distribution of the altered binding events of ERα (red), H3K4me3 (blue), 
and H3K27me3 (green) depicted over all chromosomes.
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VA L I DAT I O N, I N T EG R AT I O N W I T H G E N E E X P R E S S I O N, A N D C L I N I C A L 
OUTCOME
Next, differential enriched binding patterns between good and poor outcome patients 
were validated in an independent group of 10 patients (4 good outcome and 6 poor 
outcome) using qPCR, Figure 4A (for clinicopathologic parameters, see Supplementary 
Table S2). For each of the ChIP conditions, four to six primer pairs were designed, 
detecting randomly picked regions enriched in the good or poor outcome patients from 
the discovery set. ChIP efficiency can vary among samples due to tumor cell percentage, 
expression levels, and experimental variations, making inter-sample normalization 
an essential step in the DBA for the ChIP-seq pipeline. To implement inter-sample 
normalization in qPCR, the ratios of average good outcome over poor outcome–enriched 
binding site intensities were calculated. For ERα and H3K27me3, qPCR ratio separated 
poor outcome patients from good outcome patients, whereas differential enrichment 
could not be confirmed for H3K4me3.
After qPCR validation, all ChIP-seq–identified differential binding patterns were coupled 
to genes, based on proximity (gene body plus 20 kb upstream from the transcription 
start-site), enriching for ERα–binding sites involved in gene regulation (8). For the good 
outcome binding sites, this resulted in 84 (ERα), 19 (H3K4me3), and 29 (H3K27me3) 
genes. For poor outcome sites, 99 (ERα), 22 (H3K4me3), and 158 (H3K27me3) genes 
were found (Supplementary Table S6).
Gene Ontology (GO) analyses were performed on the proximal gene sets to identify 
plausible functional regulatory networks (Supplementary Table S7). Genes between 
the different classifiers only marginally overlapped (Figure 3D), whereas pathways 
between ERα, H3K4me3, and H3K27me3-based classifiers showed no overlap. The 
ERα–based classifier was enriched for metabolic processes, whereas nucleoside 
transport, chemotaxis, and angiogenesis were enriched GO terms for H3K4me3. For 
the H3K27me3 classifier, developmental processes were strongly enriched. Comparing 
our data with pathways identified in mutational analysis of aromatase inhibitor–treated 
patients with breast cancer (4) showed shared processes involved in cell adhesion, cell 
cycle, chemotaxis, developmental processes, immune responses, metabolism, signal 
transduction, and transcriptional regulation (Supplementary Table S8).
Next, array-based mRNA expression levels of all proximal genes for ERα, H3K4me3, and 
H3K27me3 sites were tested for a correlation with time to progression (TTP) in a second 
independent set of 72 tumors (validation set), of aromatase inhibitor–treated patients 
with metastatic disease (Figure 4B, clinicopathologic parameters Supplementary Table 
S2). Expression of proximal genes for differential ERα (183 genes), H3K4me3 (41 genes), 
and H3K27me3 (187 genes) binding was used to classify tumors as “poor” and “good 
outcome.” Classifications for altered ERα (P = 0.0016; HR, 2.42; 95% CI, 1.40–4.19) and 
H3K27me3 (P = 0.0001; HR, 3.19; 95% CI, 1.83–5.57) binding events correlated with a 
differential TTP, in contrast to H3K4me3 (P = 0.386; HR, 1.38; 95% CI, 0.76–2.49).
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Previously reported classifiers, PAM50 (P = 0.0093; HR, 2.11; 95% CI, 1.20–3.71) (32), 
Oncotype DX (P = 0.0256; HR, 1.87; 95% CI, 1.08–3.23) (33), and the TAM78 Rotterdam 
classifier (P = 0.0151; HR, 1.98; 95% CI, 1.14–3.42) (34), classified patients in this 
cohort, performing equally well as the ERα–proximal gene classifier (Figure 4E). The 
H3K27me3-proximal gene classifier showed a higher HR, even though the 95% CI did 
overlap (Figure 4E). ERα and H3K27me3 ChIP-seq–based classifiers remained significant 
after multivariate correction analyses (Supplementary Table S9). The classifier genes are 
listed in Supplementary Table S6. As a second expression-based validation, a cohort of 
neoadjuvant letrozole treatment patients (N = 54) was used, analyzing samples before 
and after treatment, where patients were stratified in responsive and non-responsive 
groups (Figure 4C) (5, 6). PAM50, Oncotype DX, and TAM78 as well as our ChIP-seq 
classifiers successfully identified patients with differential outcome.
ERα can affect gene regulation by long-range genomic chromatin-loop interactions, as 
shown by ERα ChIA-PET (8). Therefore, these published long-range interactions were also 
considered in our study. In addition, binding sites were analyzed for any transcription 
factor enrichment, DNAse hypersensitivity, and H3K27Ac, representing active enhancers 
(35), using ENCODE datasets (Supplementary Table S10). Genes were selected that 
either had a binding event at a promoter region, or chromatin looping toward the 
promoter was found, generating three separate lists of 92 (ERα), 38 (H3K4me3), and 
150 (H3K27me3) genes. Overlap between the “proximity-based” and “ChIA-PET–based” 
gene sets was high for H3K4me3 (76%) and H3K27me3 (78%), but considerably lower for 
ERα (49%; Supplementary Figure S5). Analogous to our initial classifiers, ChIA-PET–based 
classifiers for ERα (P = 0.0041; HR, 2.45; 95% CI, 1.41–4.26) and H3K27me3 (P = 0.0002; 
HR, 3.02; 95% CI, 1.73–5.27) could classify patients, in contrast to H3K4me3 (P = 0.606; 
HR, 1.30; 95% CI, 0.71–2.37; Supplementary Figure S6A and Supplementary Table S9). 
Also for this “ChIA-PET–based” classifier, samples from the neoadjuvant treated letrozole 
cohort were analyzed (6), identifying patients with differential response (Supplementary 
Figure S6B). Conserved genes between both gene classifiers performed equally as the 
separate classifications (ERα: P = 0.05; HR, 1.96, 95% CI, 1.10–3.49; H3K27me3: P = 
0.0001; HR, 3.68, CI 95%, 2.09–6.50; H3K4me3: P = 0.3944; HR, 1.30, 95% CI, 0.711–2.37; 
Supplementary Figure S6C and S6D).
A third cohort of patients was analyzed, receiving first-line tamoxifen for metastatic 
disease instead of aromatase inhibitors (Figure 4D) (27). The metastatic setup of this 
cohort enabled a direct comparison between the patient sets. No significant correlation 
with TTP after tamoxifen was found for the H3K4me3 and H3K27me3 ChIP-seq–based 
classifiers (H3K27me3: P = 0.0838, HR, 1.53, 95% CI, 0.95–2.47; and H3K4me3: P = 
0.0602, HR, 1.556, 95% CI, 0.98–2.47). However, significance was reached for the ERα–
based classifier (P = 0.0426, HR, 1.63, 95% CI, 1.02–2.63). These data indicate that 
while the ERα ChIP-seq–based classifier may identify breast cancer patients with a poor 
outcome, irrespective of the type of endocrine treatment, the H3K27me3 classification 
suggests aromatase inhibitor–treatment selectivity in patients with metastatic breast 
cancer (Figure 4E).
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F I G U R E 4.  ChIP-qPCR validation and correlation with survival and treatment selectivity.
A.  Heatmap, illustrating qPCR-ChIP–based enrichment of regions enriched for patients with a good or poor 
outcome after aromatase inhibitor treatment, normalized over negative control CCND1 primers. Average 
signals for the good outcome and poor outcome sites were calculated and ratio was determined, as also 
visualized in a bar plot (bottom). Separate primer sets were used for the altered ERα (red), H3K4me3 (blue), 
and H3K27me3 (green) binding events.
B.  Kaplan–Meier survival curves of aromatase inhibitor–treated patients, using the proximal genes from the 
differentially enriched binding patterns of ERα, H3K4me3, or H3K27me3, as well as the established Oncotype 
DX, PAM50, and TAM78 as classifiers. TTP is shown with time expressed in months.
C. Heatmap visualization of patient classification. Gene expression data from the Miller dataset were 
applied, where 54 patients received neoadjuvant letrozole treatment. Patients were stratified in responders 
and nonresponders, and pre- and posttreated samples from the same patients were separately analyzed. 
Adherence to the gene classifier is visualized in a heatmap, where green indicates a good outcome signature 
and red a poor outcome signature.
D.  Identical analyses as depicted in B, but now applying the aromatase inhibitor ChIP-seq–based classifiers 
on a cohort of breast cancer patients who received tamoxifen for metastatic disease.
E. Hazard rates (HR), including 95% CI values, for the ChIP-seq–based classifiers (ERα, H3K4me3, or 
H3K27me3) as compared with established Oncotype DX, PAM50, and TAM78 classifiers. Both the aromatase 
inhibitor cohort (red) and tamoxifen cohort (blue) of patients treated for metastatic disease are shown.
Processed on: 17-10-2016
505830-L-sub01-bw-Reijm
97
D I S C U S S I O N
Estrogen receptor genomics has greatly increased our knowledge of hormone receptor 
functioning in breast cancer cell lines and tumors. The number of ERα/chromatin–binding 
events greatly exceeds the amount of estradiol-responsive genes (11, 36), suggesting a 
high level of complexity in ERα–mediated gene regulation (8). ERα/chromatin–binding 
events have been found to correlate with survival of patients with breast cancer (12), 
but survival in this heterogeneous study also correlated with traditional pathologic 
parameters, including PR and HER2, potentially hampering further clinical interpretation 
of the data. Therefore, we selected ERα+, PR+, and HER2− tumors from a homogeneous 
cohort of breast cancer patients whose metastasis were all treated with aromatase 
inhibitors.
Altered ERα–binding patterns between patient groups were not accompanied with 
altered epigenetic profiles of H3K4me3 and H3K27me3. Our data suggest that any 
dynamic behavior of ERα uses the accessible regions in the genome that are imprinted 
and readily accessible in a static epigenetic landscape. Still, H3K27me3-binding events 
enable the identification of patients with a poor outcome after aromatase inhibitor 
treatment, in contrast to H3K4me3. The presented data suggest that aromatase inhibitor 
resistance is accompanied by a specific gain of polycomb-mediated gene repression 
at distinct sites. Moreover, it suggests an ERα–independent mechanism of therapy 
resistance in ERα–positive tumors. Our data could be validated in two other cohorts of 
breast cancer patients, using two different technologic approaches, namely ChIP-qPCR 
and gene expression analysis.
Because genomic patterns of ERα and H3K27me3 were indicative for patient survival, 
the enriched motifs may provide clues for transcription factors involved in treatment 
outcome. For ERα, TFAP2 and TCF4 motifs were selectively enriched for the poor 
outcome patients. AP-2 can directly guide ERα/chromatin interactions (13), promotes 
breast cancer cell proliferation (37), and correlates with poor outcome (38). TCF4 
enhances breast cancer cell invasion (39) and binds ERα (40), providing a level of cross-
control between estradiol and wnt pathways (40).
For H3K27me3, “good outcome” sites were enriched for TERF1 and PPARG:RXRA motifs. 
TERF1 is a component of the telomere nucleoprotein complex. SNPs in TERF1 have 
been tested for breast cancer susceptibility and prognosis, but no correlations were 
found (41). PPARG:RXRA ligands can trigger breast cancer cell apoptosis (42) and PPARγ 
activation blocks breast cancer cell invasion (43) and induces terminal cell differentiation 
(44). For poor outcome–enriched H3K27me3 regions, motifs were found for ERG and 
SIX1/SIX3. ERG and ERα mutually repress each other’s activities (45). SIX1 is expressed 
in breast cancer, stimulating tumor cell proliferation (46), inducing genomic instability 
and malignant transformation (47), correlating with poor prognosis (48). Collectively, 
these data highlight possible transcriptional mechanisms that may form the basis for 
aromatase inhibitor response.
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The ERα ChIP-seq classifier was applicable for aromatase inhibitor- and tamoxifen–treated 
patients with breast cancer with metastatic disease. Because aromatase inhibitors and 
tamoxifen both affect the functionality of ERα, the genomic downstream signatures for 
treatment outcome could overlap as well. Because ERα is targeted by these endocrine 
agents, the ChIP-seq approach could aid in removing noise from expression analyses to 
exclusively monitor genes that are directly affected by this hormone receptor.
Testing the aromatase inhibitor ChIP-seq classifiers in tamoxifen-treated tumors showed 
no significant difference in TTP for H3K27me3. Aromatase inhibitor–treated patients 
cohorts are relatively rare, and our cohort is on metastatic disease. To compare between 
endocrine treatments, data from a metastatic cohort of tamoxifen-treated patients 
were used. Performing these ERα ChIP-seq experiments and epigenetic assessments in 
the adjuvant setting would enable a direct comparison with any of the large (adjuvant-
treated) breast cancer patient cohorts (34, 49, 50) for more extensive in silico validations.
Tumor-intrinsic plasticity of ERα and H3K27me3 can be a hallmark of endocrine therapy 
resistance in breast cancer and may ultimately be applicable to guide endocrine 
treatment selection for patients with breast cancer.
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CHAPTER 6
An 8-gene mRNA expression profile in circulating tumor cells predicts 
response to aromatase inhibitors in metastatic breast cancer patients 
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A B S T R A C T
 
B AC KG R O U N D
Molecular characterization of circulating tumor cells (CTC) is promising for personalized 
medicine. We aimed to identify a CTC gene expression profile predicting outcome to 
first-line aromatase inhibitors in metastatic breast cancer (MBC) patients. 
M E T H O D S 
CTCs were isolated from 78 MBC patients before treatment start. mRNA expression 
levels of 96 genes were measured by quantitative reverse transcriptase polymerase 
chain reaction. After applying predefined exclusion criteria based on lack of sufficient 
RNA quality and/or quantity, the data from 45 patients were used to construct a gene 
expression profile to predict poor responding patients, defined as disease progression or 
death <9 months, by a leave-one-out cross validation.
R E S U LT S
Of the 45 patients, 19 were clinically classified as poor responders. To identify them, the 
75% most variable genes were used to select genes differentially expressed between 
good and poor responders. An 8-gene CTC predictor was significantly associated with 
outcome (Hazard Ratio [HR] 4.40, 95 % Confidence Interval [CI]: 2.17–8.92, P < 0.001). 
This predictor identified poor responding patients with a sensitivity of 63% and a positive 
predictive value of 75%, while good responding patients were correctly predicted in 85% 
of the cases. In multivariate Cox regression analysis, including CTC count at baseline, 
the 8-gene CTC predictor was the only factor independently associated with outcome 
(HR 4.59 [95% CI: 2.11–9.56], P < 0.001). This 8-gene signature was not associated with 
outcome in a group of 71 MBC patients treated with systemic treatments other than AI.
C O N C L U S I O N S
An 8-gene CTC predictor was identified which discriminates good and poor outcome to 
first-line aromatase inhibitors in MBC patients. Although results need to be validated, 
this study underscores the potential of molecular characterization of CTCs.
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I N T R O D U C T I O N
Metastatic breast cancer (MBC) is a highly heterogeneous disease leading to an urgent 
need for a more personalized treatment approach. For those patients with estrogen 
receptor (ER)-expressing tumors, endocrine therapy is the mainstay of treatment. 
Although many patients greatly benefit from such endocrine therapies, approximately 
30% of the MBC patients never respond while virtually all initial responders eventually 
relapse and develop progressive disease. Numerous factors accounting for resistance 
to endocrine treatment have been revealed, including loss of ER expression (1-3), 
overexpression of the HER2 receptor (4), hyperactivation of the phosphatidylinositol 
3-kinase (PI3K) pathway (5), and overexpression of Enhancer of Zeste Homolog 2 (EZH2) 
(6). Determination of these factors in tumor tissue may therefore contribute to a more 
personalized treatment approach of individual patients. 
Predictive factors contributing to treatment decision making are nowadays most 
commonly identified in the primary tumors. However, heterogeneity in molecular 
characteristics between primary tumor and metastases, including clinically relevant 
factors, is increasingly recognized. For example, differences in ER expression between 
primary tumor and metastases occur in approximately 20% of the patients leading to 
treatment changes in a substantial number of patients (1, 7, 8). Since this heterogeneity 
increases over time and under treatment pressure (7), repetitive analyses of the 
characteristics of metastatic tumor cells are likely to offer better guidance of treatment 
choices than characterization of the primary tumor. Unfortunately, metastatic tissue is 
often hard to obtain and only possible through invasive procedures.
Circulating tumor cells (CTCs) are tumor cells found in the peripheral blood and are 
thought to better represent the actual or clinically relevant metastatic tissue burden 
than the primary tumor does, in particular in those patients whose primary tumors have 
been removed several years prior to diagnosis of MBC. The CTC count has shown to 
be a powerful prognostic factor in MBC and a rise or decline in CTC count after the 
first cycle of systemic therapy is an early predictor of outcome (9-12). Additionally, 
CTC characterization holds great promise and for that purpose, several techniques to 
molecularly characterize CTCs for drug target expression (13-15), mutations (16) and 
gene expression (17-19) have been developed. CTCs however occur in relatively low 
numbers in patients with MBC and, even after the epithelial cell adhesion molecule 
(EpCAM)-based enrichment of the CellSearch® system, they need to be identified and 
characterized amongst approximately a thousand of remaining leukocytes (20). This 
greatly hinders the interpretation of results from techniques non-selective for tumor 
cells such as quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) on 
whole lysates. Nevertheless, by focusing on genes that are not, or only at a much lower 
level, expressed by leukocytes, we have previously shown that the expression levels of 
96 genes in CTCs can be quantified in MBC patients through qRT-PCR (18). 
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In this study, we aim to quantify this panel of 96 genes in CTCs of MBC patients with 
ER-expressing primary tumors prior to start of first-line therapy with an aromatase 
inhibitor (AI) in order to identify a CTC predictor discriminating between good and poor 
responders.
M E T H O D S
E T H I C S S TAT E M E N T
This study has been approved by the medical ethics committee of the Erasmus MC 
Rotterdam, The Netherlands and local Institutional Review Boards (ethics boards of 
Oncology Center GZA Hospitals Sint-Augustinus, Antwerp, Belgium; Ikazia Hospital, 
Rotterdam, The Netherlands; Sint Franciscus Gasthuis, Rotterdam) (METC 2006–248 and 
METC 2009–405). All patients gave their written informed consent.
We adhered to the Reporting Recommendations for Tumor Marker Prognostic Studies 
wherever possible (21).
C O L L EC T I O N O F B L O O D S A M P L E S A N D C H A R AC T E R I S T I C S O F 
R EC R U I T E D PAT I E N T C O H O R T
MBC patients had been included between October 2008 and August 2012 in 5 hospitals. 
From 78 MBC patients who were not previously treated for MBC and prior to start of 
first-line AI therapy (irrespective of type), 2 x 7.5 mL blood samples were prospectively 
drawn for CTC enumeration and isolation. Due to insufficient RNA quality and/or 
quantity and/or lack of expression of previously described CTC-specific genes (18) (for 
details see next), 33 (42%) samples were excluded, providing 45 patients for further 
analysis (Additional file 1: Figure S1). Detailed clinicopathological information for these 
45 patients is provided in Table 1.
In order to be able to decipher whether obtained results from this AI-treated patient 
cohort are of prognostic or predictive nature, we used an independent patient cohort 
composed of 71 MBC patients that received other types of first-line therapy. Of these, 
21 patients were treated with chemotherapy, 40 patients with chemotherapy combined 
with targeted therapy, and 10 patients with tamoxifen therapy. This patient cohort had 
been extracted from MBC patients described in our recently published study in which 
the same techniques for CTC enrichments and gene expression determination were 
applied (22).
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Characteristic No. of patients    %
All patients 45 100%
Time between primary surgery and CTC sampling (DFI)   
≤ 5 years 16 36%
>5 years 21 47%
Primary not removed 8 18%
Age at CTC sampling   
≤ 50 years 4 9%
>50 years 41 91%
Menopausal status   
Premenopausal 2 4%
Postmenopausal 43 96%
Histologic grade (Bloom-Richardson)   
I, well differentiated 5 11%
II, moderately differentiated 23 51%
III, poorly differentiated 4 9%
Unknown 13 29%
Pathological tumor size   
pT1, ≤2 cm 20 44%
pT2-4, >2 cm 22 49%
Unknown 3 7%
Lymph nodes involved   
No 14 31%
Yes 27 60%
Unknown 4 9%
ERα status†   
Negative 1 2%
Positive 44 98%
PgR status†   
Negative 5 11%
Positive 36 80%
Unknown 4 9%
TA B L E 1. Patients and their clinico-pathological characteristics
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HER2/neu status†   
Negative 37 82%
Positive 3 7%
Unknown 5 11%
Histological type   
Lobular 13 29%
Ductal 28 62%
Ductolobular 3 7%
Ductal, signet-cell 1 2%
Adjuvant chemotherapy   
No 31 69%
Yes 14 31%
Adjuvant hormonal therapy   
No 24 53%
Yes 21 47%
Any adjuvant therapy   
No 22 49%
Yes 23 51%
Site of metastasis   
Visceral 5 11%
Non-visceral 26 58%
Both 14 31%
1st line treatment   
Anastrozol 15 33%
Letrozol 16 36%
Exemestane 14 31%
   
Median progression-free survival (PFS in days; range)* 358 (14 - 1255)  
Median baseline CTC count (range in 7.5 mL blood) 8 (0 - 32,492)  
  
† As retrieved from pathology reports   
* Also includes censoring data from patients censored at last follow-up date  
Characteristic No. of patients    %
TA B L E 1. (continued)
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E N U M E R AT I O N O F C T C S
In order to isolate CTCs for CTC enumeration, 7.5 mL blood was drawn in CellSave tubes 
(Veridex™ LCC, Raritan, NJ, USA) and processed on the CellTracks AutoPrep System 
by using the CellSearch Epithelial Cell Kit (both Veridex LCC). CTC enumeration was 
performed on the CellTracks Analyzer (Veridex LCC) according to the manufacturer’s 
instructions and as described previously (23-25).
M R N A I S O L AT I O N F R O M C T C S, Q R T- P C R A N D Q UA N T I F I C AT I O N O F 
G E N E T R A N S C R I P T S
Together with the blood samples for CTC enumeration, another 7.5 mL blood of the 
same patients was drawn in EDTA tubes. These samples were enriched for CTCs on the 
CellTracks AutoPrep System using the CellSearch Profile Kit (Veridex LCC). Isolated cells 
were lysed by adding 250 µL of Qiagen AllPrep DNA/RNA Micro Kit Lysis Buffer (RLT+ lysis 
buffer) (Qiagen BV, Venlo, The Netherlands) and immediately stored at -80 °C until RNA 
isolation was performed with the AllPrep DNA/RNA Micro Kit (Qiagen) according to the 
manufacturer’s instructions and as previously described (18).
The generation of cDNA from isolated RNA from CTCs and subsequent pre-amplification 
and TaqMan-based PCR analysis were performed as described before (20). The 96 
measured mRNA transcripts have previously been selected and validated based on their 
clinical relevance and potential CTC-specificity (18, 20).
R E F E R E N C E G E N E S, DATA N O R M A L I Z AT I O N, A N D Q UA L I T Y C O N T R O L
The procedure of data normalization and quality control was performed as previously 
described (18, 20). In short, relative expression levels were quantified by using the delta 
Ct method, which is the difference between the average Ct of the reference genes HMBS, 
HPRT1, and GUSB and the Ct of the target genes. Samples that were able to generate a 
signal within the chosen cut-off set at 26 Ct of the average of the reference genes were 
considered of sufficient quality and quantity to be included in the study and quantified 
for the levels of the remaining 93 target genes. By the use of this threshold, 5 of our 
initial 78 CTC samples (6%) were excluded from further analysis.
Finally, samples were checked for sufficient expression levels of a 12-gene mRNA cluster 
that has previously been determined as epithelial-specific and associated with the 
presence of CTCs (18). Due to lack of sufficient expression of these genes and our aim 
to generate a CTC-specific predictor, another 28 CTC samples (36%) were excluded from 
further analysis.
S TAT I S T I C A L A N A LY S I S
Statistical analyses were done with the STATA statistical package, release 12.0 (STATA 
Corp., College Station, TX). Primary endpoint was progression-free survival (PFS), defined 
as the time elapsed between start of first-line treatment with AI and clinical and/or 
radiological progression or death, whichever came first. Patients who were alive and had 
not progressed were censored at the last follow-up date, which was at least 9 months 
after start of 1st line therapy. Those patients with progression or death <9 months were 
considered as poor responders. This 9-month cut-off was chosen based on the median 
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PFS for first-line therapy in MBC patients as reported in the literature (26, 27). In all 
45 eligible patients, a leave-one-out-cross validation (LOOCV) was conducted using the 
Support Vector Machines (SVM) method within Biometric Research Branc ArrayTools 
(http://linus.nci.nih.gov/BRB-ArrayTools.html) after selecting the top 75% most variable 
genes from the 93 genes described above. With this LOOCV method, a gene signature 
was generated that consisted out of the most differentially expressed genes that were 
identified in the individual predictions and best predicted the left-out sample. A panel of 
8 genes was identified that performed best in predicting the poor responding patients. 
The SVM method proved superior compared to the other prediction algorithms; based 
on 100 permutations, SVM was the only method with a significant P-value of 0.01. Cluster 
3.0 and TreeView (http://bonsai.hgc.jp/~mdehoon/software/cluster/clustersetup.exe 
and http://jtreeview.sourceforge.net/ [28]) were used to cluster the samples according 
to the gene expression values of these 8 genes and to visualize the results. Survival 
curves were generated using the Kaplan-Meier method and a logrank test was used to 
test for differences. All statistical tests were 2-sided with P < 0.05 considered statistically 
significant.
R E S U L T S
PAT I E N T C H A R AC T E R I S T I C S
Characteristics of the 45 patients who were eligible for our CTC-specific analyses to 
explore differentially expressed genes between good and poor responders are listed in 
Table 1. One patient was described to have an ER-negative primary tumor but received 
hormonal treatment in both adjuvant and first-line setting due to PR-positivity. Median 
baseline CTC count in the 45 patient cohort was 8 (range 0 – 32,492 CTCs/7.5 mL blood). 
The extremely high CTC count of 32,492 was assessed in a patient who did not respond 
to treatment and died within one month after treatment initiation due to progression 
of disease. The 9-month cutoff as based on literature data on the median PFS in first-
line MBC patients (26, 27) was well-chosen considering the median PFS of 11.8 months 
(range 0 – 41.3 months) in our 45 patient cohort.
8- G E N E C T C P R O F I L E P R E D I C T S F O R O U T C O M E T O T R E AT M E N T
Of the 45 patients, 19 patients were classified as poor responders due to progression of 
disease or death <9 months whereas the remaining 26 patients were considered good 
responders. A LOOCV was performed in this cohort yielding an 8-gene predictor in which 
each gene had a univariate P-value of <0.1 (Table 2). Application of this 8-gene CTC 
profile resulted in 16 patients with an unfavorable profile and were thus predicted to be 
poor responders. Twelve of them truly showed resistance to therapy <9 months (disease 
progression or death) and four did not, resulting in a sensitivity of 63% and a positive 
predictive value (PPV) of 75% (Table 3). Applying the profile, 29 patients had a favorable 
profile and were thus predicted not to show progressive disease <9 months. Of these, 
22 indeed did not fail treatment <9 months rendering a specificity of 85% and a negative 
predictive value (NPV) of 76%. 
06
Processed on: 17-10-2016
505830-L-sub01-bw-Reijm
114
The Kaplan-Meier curves for PFS of the predicted good and poor responding patients 
according to the 8-gene CTC predictor are shown in Figure 1 and were statistically 
different (Logrank P < 0.001).
In univariate analysis, the 8-gene CTC predictor was significantly associated with PFS (HR 
4.40 [95% CI: 2.17-8.92], P < 0.001). When including the traditional predictive factors, 
disease-free interval (DFI), which was defined as the time between primary surgery 
and CTC sampling,  the dominant site of relapse, and the CTC count at baseline in a 
multivariate analysis, only the 8-gene CTC-profile was an independent predictor of PFS 
(HR 4.59 [95% CI: 2.16-9.75], P < 0.001) (Table 4). The CTC count at baseline was not 
associated with PFS in this 45 patient cohort, but showed to be significant in the total 
cohort of 78 patients (HR 2.47 [95% CI: 1.43-4.27], P = 0.001) (Additional file 2: Figure 
S2).
Gene  P-value  t-value
TWIST1  0,001  -2,879
KRT81  0,018  -2,453
PTRF  0,029  -2,024
EEF1A2  0,031  -1,895
PTPRK  0,049  -1,793
EGFR  0,065  -1,701
CXCL14  0,080  2,229
ERBB3  0,096  2,260
A negative t-value corresponds to higher expression in poor responding patients; a positive t-value to higher 
expression in  good responding patients.
TA B L E 2. Significantly differentially expressed genes between 45 good and poor responders
 8-gene CTC profile  
PFS <9 months Favorable Unfavorable Total
     No 22 4 26
     Yes 7 12 19
Total 29 16 45
    
Pearson’s X2 statistic 10,93   
P <0.001   
    
TA B L E 3. Test performance
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F I G U R E 1. Kaplan-Meier curve for patients as defined by the 8-gene CTC predictor.
Blue (0): favorable profile; red (1): unfavorable profile; green (2): total cohort (N=45)
H I E R A R C H I C A L C L U S T E R I N G T O I D E N T I F Y C L U S T E R S O F PAT I E N T S 
AC C O R D I N G T O T H E 8- G E N E C T C P R E D I C T O R
Two-dimensional average linkage hierarchical cluster analysis (28) was performed to 
compare the difference in gene expression of the 8 identified genes in our 45 patients. 
This analysis resulted in a clustering of 2 major and 5 minor groups of patients in 
which cluster 1 mainly contained the good responders (10 out of 12), whereas cluster 
2 consisted of both good and poor responders (Figure 2). In this cluster, however, a 
subcluster existed that, with 10 out of 12, predominantly contained poor responders 
with higher expression of most of the identified 8 genes. 
T E S T I N G T H E 8- G E N E C T C P R O F I L E I N A N I N D E P E N D E N T D I F F E R E N T LY 
T R E AT E D PAT I E N T C O H O R T
Having identified the 8-gene CTC profile in AI-treated patients, it was assessed whether 
this signature was prognostic or predictive by investigating the association between this 
profile and outcome in an independent patient cohort composed of 71 MBC patients 
that received other first-line therapies than AI. Of these, 21 patients were treated with 
chemotherapy, 40 with chemotherapy combined with a type of targeted therapy such 
as trastuzumab, and 10 with tamoxifen therapy. Of this group, 35 patients had a PFS of 
less than 9 months and were therefore classified as having a poor outcome. Application 
of the 8-gene CTC profile resulted in 33 patients with a favorable CTC profile. The CTC 
profile however, could not properly discriminate the patients with a good versus those 
with a poor outcome (P = 0.899; Table 5).
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F I G U R E 2. Unsupervised hierarchical cluster analysis comparing the 8-gene CTC predictor in 45 MBC 
patients treated with first-line AI therapy. Each horizontal row represents a gene, and each vertical column 
corresponds to a sample. Red color indicates a mRNA expression level above the median level, black color 
indicates a median expression level, and green color indicates an expression level below the median level 
of the assay as measured in all 45 samples. The number of CTCs as established by the CellSearch Epithelial 
Kit is depicted below the figure. Blue: good responder; red: poor responder. CTC count: blue: <5 CTCs; red: 
≥5 CTCs
Factor of base model Univariate analysis  Multivariate analysis
 PFS  PFS
 HR 95% CI P  HR 95% CI P
<5 vs. ≥5 CTCs at baseline 1.11 0.57-2.15 0.753  1.31 0.65-2.62 0.455
Disease-free interval* 1.09 0.74-1.61 0.653  0.95 0.62-1.43 0.790
Dominant site of relapse** 1.34 0.69-2.58 0.384  1.11 0.56-2.18 0.768
8-gene CTC profile 4.40 2.17-8.92 <0.001  4.59 2.16-9.75 <0.001
* Defined as the time between primary surgery and CTC sampling and analyzed in 3 groups: ≤5 years (N= 12), 
>5 years (N= 21) and metastatic disease upon diagnosis (N= 12) 
** Divided into non-visceral vs. visceral metastases
TA B L E 4. Predictive value of the 8-gene CTC profile in uni- and multivariate analysis
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D I S C U S S I O N
Characterization of CTCs holds great promise to predict response to treatment and to 
gain more insight into mechanisms underlying resistance to systemic anti-tumor agents. 
Although whole transcriptome analysis would be most preferable, isolation of CTCs by the 
CellSearch technique does not result in pure fractions of CTCs but only in fractions enriched 
for CTCs in which an overload of leukocytes is still present. This makes interpretation of 
whole transcriptome analysis impossible since only techniques yielding pure CTC fractions 
would allow such analyses. We have previously shown to be able to measure mRNA 
expression levels of multiple epithelial genes in CTCs enriched by CellSearch (18). By using 
these selected genes and applying the same technique, the current study demonstrates 
the ability of using CTC characterization as a predictor for response to endocrine therapy. 
To our best knowledge, this is the first study that has generated an unique CTC-based 
gene expression panel that is able to distinguish good and poor responders to first-line AI 
therapy. From a clinical point of view, it is probably more relevant to identify the poor rather 
than the good responding patients, since these patients might benefit more from another 
treatment. Our identified 8-gene CTC profile however performed better in predicting the 
good responders, since the specificity of the predictor outperforms its sensitivity (85% 
vs. 63%; Table 3). Nevertheless, this could still impact clinical decision making since good 
responding patients could undergo less intensive follow-up strategies and fewer laboratory 
procedures which is not only less demanding for patients but can also reduce health care 
costs.
In order to explore whether this signature associated with outcome in AI-treated patients 
is prognostic or predictive, we tested the profile in CTCs of a group of 71 patients who were 
treated with types of systemic treatments other than AI including chemotherapy (N= 21), 
chemotherapy combined with a type of targeted therapy (N= 40), or tamoxifen therapy (N= 
10). In contrast to the AI-treated patients, the 8-gene CTC profile could not discriminate 
patients with a good versus those with a poor outcome in this group of patients (P = 0.899; 
Table 5). Although this is not a true validation of the test, it strongly supports that the 
identified profile is predictive for outcome to AI therapy and not for outcome to other 
agents. It needs to be underscored that the identified CTC profile has been obtained in a 
small number of patients for which an LOOCV procedure to reveal such a profile is commonly 
                8-gene CTC profile  
PFS <9 months Favorable Unfavorable Total
     No 16 19 35
     Yes 17 19 36
Total 33 38 71
Pearson’s X2 statistic 0.016   
P 0.899   
TA B L E 5.  Test performance of the 8-gene CTC predictor in 71 patients not treated with AI therapy
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applied. It important to realize that such an approach bears the risk of overfitting the data 
as a consequence of which validation in an independent patient cohort is needed before 
implementation in clinical practice.
The development of a CTC-specific predictor required exclusion of patients who lacked 
sufficient expression of epithelial-specific genes. These are mainly patients with no 
or few counted CTCs and are therefore more likely to have a longer PFS which might 
have biased our patient set (9). Although most characteristics do not show differences 
between in- and excluded patients (Additional file 3: Table S1), the median PFS in the 33 
excluded patients was 548 (40-1694) days which significantly differs from the median 
PFS of 358 (14-1255) days in the 45 included patients (Logrank P < 0.001). This exclusion 
criterion highly affected the number of patients available for further analysis. The low 
number of remaining patients might be the reason for the insignificant association 
between the CTC count at baseline (divided in <5 vs. ≥5 CTCs) and PFS. In the total 
cohort of 78 patients, CTC count was significantly related to PFS (Additional file 2: Figure 
S2). Since cohorts with few patients cannot be divided into independent discovery and 
validation sets, resampling the original data through cross-validation is statistically the 
best method (29).
Amongst the 8 genes that we found to be associated with outcome to AI therapy through 
LOOCV, was the epithelial marker KRT81. Many cytokeratins are highly expressed in both 
normal and tumor epithelium in which the pattern of expression can be used to identify 
the tissue of origin (30). Not much is known about this specific cytokeratin and why high 
expression would lead to a worse outcome. Mutations in KRT81 have been described in 
monilethrix, a condition in which patients develop diffuse hypothrichosis (31). 
CXCL14 and ERBB3 were the only genes that were more abundantly expressed in the 
good responding patients. This is discordant to what is currently known in primary tumor 
tissue with respect to both genes. The published literature, however, only considers 
gene expression in primary tumors which cannot easily be extrapolated to CTCs. CXCL14 
is a chemokine that has been shown to be upregulated in tumor myoepithelial cells 
and enhances the proliferation, migration, and invasion of epithelial cells after binding 
to their receptors (32). Expression of ERBB3 has, similar to EGFR in our CTC predictor, 
previously been associated with endocrine therapy resistance when highly expressed 
in primary tumor tissue (33, 34). The predictor also contained high expression of PTRF 
and EEF1A2 to be associated with poor outcome. This is in contrast with previously 
published literature in which PTRF has been shown to interact with pS2/TTF1 (35) 
which on its turn needs ER as key transcriptional factor in order to be expressed (36) 
and is associated with a better clinical outcome in breast cancer (37-39). EEF1A2 is an 
eukaryotic elongation factor of which its expression downregulates through interaction 
with protein p16(INK4a) leading to inhibition of cancer cell growth (40). It is mainly 
known as a potential oncogene in ovarian cancer in which its expression enhances cell 
growth in vitro (41). Overexpression of EEF1A2 has also been seen in breast tumors (42) 
and it is one of the genes in the 76-gene signature as identified in the ER-positive subset 
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of 115 primary breast tumors that represent a strong prognostic factor for patients at 
high risk for developing metastases (43, 44). With respect to the other genes of the 
predictor, PTPRK belongs to the group of protein-tyrosine phosphatases (PTPs) that 
control tyrosine phosphorylation. PTPs regulate the signaling of growth-factor receptors 
and can, when deregulated, be associated with tumorigenesis (45). Deregulation of 
PTPs can result in both their up- and downregulation, which can explain the discordance 
between our established association between high expression of PTPRK and poor 
outcome to AI therapy, while decreased expression of PTPRK has previously been related 
to poor prognosis in MBC suggesting a more tumor suppressive role (46). TWIST1, at last, 
is a transcription factor that is one of the most widely known factors to be involved in 
the process of epithelial-to-mesenchymal-transition (EMT). Its overexpression has been 
associated with endocrine therapy resistance due to downregulation of ER promoter 
activity (47). Moreover, through direct repression of E-cadherin cells and activation of 
mesenchymal markers, TWIST1 plays an essential role in tumor metastasis (48). The 
appearance of TWIST1 in our 8-gene CTC predictor is remarkable since our applied CTC 
isolation method relies on an EpCAM-based enrichment step and tumor cells undergoing 
EMT might become EpCAM-negative (49). The dependency on EpCAM-expression by 
CTCs renders the CellSearch method therefore not the best method to capture all CTCs, 
but it is still the only FDA-cleared method which will enable its implementation and 
obtained results in clinical studies. In addition, whether EpCAM loss always accompanies 
EMT is still under debate (50).
Although ER is amongst the 93 target genes that were measured, its mRNA expression 
in this study was not associated with outcome to AI therapy. Several techniques have 
been explored to determine ER expression in CTC, but so far, none of these studies could 
show an association with outcome (reviewed in (19)). Recently, Babayan et al. have 
demonstrated the possibility of measuring ER protein expression in single CTCs through 
immunofluorescence. This study revealed that CTCs of individual MBC patients with ER-
positive primary tumors are frequently a heterogeneous population consisting of both 
ER-positive and ER-negative CTCs (51). Similar to primary tumor tissue, the percentage 
of ER-positive CTCs may be the best parameter associated with outcome rather than ER 
mRNA expression of the total CTC fraction as was measured in our study.
C O N C L U S I O N
In conclusion, we have here defined an 8-gene expression predictor established in CTCs 
that is associated with outcome to first-line AI therapy in MBC patients. Importantly, 
before the results of the current study can be implemented, an independent patient 
cohort is warranted to validate the results found here. Nevertheless, this study 
underscores the enormous potential that molecular characterization of CTCs has.
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D I S C U S S I O N  O F  T H E  T H E S I S
The field of oncology is constantly moving and we continuously obtain more insight into 
carcinogenesis, the development of metastases, and therapy resistance. Meanwhile, 
measures for prevention and tailored treatment are evolving. However, despite all the 
progress achieved, therapy resistance remains a constant hurdle in the treatment of 
cancer patients. The complexity of the mechanisms involved in the development of 
metastases and drug response hinders the discovery of good predictive and prognostic 
factors.
Overall, the implementation of new cancer therapies has improved the survival and 
quality of life of cancer patients but the incidence and prevalence is dramatically 
increasing resulting in high health care costs. Since we know that only a subset of patients 
will benefit from a certain treatment it is crucial to select the right patient for the right 
treatment. Better selection of patients and treatment is not only necessary to improve 
cancer care affordability but will also lead to better quality of life since the trade-off 
between efficacy and toxicity will become more favorable. Improved prognostic and 
predictive factors will not only estimate life expectancy more adequately but will thus 
also result in true personalized medicine. 
The current prognostic and predictive factors for breast cancer encompasses tumor 
characteristics as size, lymph node status and molecular profiles. The discovery of the 
role of ER, PR and HER2 in the tumor biology of breast cancer and the development of 
therapies targeting these factors have dramatically changed clinical decision making in 
breast cancer treatment and favorably changed the prognosis. 
ER targeting therapies form the mainstay of treatment for patients with ER-positive 
breast cancer. Although the majority of breast tumors express the ER, approximately 
30% of the patients with ER-positive advanced disease never respond to endocrine 
therapy and all initial responders will eventually develop resistance (1). Therefore, 
there is a high need for markers to identify patients likely to benefit from therapy for 
which a better insight into the mechanisms conferring endocrine treatment resistance 
is required.
In this thesis, we have investigated several factors involved in endocrine therapy 
resistance measured in both cell line models as well as primary tumors and circulating 
tumor cells (CTC) from patients.
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ADVANCES IN INSIGHTS INTO ENDOCRINE THERAPY RESISTANCE
 
E Z H2 I N H I B I T I O N A N D T H E R A P Y
Over the years, multiple factors accounting for resistance to endocrine therapy have 
been revealed. The development of new drugs and new combinations is usually based 
on these factors. We have described Enhancer of Zeste Homolog 2 (EZH2) as a potential 
new marker to better predict response to tamoxifen. A genome-wide profiling study 
in metastatic breast cancer (MBC) patients treated with first-line tamoxifen therapy 
revealed a higher EZH2 expression in patients that had early progressive disease (2).
EZH2 is the catalytic subunit of the Polycomb Repressor Complex 2 (PRC2) which also 
contains EED, SUZ12 and RBBP4/RbAp48/NURF55 that are required for the histone 
methyltransferase activity that EZH2 exerts. EZH2 is a member of the Polycomb group 
(PcG) proteins and mediates di- and trimethylation of lysine residue 27 on histone 3 
(H3K27). This modification results in chromatin compaction and transcriptional silencing 
(3). As a consequence, EZH2 plays an important role in embryonic development, cell 
differentiation, but also carcinogenesis (4-6). Overexpression of EZH2 was first found 
in prostate cancer and linked to a poorer prognosis (7). Nowadays, it is known that 
overexpression of EZH2 also appears in multiple tumor types like lymphomas (8, 9), 
urogenital tract tumors (10-12), ovarian cancer (13) and breast cancer (14). Excessive 
expression of EZH2 can result through loss of EZH2-targeting miRNAs (e.g. miR-101 and 
miR-26A), increased E2F activity (loss of RB1 or CDKN2A), or amplification of EZH2 itself 
(15). The type of EZH2 dysregulation often correlates with the type of malignancy. For 
example, EZH2 overexpression is mainly found in solid tumors, whereas EZH2 activating 
mutations have been described in lymphomas. These result in an excess of H3K27me3 
repressive marks impairing gene expression of tumor suppressor genes. EZH2-
inactivating mutations, which lead to reduced H3K27me3 and derepression of genes 
contributing to leukemogenesis, have been found in myelodysplastic syndromes (3).
Increased expression of EZH2 has been associated with increased tumor cell proliferation 
and therefore worse survival (10, 14, 16, 17). The association between EZH2 and tumor 
aggressiveness has been confirmed in several tumor types (13, 18, 19) and resulted in 
the consideration of EZH2 as an important therapeutic target. The prognostic value of 
EZH2 seems to be clear but its predictive value was yet unknown. We described the 
association between high EZH2 levels and a poor outcome to tamoxifen therapy. A 
possible explanation can be the derived finding that less expression of EZH2 associates 
with a higher expression of ER which is the treatment target of tamoxifen. Based on 
cell line model studies, we proposed ER as a target of EZH2 where silencing of EZH2 
would result in less H3K27me3 repressive marks on the promoter region of ER and 
as a consequence increased ER expression. There might be a role for Repressor of 
Estrogen receptor activity (REA) since this is a binding partner of EZH2 and binds the 
ER. It thus acts as a corepressor in estrogen-dependent transcription and regulates the 
transcription of estrogen-dependent genes. In line with our findings it has been shown 
that silencing of REA results in an increase of ER-dependent transcription (20).
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EZH2 thus seems to be involved in endocrine therapy resistance and strategies reducing 
its expression might prevent or postpone therapy resistance. The development of 
targeted EZH2-inhibitors is therefore of great interest. It has been shown that two 
microRNAs (miRs) are able to regulate EZH2 expression in different tissues, i.e. miR-
26a and miR-101 (21, 22). miRs are small non-protein coding RNAs that target coding 
mRNAs to repress translation or induce degradation of their target mRNAs. miR-26a 
has been found to be significantly active in lymph node negative disease suggesting 
its role as suppressor of lymph node invasion and is therefore associated with a better 
survival (23). This is in line with our findings that high miR-26a is associated with clinical 
benefit and favorable PFS in a group of MBC patients treated with first-line tamoxifen 
therapy (Chapter 3, this thesis). The overlapping genes between miR-26a and EZH2 were 
CCNE1 and CDC2, both involved in the cell cycle regulation and associated with shorter 
PFS when highly expressed. Moreover, miR-26a inhibits the epithelial-to-mesenchymal 
(EMT) process by repressing EZH2 (24). It might therefore be interesting to target EZH2 
through upregulation of miR-26a through nanoparticles therapy. In this way, therapy 
resistance can possibly overcome while the development of metastases through 
inhibition of EMT gets suppressed.
One of the best known used EZH2 inhibitors is 3-dezaneplanocin-A (DZNep) which is 
a hydrolase inhibitor that targets S-adenosyl-L-homocysteine hydrolase (SAH). DZNep 
leads to an increase of SAH levels and thus to a repression of the activity of S-adenosyl-
L-methionine (SAM)-dependent histone lysine methyltransferase activity such as EZH2 
(25). The effect of DZNep in inhibiting histone methylation is not specific to EZH2 but 
has shown to induce antitumor activity in multiple cancer types and can at least be 
partly due to inhibition of PRC2 and removal of H3K27me3 marks (26). However, it has 
been shown that DZNep can also inhibit the active histone mark H3K4me3 (27). The 
lack of specificity of DZNep together with its short plasma half-life, its unknown effect 
on global methylation status and poor toxicity profile does not make it an attractive 
agent to introduce into the clinic. The development of more selective EZH2 inhibitors 
was therefore of great interest and has identified several potent inhibitors. In 2012, 
EPZ005687 has shown to be a potent inhibitor of EZH2 with a greater than 500-fold 
selectivity against 15 other protein methyltransferases and has 50-fold selectivity 
against the closely related enzyme EZH1 (28). EPZ005687 has exerted inhibition of 
H3K27me3 in EZH2-wild type and Y641- and A677-mutant lymphoma cells as well as in 
cell lines of breast and prostate cancer (25, 28).
An even more selective EZH2-inhibtor is GSK126 that has shown to be more than 
1,000-fold selective for EZH2 versus 20 other human methyltransferases and 150-fold 
as compared to EZH1. GSK126 has shown to induce a 50% loss of H3K27me3 in both 
EZH2 wild-type and mutant lymphoma cell lines and did not affect PRC2 components 
in contrast to DZNep. Moreover, it has shown to be effective and well tolerated in an 
animal model (29). During the development of EPZ005687 and GSK126, a third selective 
SAM-competitive inhibitor, El1, was developed and showed to be highly selective (30).
The discoveries of these agents have been an important development in the field of 
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epigenetic therapy. However, these compounds require frequent injection and are 
therefore less useful in the clinic. Hence UNC1999 has been synthesized as the first 
orally bioavailable inhibitor and showed to be highly selective for wild-type EZH2 and 
Y641 mutant as well as EZH1 (31).
The first EZH2-inhibitor that has led to phase I/II clinical trial is EPZ-6438 (tazemetostat). 
In this trial, 45 patients were included of whom 26 had relapsed or refractory solid tumors 
and 19 had lymphoma. There was an acceptable safety profile and preliminary results 
of the 15 tested patients with non-Hodgkin lymphoma showed partial or complete 
response in 9 of them (http://www.epizyme.com/wp-content/uploads/2015/07/ICML-
Slides-Presented-062015-v2.pdf).
F U T U R E P E R S P EC T I V E S O N E R , E Z H2, A N D E N D O C R I N E T H E R A P Y
Although the prognostic value of EZH2 has already been widely investigated and 
recognized, the predictive value has been hardly studied. Since EZH2 has been shown 
to be highly expressed in more aggressive tumor types, its determination in clinical 
practice could be of use in choosing the right treatment strategy. Additionally, in this 
thesis, we have demonstrated  that the expression of EZH2 is associated with outcome 
to both tamoxifen and AI therapy which underscores its predictive value. Before EZH2 
can be introduced as a valuable marker in the clinic, prospective clinical trials should 
be conducted in order to identify subsets of patients that will benefit from a certain 
treatment based on their EZH2 expression levels. At first, it needs to be clarified if EZH2 
expression can be measured in a standardized matter without much variability. Next, it 
would be interesting to determine if EZH2 can be adequately measured in both primary 
tumors and circulating biomarkers. At last, it needs to be further clarified if EZH2 itself 
can be used as a possible treatment target with an acceptable toxicity profile. Until now, 
the results of EZH2 inhibition are promising. It might be interesting to continue clinical 
trials specifically focused on the downstream effects of EZH2 inhibition. If, like in our 
cell line studies, it shows to upregulate or reinduce ER expression in patients with breast 
cancer, EZH2 inhibition could be a solution to endocrine therapy resistance. Nowadays, 
loss of ER expression due to clonal selection of ER negative cells or transcriptional 
repression of ER gene expression is one of the most known causes of resistance (32-34) 
and it has been shown that demethylating agents or histone deacetylase inhibitors can 
reactivate ER expression when its promotor has been methylated leading to renewed 
sensitivity to endocrine therapies (35, 36). Although these drugs have shown advantages 
in hematological disorders, challenges remain in the use of these compounds due to 
their instability in aqueous solutions and their rapid inactivation (37). In the area of solid 
malignancies, no epigenetic agents have yet been introduced into clinical practice but 
several trials have shown potential clinical benefit, e.g. a double-blind phase II study 
of exemestane with the HDAC inhibitor entinostat versus exemestane alone in 130 
patients with ER-positive MBC who had previously progressed on an non-steroidal AI in 
which modest improvement in PFS was shown but an impressive difference in overall 
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survival was seen, indicating that epigenetic therapy may improve long-term outcomes 
for patients (38).
Although EZH2 inhibition seems to be promising to overcome endocrine resistance, it is 
known that genomic changes and clonal expansion of rare mutant clones occur over time 
and under treatment pressure, which may also yield endocrine resistance. Induction of 
different mutational profiles during therapy with EZH2 inhibition is therefore very well 
possible. For example, ESR1 mutations are frequently acquired during the process of 
endocrine therapy resistance, especially during treatment with estrogen deprivation 
therapy like aromatase inhibitors (39, 40). These mutations are clustered in the ligand-
binding domain (LBD) of the ER and induce constitutive ligand-independent ER activity 
that promotes tumor growth, contributing to the development of resistance  (41-43). It 
has been shown that the mutant transcriptional activity can partly be reduced through 
higher doses of tamoxifen and fulvestrant (43) which might explain the finding that a 
higher dose of fulvestrant improved PFS and OS in a phase III trial including patients 
with ER-positive advanced breast cancer (44, 45). In contrast, it has been shown that 
patients with detected ESR1 mutations in circulating tumor DNA (ctDNA) do not have 
a differential PFS with fulvestrant treatment compared with patients without ESR1 
mutations. However,  a substantial majority of the ESR1 mutations show a persistent 
decrease in allele frequency over time during treatment with fulvestrant or remain free 
of detectable plasma ESR1 mutations (40). Presumably, selective estrogen receptor 
degraders (SERD) like fulvestrant are able to both degrade wild type and mutant ER.
E R , P I3K PAT H WAY, A N D E N D O C R I N E T H E R A P Y
New therapeutic strategies have been developed due to the expansion in knowledge on 
the molecular biology of both primary and secondary resistance. The PI3K/AKT/mTOR 
pathway has been shown to be one of the activated key pathways during endocrine 
therapy resistance (46, 47). Preclinical data provided evidence for combining mTOR 
inhibition and endocrine therapy due to its synergistic effect on inhibition of proliferation 
(48). Two landmark clinical trials confirmed these data. The phase II TAMRAD study in 
which tamoxifen was combined with everolimus showed an improvement in PFS and OS 
compared to tamoxifen alone in patients with MBC that had progressed during or after 
non-steroidal AI therapy (49). The BOLERO-2 study largely confirmed these findings 
but compared everolimus with exemestane to exemestane alone in MBC patients who 
failed previous treatment with non-steroidal AI therapy. The observed statistically 
prolonged PFS has led to the new standard of care for the treatment of endocrine-
resistant postmenopausal MBC (50, 51). However, the combination therapy has recently 
shown not to significantly improve OS (52). Several other agents that target this pathway 
upstream of mTOR are currently under investigation and have shown promising results 
(53, 54). 
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Interestingly, treatment with agents targeting the PI3K/AKT/mTOR pathway only seems 
to be effective when secondary endocrine resistance has been developed as the 
HORIZON trial showed no improvement in PFS when endocrine-naïve patients were 
treated with letrozole and temsirolimus (mTOR antagonist) compared to letrozole alone 
which underscores the existence of more treatment options after failure of first-line AI 
therapy (55).
Preclinical studies resulted in evidence for increased cross-talk between growth factor 
receptor signaling pathways and ER at the time of relapse on endocrine therapy, 
providing a rationale for targeting both (56, 57). Although there are no conclusive 
clinical data to support the combination of EGFR-inhibition and endocrine therapy as 
first-line therapy, several clinical studies have shown improvement in PFS when ER+ 
HER2+ tumors are concurrently treated with anti-HER2 and endocrine therapy (54).
However, blockade of the HER2 pathway in ER+ HER2- MBC patients did not show an 
improvement in PFS thus fails to delay resistance (58). The combined therapy in these 
patients could probably become effective once resistance against endocrine therapy 
has developed, presumably due to induction of HER2 expression, as supported by 
xenograft studies (57).
Inhibition of the cell cycle forms a new therapeutic strategy since dysregulation of the 
cyclin-D-CDK4/6-INK4-Rb pathway is frequently observed in cancer and contributes to 
continuous growth. However, a major concern is that CDKs play an important role in 
the proliferation of both normal cells as well as cancer cells which creates a narrow 
therapeutic window. CDK4/6 activity plays key role in cell proliferation and thus forms 
an attractive therapeutic strategy. Palbociclib, an oral CDK4/6 inhibitor, prevents cellular 
DNA synthesis by blocking cell cycle progression from G1 to S phase. The combination 
of palbociclib and letrozole has shown an impressive and significantly improved PFS 
compared to letrozole alone in patients with ER+ MBC and has led to an accelerated 
FDA-approval (59). This approach seems also be attractive in endocrine resistant disease 
considering the improved PFS as shown in a recent study that compared palbociclib 
and fulvestrant with fulvestrant alone in patients with ER+ MBC that had progressive 
disease during prior endocrine therapy (60).
It would be interesting to combine a CDK4/6 inhibitor with an EZH2 inhibitor 
since EZH2 is a downstream target of CDK6 and inhibition of CDK6 has shown to 
downregulate the protein expression levels of both pRB and EZH2 (61). Combining 
both inhibitors could possibly lead to a synergistic effect on inhibition of cell growth. 
The combination of CDK4/6 inhibitors and PI3K inhibitors has already proven to be 
effective in vitro. In breast cancer cell lines where PI3K inhibition alone was relatively 
ineffective, the addition of a CDK4/6 inhibitor demonstrated a synergistic interaction in 
suppressing cell proliferation by induction of cell cycle arrest rather than apoptosis (62).
Processed on: 17-10-2016
505830-L-sub01-bw-Reijm
133
F U T U R E  P E R S P E C T I V E S  O N  C I R C U L A T I N G  T U M O R 
C E L L S  ( C T C S )  A N D  C T D N A
It has been shown that mutational profiles and ESR1 mutations can extensively vary 
within the primary tumor of a patient but also between different metastatic sites within 
a patient (63, 64). It is thought that one of the major reasons for the current failure 
of cancer treatments is the inability to accurately monitor this spatial and temporal 
heterogeneity during tumor evolution. New technological advances using circulating 
biomarkers have been developed which have shown to be able to capture, amongst 
others, ESR mutations, leading to early treatment changes (65).
Until the development of circulating biomarkers it was necessary to take multiple 
biopsies in order to adequately monitor disease. However, this is an invasive and 
sometimes risky procedure and not always feasible. Moreover, the heterogeneity within 
a tumor harboring different mutational profiles requiring other treatment decisions 
can easily be missed. Hence, the characterization of circulating biomarkers poses an 
attractive alternative. Both CTCs and ctDNA are thought to originate from either the 
primary tumor or metastases and can be obtained through venipunctures. This way, 
analyses of CTCs and ctDNA are considered a real-time ‘liquid biopsy’.
T H E D E T EC T I O N A N D U S E O F C T C S
The detection of CTCs is challenging with a median CTC count of 3 – 5 per 7.5 mL of 
blood in MBC patients (66). Over the years many CTC detection assays have been 
developed but the CellSearch system is yet the only FDA-cleared system. It isolates CTCs 
using surface protein expression of the epithelial marker EpCAM. Major drawback is 
that CTCs undergo epithelial-to-mesenchymal transition (EMT) that results in reduced 
expression of epithelial markers which might lead to false-negative findings when using 
techniques like CellSearch (67). During the process of EMT, different subsets of CTCs 
show a range of phenotypes. In order to isolate these CTCs a large cocktail of both 
epithelial and mesenchymal markers would be necessary increasing the risk of isolating 
individual blood cells expressing at least one of these markers resulting in false-positive 
results (68, 69). This limitation can be overcome by using actin bundling protein plastin 
3 which is not expressed by blood cells and does not to get downregulated during EMT 
(70). In breast cancer, this marker has recently been identified as a biomarker to identify 
patients at risk of recurrence or with a poor prognosis (71).
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The first study that reported the prognostic value of CTC count in MBC dates from 2004 
(72) which has been confirmed in a pooled analysis ten years later in which CTC count 
showed to be a dynamic prognostic marker of PFS and OS (73).
Interestingly, CTCs can also be detected in patients presenting with primary breast 
cancer without overt metastatic disease and appear to be an independent predictor of 
poor disease-free, overall, breast cancer-specific, and distant disease-free survival (74). 
The reported rates might be an underestimation since this study used the CellSearch 
system in which the more aggressive CTC types that have undergone EMT are possibly 
missed. 
There already have been performed several CTC-driven clinical trials of which the SWOG 
S0500 trial is the most widely known. In this trial patients with persistently elevated 
CTCs (≥5 CTCs/7.5 mL) after one cycle of chemotherapy were randomized between 
continuation of the first-line chemotherapy or early switch to another chemotherapy 
regimen. The study confirmed the prognostic significance of CTC measurements since 
patients who had a decline in CTC number after the first cycle of chemotherapy had a 
longer OS compared to patients whose baseline CTCs did not decline. However, an early 
switch to an alternative chemotherapy regimen failed to improve OS or PFS (75). The 
trial however included a heterogeneous population of MBC patients that could have 
received endocrine or biologic therapies before inclusion. Moreover, CTC change was 
only assessed as a binary categorical variable which implies that major changes in CTC 
numbers were not scored unless they crossed the threshold of 5 CTCs/7.5 mL at the 
second measurement. Next, it is uncommon for breast cancer that has resistance to one 
chemotherapy regimen to exhibit a high degree of sensitivity to a randomly selected 
alternative chemotherapy. 
Future clinical trials, taking into account the missed aspects in SWOG S0500, should 
further investigate the potential contribution CTCs can have in clinical decision making. 
Besides detection and enumeration of CTCs the major clinical challenge encompasses 
molecular characterization of CTCs in order to base clinical decision making on the 
current tumor characteristics. CTCs can be characterized on different levels of which 
protein level might be the most interesting as ER is a key target in breast cancer. It has 
been demonstrated that ER+ breast tumors can frequently harbor ER- CTCs which may 
reflect an escape mechanism to endocrine therapy (76). ESR1 mutations were not found 
in this study when performing single cell analysis on the CTCs drawn from ER+ MBC 
untreated patients which is consistent with the finding that these mutations only occur 
after endocrine treatment failure.
The HER2 oncogene has also shown to have a discrepant status between primary 
tumor and CTCs in up to 30% of cases (77). This is particular interesting in patients with 
HER2-negative primary tumors and HER2+ CTCs since it could lead to more extensive 
treatment options if these patients respond to HER2-targeting therapies.
More recently, immune checkpoint regulators such as PD-1/PD-L1 have become new 
therapeutic targets which is in line with the lack of immunologic control as one of 
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the emerging hallmarks of cancer (78). It has shown promising results in many tumor 
types including advanced melanoma and non-small cell lung cancer (NSCLC) patients. 
Recently, it has been demonstrated that PD-L1 is expressed on CTCs of ER+ HER2- MBC 
patients (79) which might form a rationale to select these patients for anti-PD-1/PD-L1 
therapy.
In addition to determining protein expression in CTCs of breast cancer patients, mRNA 
analyses can also be performed (80) but have not yet shown to lead to treatment 
changes. Our 8-gene CTC profile is the first study that has generated a unique mRNA 
CTC-based gene panel that is able to distinguish good and poor responders to first-line AI 
therapy which could impact clinical decision making. This way, CTC characterization can 
be used as a predictor for response to endocrine therapy which may better reflect the 
current disease burden and therapy sensitivity of an MBC patient in order to overcome 
over- or undertreatment. Before it can be implemented in clinical practice, extensive 
prospective validation is warranted. This can be difficult since it should be taken into 
account that this profile has been based on CTCs captured with the CellSearch system 
potentially missing out on the CTCs that have undergone EMT. Moreover, the CTC 
profile has been measured in the total amount of detected CTCs thus heterogeneity 
between CTCs has not been taken into account. Although single cell analyses of CTCs 
might therefore be of more interest, CTC characterization of the total amount of CTCs 
is possibly an adequate reflection of the overall tumor burden and, moreover, easier to 
implement in clinical practice.
On DNA level, both TP53 and PIK3CA mutations have been detected in CTCs (81, 82). 
This could lead to treatment changes since it has been reported that PI3K hyperactivity 
contributes to a lower response to trastuzumab and lapatinib in patients with HER2+ 
tumors as well as to resistance to anti-estrogen therapies (83, 84). The combination of 
PI3K-inhibition and antiestrogen therapy has shown to induce regression of ER+/PIK3CA 
mutant breast tumors. However, there has been demonstrated a strong heterogeneity 
in the mutational status among CTCs from individual patients making it difficult to come 
to an appropriate treatment strategy (82).
C I R C U L AT I N G T U M O R D N A (C T D N A)
Another circulating biomarker that can serve as a new target for antitumor therapy 
is ctDNA, i.e. DNA that is shed by damaged, apoptotic, and necrotic tumor cells into 
the blood. It can be released from primary tumors, CTCs, micrometastasis, or overt 
metastases (85, 86). Since ctDNA has a half-life of less than 2 hours it is thought to 
be a good representation of the present tumor load (87). Levels of ctDNA vary a lot 
between patients and can be hard to detect amongst background levels of circulating 
wild-type DNA, especially for small tumors in early stages. The development of sensitive 
techniques such as BEAMing and digital PCR made it possible to detect and quantify 
minute amounts of DNA. False positives are expected to be rare because ctDNA is 
defined by mutations and other genomic changes that are hallmarks of cancer cells (87).
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In a large study that included multiple cancer types it was shown that ctDNA can be 
detected in most solid tumors outside the brain although the fraction varied with tumor 
type and among patients with the same tumor type. ctDNA can also be detected in 
patients with localized disease but in a lower fraction than patients with advanced 
disease (88, 89). In patients with localized disease, the level of baseline ctDNA showed 
not to be predictive for disease-free survival but ctDNA detection in a postoperative 
sample was highly predictive of early relapse even so was ctDNA detection in serial 
samples. The presence of ctDNA seems to identify relapse before clinical relapse on 
conventional imaging (89). Although results are fairly promising, it needs to be taken into 
account that this study included only patients treated with neoadjuvant chemotherapy 
and sample size was quite small.
ctDNA might be more sensitive than CTCs as ctDNA fragments outnumbered CTCs in 
the previous described study. All patients with CTCs had ctDNA whereas not all patients 
with ctDNA had a trace of CTCs (88). However, most of the included patients in this 
subanalysis had low stage cancer whereas CTCs are thought to be mainly present in 
advanced disease whereas ctDNA is more often detected in both localized and advanced 
disease.
Just as in CTCs, the major clinical challenge in ctDNA is not to detect its presence but to 
detect the molecular characteristics it harbors. At present, several genomic alterations 
can be detected in ctDNA of various tumor types (90). For example, it has been shown 
to be possible to detect PIK3CA mutations in ctDNA of primary breast cancer patients. 
The amount of detected PIK3CA mutated ctDNA was related to a shorter recurrence-
free survival and OS (91). 
In a study with patients with MBC, ctDNA was collected and somatic genomic alterations 
were identified in TP53 and PIK3CA. In this study, ctDNA levels showed a greater 
dynamic range, and greater correlation with changes in tumor burden, than did CA15-3 
or CTCs detected by the CellSearch system (92). However, this study only investigated 
52 patients.
Next, ESR1 mutations can robustly be identified in ctDNA of ER+ MBC patients. ESR1 
mutations are rarely acquired during adjuvant AI therapy but commonly selected during 
first-line AI therapy and can occur in a polyclonal manner (39, 93). Since these mutations 
predict for resistance to subsequent AI therapy, detected ESR1 mutations in ctDNA 
before disease progression occurs can lead to an early change in therapeutic options 
with potential benefit to patients (94).
It will be crucial to select the correct time point for ctDNA screening in order to detect 
those ctDNA variants that are derived from the resistant tumor cell clones. Parallel 
determination of viable CTCs might provide the required additional information to tailor 
the therapy to the need of the cancer patient (86). Moreover, before ctDNA analysis can 
be implemented in the management of cancer patients, tests need to be standardized 
to make them as reliable and reproducible as CTC tests already are.
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F U T U R E  P E R S P E C T I V E S  O N  M E D I C A L  O N C O L O G Y
The development of new endocrine and targeted therapies has prolonged the 
clinical benefit for women with ER+ MBC in such manner that the time that cytotoxic 
chemotherapy is required has been extensively delayed. However, targeting a solitary 
signaling pathway will not reverse all endocrine therapy resistance mechanisms. 
Blockade of one signaling pathway will promote the development of compensatory 
escape mechanisms which forms the rationale for the development of combination 
therapies that target key signaling pathways in parallel (horizontal blockade) or in series 
(vertical blockade) (54). To select the most appropriate population for each form of 
therapy it is probably useful to find the relevant biomarker through real-time biopsy by 
using a circulating biomarker as the best representative for metastatic disease in order 
to maximize the likelihood of success in preventing, postponing or reversing endocrine 
therapy resistance.
Liquid biopsies can be used to monitor patients being treated with targeted agents to 
provide longitudinal monitoring of genomic alterations and check for the emergence 
of treatment-resistant clones over time. However, identifying tumor recurrence at an 
earlier time point does not improve clinical outcome if an effective therapy is not selected 
or available. Moreover, a risk is the detection of clinically irrelevant molecular changes 
due to the high sensitivity of the methods. Next, it might be difficult to discriminate 
between driver and passenger mutations. Large annotated datasets and bioinformatic 
tools next to sharing of clinical data will be needed to distinguish potentially important 
genomic aberrations from noise (95).
It is expected that in the near future of medical oncology new therapeutics will be 
developed especially targeting those mutations that will be discovered from circulating 
biomarker research and show to be involved in treatment resistance. It is therefore 
necessary to determine what level of alteration/mutation in a key driver is sufficient to 
initiate a switch in disease management before circulating biomarkers can be introduced 
in the clinic.
The future of medical oncology will eventually consist of precision medicine. The right 
treatment for a patient should be constantly tailored using both primary tumor and 
circulating biomarker information in which CTCs and ctDNA can both contribute in a 
different and complementary matter. Besides genomic data derived from both primary 
and circulating tumor parts, this thesis underscores the importance of epigenetics as 
has also recently been demonstrated (96). The role of epigenetics is not yet exactly 
known but its importance is recognized and has led to a broader range of targeted 
therapy. These agents warrant more research before implementation in the clinic but 
it is expected that they will contribute to a better survival, and hopefully quality of life, 
of MBC patients.
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S U M M A R Y
Over the past years, cancer has become the most common cause of death in The 
Netherlands. From all types of cancer, breast cancer is the most common cancer in 
females. Fortunately, the majority of patients presents with low stage breast cancer 
and has a relatively favorable prognosis. This prognosis is dependent on stage at 
presentation, which encompasses tumor size, lymph node status and presence or 
absence of distant metastases. Besides, the molecular classification is an important 
prognostic and predictive factor of which the estrogen receptor (ER), the progesterone 
receptor (PR), and HER2-neu are best known. The development of many therapies 
that target the ER have dramatically improved the prognosis of breast cancer and is 
considered as endocrine therapy. Tamoxifen, a selective estrogen receptor modulator, 
forms the mainstay of treatment for premenopausal women for more than 30 years. It 
competes with estradiol for the binding to ER and represses the transcriptional activity 
of ER by inducing a conformational change of the receptor.
An alternative strategy within the spectrum of endocrine therapy is the inhibitors of 
aromatase (AI), which are mainly used for postmenopausal women. AI therapy depletes 
serum estradiol levels by inhibiting the aromatase enzyme and therefore less growth 
factor is available for the receptor and consequently for the tumor.
In metastatic breast cancer (MBC), endocrine therapy is still the mainstay of treatment 
because of the favorable toxicity profile. Although many patients greatly benefit 
from endocrine therapies, it is known that approximately 30% of the MBC patients 
never respond due to de novo resistance. Besides, all initial responders eventually 
relapse. Therefore, MBC is still not a curable disease despite the current knowledge 
on the disease and the development of new therapies. Better understanding of the 
mechanisms involved in therapy resistance could lead to a change in treatment and 
thus possibly postpone the occurrence of resistance. The generation of biomarkers can 
lead to a better and more targeted individualized treatment. Therefore, as described 
in chapter 1, the goal of this thesis is to discover and understand (epigenetic) factors 
involved in endocrine therapy resistance. To reach this goal, cell line models were used 
next to both primary tumors and circulating tumor cells (CTCs) derived from patients.
Chapter 2 describes the finding of EZH2 being involved in resistance to tamoxifen. 
After a genome-wide profiling study in MBC patients, EZH2 showed to have higher 
expression levels in patients with resistance to first-line tamoxifen. EZH2 is a histone 
methyltransferase that mediates trimethylation of lysine residue 27 on histone 3 
(H3K27me3) in order to control transcriptional processes of several target genes. This 
way, EZH2 is involved in the initiation and progression of several types of cancer and 
seems to be an important prognostic marker. In this chapter we have explored the 
predictive value of EZH2 using primary tumors of patients and cell line models. We 
demonstrated that MBC patients with higher expression levels of EZH2 in the primary 
tumor have a shorter progression-free survival (PFS) during treatment with first-line 
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tamoxifen. Downregulating the expression of EZH2 using siRNAs in a cell line model 
(MCF7) showed less tumor growth and an even stronger effect when ICI 164383, as 
surrogate for tamoxifen, was added. Moreover, we discovered that less expression of 
EZH2 in this cell line model was associated with an upregulation of the expression of ER 
which can explain the cumulative response when adding ICI.
In chapter 3, we took a closer look at the EZH2 pathway. We investigated the quantitative 
Real-Time Polymerase Chain Reaction (qRT-PCR) data from primary tumors of MBC 
patients treated with first-line tamoxifen. Through pathway analysis, we checked which 
genes were associated with a shorter PFS and thus with resistance.
High levels of miR-26a turned out to be associated with a favorable outcome in this 
setting, which can be explained through the inhibiting effect of miR-26a on EZH2. By 
investigating significantly differentially expressed genes between tumors with high and 
low expression levels of miR-26a and EZH2, it turned out that the genes associated with 
the cell cycle, CCNE1 and CDC2, were the only overlapping genes. Higher expression 
levels of these genes were associated with an unfavorable outcome. This can be 
explained by the CDC2 mediated phosphorylation on EZH2 which has an activating 
effect. The best response to tamoxifen can be expected in patients with low expression 
levels of EZH2, CCNE1 and CDC2 and high expression levels of miR-26a in their primary 
tumors.
Next to the generated data on mRNA level, we investigated whether protein levels of 
EZH2 are also involved in the response to tamoxifen in chapter 4. We therefore used a 
tissue microarray (TMA) which consisted of the primary tumor specimens of 250 MBC 
patients treated with first-line tamoxifen. The expression of EZH2 in tumor cells was 
scored on quantity and intensity and associated with PFS. With this study it became 
clear that also protein levels of EZH2 can be used to predict the response to tamoxifen 
since tumors with the highest expression of EZH2, independent of intensity, turned out 
to have a worse response to tamoxifen.
In chapter 5 we investigated whether EZH2 is also involved in the response to AI. We 
used chromatin immunoprecipation (ChIP) and sequencing techniques to determine 
where ER binds to the DNA in tumors of patients treated with first-line AI. Furthermore, 
we determined in which areas of the genome the DNA is either accessible (H3K4me3) 
or not (H3K27me3) for ER in these tumors. The tumors showed unique binding patterns 
for ER, H3K27me3 and H3K4me3 that marginally overlapped. The clearest difference 
between DNA binding events was shown between ER and H3K27me3 when comparing 
good and poor outcome patients treated with first-line AI. Next, these differential 
enriched binding patterns were validated in an independent patient cohort and showed 
to be predictive for response to AI. These results suggest that the accessibility of the 
genome can determine the behavior of ER and that H3K27me3, as a sign of activity of 
EZH2, is predictive for a poor response to AI.
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Finally, we used gene expression in CTCs to predict the response to AI in chapter 6. 
CTCs can be detected in the peripheral blood. It is thought that CTCs are a better 
representation of the metastases since differences between the primary tumor and 
metastases are increasingly recognized. These differences are caused by the course of 
time, genomic instability of a tumor and exposure to treatment.
In this study, we isolated CTCs of 45 MBC patients treated with first-line AI and 
molecularly characterized them using a previously selected 96-gene profile. Next, we 
investigated which genes were most differentially expressed between patients with 
a PFS shorter and longer than 9 months. From this selection an 8-gene profile was 
generated that happened to best identify patients with a good response to AI therapy. 
Although these results require validation, they can contribute to a more personalized 
treatment approach.
In the end, the main findings of this thesis are discussed and placed in a broader 
perspective in chapter 7. Both the underlying mechanisms of the findings as well as the 
limitations of the study are reviewed. The chapter concludes with suggestions for future 
research. 
In conclusion, in this thesis we have demonstrated that a higher expression level of 
EZH2 in the primary tumor of MBC patients is associated with a worse response to 
tamoxifen on both mRNA and protein level. The same holds true for higher expression 
levels of CDC2 and CCNE1 and a lower expression level of miR-26a which are all factors 
involved in the EZH2 pathway. Downregulation of EZH2 seems to be a good therapeutic 
strategy because it increases the sensitivity to tamoxifen which might be due to a higher 
expression of ER.
The activity of EZH2, measured through H3K27me3 binding events, has shown to 
be predictive for a shorter PFS during treatment with first-line AI. Finally, molecular 
characterization of CTCs can be used to identify patients that respond to AI therapy.
It might be possible that due to the findings in this thesis EZH2 and gene expression 
analyses of CTCs will get involved in the determination of the response profile of a 
patient to come to a personalized and more targeted treatment decision.
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S A M E N V A T T I N G
 
De afgelopen jaren is kanker de meest voorkomende doodsoorzaak in Nederland 
geworden. Borstkanker is bij vrouwen de meest voorkomende kankersoort. In de 
meeste gevallen betreft dit een laag stadium borstkanker met goede prognose. Deze 
prognose is afhankelijk van het ziektestadium bij diagnose en omvat de grootte van de 
tumor, wel/geen aangedane lymfeklieren en de aan- of afwezigheid van metastasen 
op afstand. Ook de moleculaire classificatie is een belangrijke prognostische en 
predicitieve factor waarvan de bekendste factoren de oestrogeen receptor (ER), de 
progesteron receptor (PR) en HER2-neu zijn. De ontwikkeling van therapieën gericht op 
de ER heeft de prognose van borstkanker enorm verbeterd en wordt geschaard onder 
de endocriene therapie. Tamoxifen, een selectieve oestrogen receptor modulator, 
speelt al meer dan 30 jaar een hoofdrol in de behandeling van borstkanker. Het gaat 
de competitie aan met oestradiol om aan de ER te kunnen binden en onderdrukt de 
transcriptionele activiteit van ER door een conformatie verandering in de eiwitstructuur 
van de receptor te induceren.
Een andere groep medicamenten binnen de endocriene therapie wordt gevormd 
door de aromatase remmers (AI). Door het remmen van het aromatase enzym wordt 
er minder oestradiol gevormd en is hiermee minder hormoon beschikbaar voor de 
receptor en dientengevolge voor de tumor.
Endocriene therapie is ook in de gemetastaseerde setting een veelgebruikte vorm van 
therapie, met name vanwege het gunstige toxiciteitsprofiel. Hoewel veel patiënten 
goed reageren op deze vorm van behandeling is bekend dat circa 30% van de patiënten 
met gemetastaseerde borstkanker (MBC) reeds bij aanvang van de behandeling niet 
responderen vanwege (intrinsieke) resistentie. Tevens zal iedere behandelde patiënt 
uiteindelijk resistentie ontwikkelen. Hierdoor is MBC nog steeds een ongeneeslijke ziekte, 
ondanks de huidige kennis van de ziekte en de ontwikkeling van nieuwe therapieën. Het 
beter begrijpen van de mechanismen betrokken bij resistentie zal kunnen leiden tot een 
verandering in behandeling en hiermee tot uitstel van het optreden van resistentie. Met 
het genereren van biomarkers kan per patiënt een beter en gerichter geïndividualiseerd 
behandelplan opgesteld worden. Daarom, zoals beschreven in hoofdstuk 1, is het doel 
van dit proefschrift om (epigenetische) factoren betrokken bij endocriene therapie 
resistentie te ontdekken en te begrijpen. Om tot dit doel te komen is gebruik gemaakt 
van cellijnmodellen naast zowel primaire tumoren als circulerende tumorcellen (CTCs) 
afkomstig van patiënten.  
Hoofdstuk 2 beschrijft de bevinding dat Enhancer of Zeste Homolog 2 (EZH2) betrokken 
is bij tamoxifen resistentie. EZH2 was uit een eerdere genome-wide studie naar voren 
gekomen als een gen dat hoger tot expressie komt in patiënten met MBC met resistentie 
tegen eerstelijns therapie met tamoxifen. EZH2 is een histon methyltransferase en in staat 
om van verschillende targetgenen histon 3 lysine residu 27 te trimethyleren (H3K27me3) 
en zo de expressie hiervan te veranderen. EZH2 is op deze manier betrokken bij het 
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ontstaan en de progressie van diverse tumorsoorten en lijkt hiermee een belangrijke 
prognostische marker te zijn. In dit hoofdstuk hebben we de predictieve waarde van 
EZH2 onderzocht waarbij we gebruik hebben gemaakt van tumormateriaal afkomstig 
van patiënten en cellijnmodellen. We hebben aangetoond dat de patiënten met MBC 
met een hoge expressie van EZH2 in de primaire tumor een kortere progressievrije 
overleving (PFS) hebben gedurende behandeling met tamoxifen. Bij het verminderen 
van de expressie van EZH2 met behulp van zogenoemde siRNA’s in een cellijnmodel 
(MCF7) bleek dat de tumorcellen langzamer gingen groeien en dat dit versterkt werd 
wanneer ICI 164383, als surrogaat voor tamoxifen, werd toegevoegd. Tevens zagen 
we in dit cellijnmodel dat verminderde expressie van EZH2 was geassocieerd met een 
verhoging van de expressie van ER, wat een goede verklaring kan zijn voor de versterkte 
respons op het toevoegen van ICI.
In hoofdstuk 3 zijn we dieper ingegaan op de signaaltransductie route waar EZH2 op 
ingrijpt. We hebben gekeken naar de Real-Time Polymerase Chain Reaction (qRT-PCR) 
data verkregen vanuit de primaire tumoren van patiënten met MBC en behandeld met 
eerstelijns tamoxifen. Door middel van pathway analyse kon gekeken worden welke 
genen corresponderen met een korte PFS en daarmee met resistentie. Hoge gehaltes 
van miR-26a bleken gunstig te zijn waarbij dit te verklaren valt door de remmende 
werking van miR-26a op EZH2. Door te onderzoeken welke genen significant anders tot 
expressie kwamen tussen tumoren met respectievelijk hoge en lage expressie van miR-
26a en EZH2, werd duidelijk dat de celcyclus geassocieerde genen CCNE1 en CDC2 de 
enige overlappende genen waren. Verhoogde expressieniveaus van deze genen bleken 
gerelateerd aan een slechtere uitkomst. De verklaring kan liggen in de fosforylerende, 
en daarmee activerende, werking van CDC2 op EZH2. De beste respons op tamoxifen 
is derhalve te verwachten bij patiënten met lage expressieniveaus van EZH2, CCNE1 en 
CDC2 en hoge expressie van miR-26a in hun primaire tumoren.
Naast de gegenereerde data op mRNA niveau, hebben we in hoofdstuk 4 gekeken of 
EZH2 ook op eiwitniveau betrokken is bij de respons op tamoxifen. Hiertoe hebben we 
gebruik gemaakt van een zogenoemde tissue microarray (TMA) welke bestond uit de 
primaire tumor samples van 250 MBC patiënten behandeld met eerstelijns tamoxifen. 
De expressie van EZH2 in de tumorcellen werd gescoord op hoeveelheid en intensiteit 
en gecorreleerd aan PFS. Vanuit deze studie is gebleken dat EZH2 ook op eiwitniveau 
gebruikt kan worden om de uitkomst op tamoxifen te voorspellen daar de tumoren met 
de meeste EZH2 expressie, onafhankelijk van de intensiteit, een slechtere respons op 
tamoxifen hebben.
In hoofdstuk 5 hebben we gekeken of EZH2 ook een rol speelt in de respons op AI. 
We hebben chromatine immunoprecipitatie (ChIP) en sequencing technieken gebruikt 
om te bepalen op welke plekken in het genoom ER aan het DNA bindt in de primaire 
tumoren van patiënten met MBC die zijn behandeld met eerstelijns AI en die een goede 
of een slechte uitkomst hadden. Hiernaast hebben we bij deze tumoren gekeken in welke 
gebieden van het genoom het DNA wel (H3K4me3) of niet (H3K27me3) toegankelijk is 
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voor ER. De tumoren bleken unieke ER-, H3K27me3- en H3K4me3-bindingspatronen 
te bezitten met weinig overlap. Vooral het DNA-bindingspatroon van ER en het DNA-
toegankelijkheids-profiel van H3K27me3 verschilde voor specifieke genen tussen 
patiënten met een goede of slechte respons op AI. De expressie van deze specifieke 
genen van het ER- en het H3K27me3-bindingspatroon bleken vervolgens in tumoren 
van een onafhankelijke groep patiënten voorspellend te zijn voor de respons op AI. Deze 
resultaten suggereren dat de toegankelijkheid van het genoom het gedrag van ER kan 
bepalen en dat H3K27me3, oftewel de activiteit van EZH2, voorspellend is voor een 
slechte respons op AI.
Tot slot hebben we in hoofdstuk 6 gebruik gemaakt van genexpressieprofielen in 
CTCs om de respons op AI te voorspellen. CTCs kunnen worden gedetecteerd in het 
perifere bloed. De veronderstelling is dat CTCs een betere representatie zijn van 
gemetastaseerde ziekte, mede gezien het bekend is dat er grote verschillen kunnen 
bestaan tussen de primaire tumor en de metastasen. Dit komt onder meer door de 
tijd, de genomische instabiliteit van een tumor en de blootstelling aan behandeling.
We hebben in deze studie de CTCs van 45 MBC patiënten behandeld met eerstelijns AI 
geïsoleerd en gekarakteriseerd middels RT-PCR door gebruik te maken van een eerder 
opgesteld profiel bestaande uit 96 genen. Vervolgens hebben we gekeken welke genen 
het meest differentieel tot expressie kwamen tussen patiënten met een PFS korter dan 
wel langer dan 9 maanden. Hieruit is een 8-gen profiel gegenereerd dat vooral in staat 
bleek om de patiënten te identificeren die goed reageren op eerstelijns AI therapie. 
Hoewel de resultaten uit deze studie nog validatie behoeven, is het een stap in de 
richting van een biomarker die de gewenste individuele therapie kan voorspellen.
Tenslotte worden in hoofdstuk 7 de belangrijkste bevindingen van dit proefschrift 
bediscussieerd en in een breder perspectief geplaatst. Zowel de mogelijke onderliggende 
mechanismen van de bevindingen als de beperkingen van de studies worden besproken. 
Het hoofdstuk sluit af met suggesties voor toekomstig onderzoek.
Concluderend, in dit proefschrift hebben we op zowel mRNA- als eiwitniveau 
aangetoond dat een hoge expressie van EZH2 in de primaire tumor van patiënten met 
MBC geassocieerd is met een slechte respons op tamoxifen. Hetzelfde geldt voor een 
hoge expressie van CDC2 en CCNE1 en een lage expressie van miR-26a waarbij deze 
factoren betrokken zijn bij EZH2 activiteit. Het verlagen van de EZH2 expressie lijkt 
een goede therapeutische strategie doordat de gevoeligheid voor tamoxifen hiermee 
toeneemt en dit lijkt te berusten op een verhoogde expressie van ER.
De activiteit van EZH2, gemeten middels de H3K27me3 binding, blijkt eveneens 
voorspellend voor een slechtere respons op AI. Tot slot lijken CTCs goed gebruikt 
te kunnen worden om, middels moleculaire karakterisatie hiervan, patiënten te 
identificeren die goed responderen op AI therapie.
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Mogelijk is door de bevindingen van dit proefschrift een toekomstige rol voor EZH2 
en CTC-analyses weggelegd in de bepaling van het responsprofiel van een patiënt om 
hiermee tot een geïndividualiseerd, en daarmee gerichter, behandelplan te kunnen 
komen.
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D A N K WO O R D
Daar ben ik dan, aangekomen bij het dankwoord. Het meest gelezen deel van dit 
proefschrift en des te spannender is het om dit stuk te schrijven. Het is alweer even 
geleden dat mijn promotietijd begon en de afgelopen jaren is er veel gebeurd. Ik wil 
beginnen met het bedanken van een ieder die op wat voor manier dan ook een rol in 
mijn leven heeft gespeeld. Een aantal personen wil ik hieronder graag bij naam noemen.
Allereerst en in het bijzonder mijn promotoren. Prof.dr. Berns, lieve Els, mijn 
wetenschappelijke moeder. Ik zou bijna willen zeggen dat dit proefschrift er niet was 
geweest als jij niet zo volhardend in mij was blijven geloven. Op het moment dat ik het 
nauwelijks meer zag zitten, heb je me weten op te peppen om door te gaan en dat ene 
stapje meer te zetten. Het afgelopen jaar hebben we er samen hard aan gewerkt en ik 
hoop dat je net als ik trots bent op het eindresultaat. Ik bewonder je manier van leven 
en je enthousiasme voor het onderzoek en onderwijs. Ik ben blij dat ik er een vleugje 
van heb meegekregen. Geniet van je welverdiende pensioen, het leven zit vol mooie 
dingen!
Prof.dr. Sleijfer, beste Stefan, mijn interesse in de oncologie is bij jou in de polikamer 
begonnen. Vele jaren later kan ik zeggen dat dit proefschrift er zonder jou niet was 
geweest. Ik was de afgelopen jaren erg enthousiast voor andere dingen en de angst om 
je teleur te stellen werd steeds groter waardoor ik menigmaal struisvogelpolitiek heb 
bedreven. Ik ben blij dat je toch altijd deed wat je moest doen in de rol van promotor en 
hoop dat je trots bent dat het nu eindelijk af is. Ik bewonder je tomeloze energie voor 
de kliniek en het onderzoek, je reactiesnelheid op mailtjes en verzoek tot nakijkwerk, je 
scherpte hierin en je gave om van ieder paper een juweeltje te maken door zinnen nét 
iets anders te formuleren zodat het een pakkend verhaal wordt. Dank voor al je inzet 
en begeleiding!
Prof.dr. Foekens, beste John, hoewel je nu in mijn grote commissie zit vind ik dat je 
een plekje bovenaan het dankwoord verdient. Je had aanvankelijk de rol van promotor 
en hoewel we in die hoedanigheid stiekem weinig met elkaar te maken hadden, heb 
ik je input altijd erg gewaardeerd. Je bent kritisch en scherp en weet als geen ander 
zelfs de verkeerd geplaatste punten en komma's uit een stuk te halen. Daarnaast ken ik 
niemand die zó goed op de hoogte is van de literatuur; zelfs mijn referentielijsten wist 
je te corrigeren.
Prof.dr. Touw, beste Ivo, dank voor je rol als secretaris van mijn kleine commissie en het 
lezen en beoordelen van mijn proefschrift. We hebben vaak vergaderd over het reilen 
en zeilen rondom promovendi en ik kijk terug op een tijd waarin we, met een blik op de 
huidige gang van zaken tijdens een promotietraject, een hoop positieve veranderingen 
voor elkaar hebben weten te krijgen. Derhalve vind ik het des te leuker dat we nu in een 
andere hoedanigheid tegenover elkaar staan.
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Beste prof.dr. Van Kemenade en prof.dr. Linn, dank voor het plaatsnemen in de kleine 
commissie en de tijd en moeite die de beoordeling van het proefschrift van jullie heeft 
gevraagd.
Prof.dr. Van Laere, beste Steven, dank voor het naar Nederland afreizen om met mij in 
discussie te gaan over de bevindingen van dit proefschrift. Ik kijk nog steeds met veel 
plezier terug op de samenwerking en het daarbij behorende memorabele etentje in 
Antwerpen.
Beste dr. Stouthard, beste Jacqueline, ook u wil ik graag bedanken voor het plaatsnemen 
in mijn commissie. Ik zie het als een mooi begin van een samenwerking in het Antoni van 
Leeuwenhoek ziekenhuis; ik ben ervan overtuigd dat ik veel van u kan leren en kijk erg 
uit naar deze periode.
Prof.dr. Zwarthoff, dank voor uw bereidheid met mij van gedachten te wisselen over de 
inhoud van dit proefschrift.
Gedurende het onderzoek heb ik een hoop geleerd en ben ik uitstekend begeleid door 
alle medewerkers van het lab. Ik heb een erg leuke tijd gehad en wil dan ook iedereen 
hiervoor bedanken. Enkele personen in het bijzonder. Dr. M.P.H.M. Jansen, beste 
Maurice, ik heb de afgelopen jaren getraind op jouw voorletters en kan ze nu op ieder 
willekeurig moment uitspellen. Dank voor al je geduld en je goede begeleiding. Ik heb je 
harde werk altijd erg gewaardeerd. Ik vind het knap om te zien hoe je je werk met passie 
uitvoert en daarnaast een groot gezin draaiende weet te houden; dat zal, zeker gezien 
de gebeurtenissen, niet altijd makkelijk zijn.
Anieta, zonder jou waren vele CTCs niet geïsoleerd en vele samples niet door de PCR 
gegaan. Ik ken niemand die deze techniek zo goed beheerst als jij. Jouw berekeningen 
en normalisaties zijn me altijd een raadsel geweest. Jouw werkritme overigens ook ;). 
Dank voor je tomeloze inzet voor de CTC-studies!
Marcel Smid, dank voor al je analyses de afgelopen jaren! Vraag na vraag heb je altijd 
geduldig beantwoord, hoewel er vast een aantal minder intelligente tussen hebben 
gezeten. Dank ook voor je nuchtere houding, de appelrondes en de gezelligheid.
Joan, de spil van het lab. Ik heb vaak gedacht dat je niet met pensioen kan gaan en nu 
ik al 3 jaar weg ben van het lab, krijg ik die indruk nog steeds op de momenten dat ik er 
ben. Je houdt het lab in al zijn vezels draaiende, dank daarvoor!
Kirsten en Iris, de twee technici die mij de kneepjes van het vak hebben geleerd. Iris, 
de vele uren samen in de celkweek om de si-experimenten uit te voeren, ongeacht de 
dag van de week, vond ik erg leuk en leerzaam. Ik vond het jammer dat je het lab hebt 
(moeten) verlaten, maar volgens mij heb je genoeg andere werkzaamheden waarin je 
al je energie kwijt kan.
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Kirsten, de meest secure persoon die ik ken! Vele experimenten waren vast mislukt als 
jij er niet was geweest. Wat heb je een oog voor detail en wat weet je goed hoe het 
allemaal werkt! Ook jou bewonder ik voor je combinatie werk-privé; het is niet altijd 
makkelijk geweest, ik hoop dat je je draai hebt gevonden.
Jean en Wendy, zonder jullie waren er een stuk minder data! Jean, je hebt een hoop 
experimenten gedaan en ik vond het altijd mooi om te zien hoe je ze allemaal wist 
te analyseren. Wendy, jij kan vast geen gel of Western Blot meer zien. Je hebt veel 
geoptimaliseerd en uitgevoerd, daar heeft iedereen vast nog profijt van. Leuk dat je nu 
een andere weg op bent gegaan, ik weet zeker dat die je heel goed ligt!
Jozien en Corinne, dank voor het samenwerken. Jullie zaten op andere projecten, 
maar de vele werkbesprekingen over mijn projecten zijn door jullie visie zeker beter 
geworden.
John Martens, qua werk hebben we niet veel met elkaar te maken gehad, maar 
jouw aanwezigheid tijdens de CTC-besprekingen vond ik altijd erg waardevol. Jouw 
intelligentie en brede kennis zijn een kostbaar goed. Knap hoe je bent uitgegroeid tot 
een ware werkgroepleider.
Mieke Timmermans, dank voor het mede-beoordelen van de gehele TMA. Ik ben trots 
op het paper dat daaruit voortgekomen is. Maxime, dank voor al je statistische analyses.
Arzu, dank voor jouw altijd motiverende woorden tijdens onze ontmoetingen op de 
gang. Ik heb er veel aan gehad! Fijn dat je een nieuwe uitdaging hebt gevonden die je 
goed bevalt.
Dr. Kraan, beste Jaco, Sjakie! Ik kan hier moeilijk gaan zeggen dat jij mijn favoriete 
roomie was, want stiekem hadden we allebei een ander. Maar toch, wat heb ik een 
leuke tijd met je gehad! Het was niet alleen gezellig op onze kamer (althans, dat vond 
ik), maar er was zeker ook ruimte om te ventileren. Soms had ik daar enige muzikale 
ondersteuning of spanddoek-uitspatting bij nodig zoals je vast hebt gemerkt. Dank voor 
al je medewerking, vooral in de laatste fase van mijn proefschrift!
Ook wil ik alle co-auteurs bedanken voor hun bijdrage aan de artikelen waaruit dit 
proefschrift bestaat. Mijn specifieke dank gaat uit naar alle oncologen uit het Erasmus 
MC die hebben meegewerkt aan de inclusie in de CTC 09-405 studie. Tevens wil ik 
dr. Paul Hamberg uit het Sint Franciscus Gasthuis en dr. Felix de Jongh uit het Ikazia 
Ziekenhuis bedanken voor hun tomeloze inzet bij de inclusie in deze studie en het 
kritisch beoordelen van het manuscript dat uiteindelijk heeft geleid tot het 8-gen paper. 
Dank ook aan alle research verpleegkundigen uit de diverse centra. Zonder jullie inzet is 
het niet mogelijk om alle logistiek zo strak georganiseerd te krijgen.
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Niet op de minste plaats behoort hier ook mijn dank aan alle patiënten voor hun 
belangeloze bijdrage aan het wetenschappelijk onderzoek en het hierdoor van zeer 
grote betekenis zijn voor de toekomst van de oncologie met haar toekomstige patiënten.
De goede samenwerking tussen de afdeling Interne Oncologie en Pathologie (Carolien 
van Deurzen) heeft geresulteerd in een aantal mooie papers en dank ik hiervoor.
Ook de samenwerking met het Center for Oncological Research van het Sint-Augustinus 
Ziekenhuis/Universiteit van Antwerpen wil ik hartelijk danken. Prof.dr. Steven van Laere 
en prof.dr. Luc Dirix, dank voor al jullie input tijdens de inter-lab meetings. Dieter, dank 
voor al jouw werk voor de CTC 09-405 studie.
Promeras, wat een mooie tijd hebben we gehad! Martijn, Jacqueline en Anne; ik zat het 
grootste gedeelte met jullie in het bestuur en vond het niet alleen gezellig, maar ook 
erg leerzaam. Ik kijk met veel plezier terug op alle activiteiten. Alle leden van de PhD-
committee, dank voor alle leerzame momenten; ik heb mijn liefde voor bestuurlijke 
activiteiten bij jullie ontwikkeld.
 
Alle mede-promovendi door de jaren heen: Bianca, Wendy, Arjen, Nick, Marjolein, Inge, 
Lisanne en Lindsey en van de 'andere groep' Sander, Jacqueline, Anne-Joy en Annemieke. 
Bianca, dank voor al je pioneerswerk op het gebied van de CTCs. Mooi om te zien dat je 
zowel de kliniek als het onderzoek combineert alsmede werk en privé. Ik heb stiekem meer 
aan je gehad dan je weet; jouw proefschrift is voor mij een voorbeeld en drijfveer geweest! 
Nick, een vreemde eend in de bijt na Stefan's angels maar je hebt je kranig geweerd. 
Veel succes in de kliniek!
Inge, leuk dat je eerst mijn Amphia-collega was en nu mijn onderzoekscollega; dat 
belooft wat voor de toekomst!
Sander, dank voor je gezelligheid en jouw passie voor wielrennen. Die is zeker op mij 
overgeslagen nadat ik aanvankelijk noodgedwongen de Stelvio op moest toen mijn 
naam ineens op de reclameposter verscheen als onderdeel van het fietsteam zonder 
dat ik een racefiets had, laat staan er ooit op één had gezeten. Ik kijk met veel plezier 
terug op onze tijd in Bormio!
Mooi om te zien dat de AIO-groep inmiddels flink is uitgebreid; dit levert vast mooie 
resultaten op. Ik wens iedereen succes!
Wendy, dr. W., mijn favoriete roomie en partner in crime! Jammer dat de écht goede 
grappen werden uitgevoerd toen ik al in Breda zat, maar onze ondernemingen om Jaco 
te laten genieten van onze aanwezigheid (met spandoek in het zwembad, op zoek in 
Bergambacht; dit laatste heeft overigens jammerlijk gefaald) vond ik geweldig. Fijn 
dat je een luisterend oor had als ik het gevoel kreeg in de huid van Ariel te moeten 
kruipen, maar ook op serieuze momenten om onze perikelen, op welk gebied dan 
ook, te bespreken. Ik kijk met veel plezier terug op onze tijd in het JNI, in onze villa in 
Amsterdam en in onze wolkenkrabber in Chicago (mét Walmart in de kelder die na ons 
bezoek, hoewel, vooral na jouw bezoek, 30 lipgloss minder rijk was). Hopelijk creëren 
we nog meer mooie momenten in de toekomst! Dank dat je op deze bijzondere dag mijn 
paranimf wilt zijn!
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Lieve bazen uit het Amphia ziekenhuis, bedankt voor jullie begeleiding, geduld en 
kennisoverdracht. Daarnaast dank voor alle gezelligheid, onder meer tijdens de borrels 
en skiweekenden. Tevens wil ik jullie allen danken voor jullie tomeloze vertrouwen in 
een succesvolle afloop van mijn promotietraject. Ik heb me altijd erg thuis gevoeld in 
het Amphia, heb enorm veel geleerd en vind het dan ook jammer dat mijn tijd er bijna 
op zit. De sfeer in het ziekenhuis en in de maatschap heb ik altijd als bijzonder goed en 
vertrouwd ervaren. Jullie allen vormen een voorbeeld voor hoe ik het later graag zou 
willen hebben en doen. In het bijzonder wil ik enkele mensen noemen. 
Allereerst dr. Van Esser, beste Joost, wat ben ik blij met een opleider als jij! Je bent niet 
alleen een goede dokter met veel kennis van zaken, maar ook een goede opleider. Je 
creëert een prettige werksfeer voor alle assistenten. Ik hoop, mocht ik ooit opleider 
worden, dat ik op je zal lijken. Dank ook voor de prettige samenwerking in mijn eerste 
jaren om de zaken zo goed mogelijk te organiseren binnen de assistentengroep. Als 
Toos heb ik dit samen met Bep altijd met veel plezier gedaan. Ook dank voor je optreden 
als referent tijdens mijn sollicitatie!
Dr. Van Guldener, beste Coen, in mijn eerste jaar was jij nog de opleider en heb ik je 
vanaf het begin bewonderd. Jouw kennis is eindeloos en jouw onderwijsvaardigheden 
zijn briljant. Ik ben blij en voel me vereerd dat ik onder jouw supervisie in het Amphia 
ziekenhuis heb mogen werken.
Drs. Ennecker, beste Simone, dank voor je vertrouwen en stimulatie om mijn proefschrift 
af te ronden.
Lieve mede arts-assistenten uit het Amphia, dank voor jullie collegialiteit en gezelligheid! 
Ook alle collega’s van mijn stages bij de Longgeneeskunde, Cardiologie en Intensive 
Care wil ik hartelijk danken voor de begeleiding en leuke en leerzame tijd.
Jurjen, bijna dr. Versluis, labrador, lieve Bep. We zijn samen begonnen aan onze tijd 
in het Amphia ziekenhuis en vanaf het begin onafscheidelijk geweest. Hoewel we 
compleet andere personen zijn, klikte het vanaf het eerste moment. Ik bewonder je 
discipline, intelligentie en relaxte houding. Dank voor de samenwerking en je steun, 
dank voor alles!
Lieve mede-Alpha, lieve Sophie, wat ben ik blij met een collega als jij. We delen niet 
alleen onze liefde voor de oncologie, maar ook voor kleding, lekker eten, slechte 
grappen en gezelligheid. Ik vind het erg bijzonder dat je naast en achter me staat op 
deze dag. Dank voor alles! We gaan er een mooie tijd van maken in Amsterdam.
Lieve Danick, ik kijk terug op een fijne tijd in de flexkamer tijdens mijn poli- en 
consultenstage. Je verlicht de dagen met jouw eeuwige enthousiasme en energie. Ik 
ken ook niemand die zo attent is als jij! Jurjen, Sophie en Danick, hopelijk volgen er nog 
vele Alpha-dates!
Diane, wat heb ik een geluk gehad dat ik op mijn eerste dag door jou werd ingewerkt. 
Ik weet dat jij er anders over denkt, maar voor mijn gevoel is in dat hokje op afdeling 27 
(de assistentenkamer) de basis gelegd voor een mooie vriendschap. Ik vind onze band 
erg bijzonder en koester deze. Je bent een lieve vriendin!
Eva, wat ben jij een kanjer! Ik ben trots op alles wat je hebt bereikt en bewonder je 
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drive. Daarnaast geniet ik van onze oeverloze gesprekken en slechte grappen. Dank voor 
je gezelligheid maar bovenal dank voor je vriendschap!
Lieve Sophia, hoewel we niet lang collega’s zijn geweest klikte het meteen tussen ons. 
Onze koffie- en eetdates zijn momenten waar ik altijd naar uitkijk. Onze vakantie naar 
Maleisië is wat mij betreft een absoluut hoogtepunt van onze vriendschap. Op naar 
meer fijne momenten!
Lieve Carlijn, jouw aanwezigheid in mijn leven geeft het leven kleur! Ik kan met je 
lachen, huilen en carnaval met je vieren: de perfecte basis om onze vriendschap nog 
lang te laten bestaan. Je bent altijd welkom om te blijven logeren, ook als ik niet meer 
in Rotterdam woon!
Lief (ex-)hockeyteam, 22 jaar van mijn leven heb ik met jullie lief en leed gedeeld. Jullie 
waren van alles het eerst op de hoogte en samen hebben we ups en downs beleefd. Ik 
vind het fantastisch dat we elkaar, ook zonder trainingen en wedstrijden, niet uit het 
oog verloren zijn. In het bijzonder wil ik hier enkele teamgenoten/vriendinnen noemen. 
Lieve Andrea, onze vriendschap begon eigenlijk al op de middelbare school maar kwam 
pas echt van de grond toen we bij elkaar in het team kwamen. We hebben er inmiddels 
vele mooie avonden en wintersportvakanties op zitten en ik weet zeker dat we dit gaan 
voortzetten. Ik ben blij dat je je liefdesgeluk hebt hervonden!
Lieve Charlène, ik word altijd blij van jou! Je bent lief, grappig en behulpzaam. Ik 
moet altijd lachen als ik terugdenk aan de, soms wat knullige, dingen die we hebben 
meegemaakt. Dank voor alle ritjes Rotterdam-Capelle waarin we elkaar op de hoogte 
stelden van het wel en wee in onze levens. Ik vind het erg bijzonder dat ook jouw 
moeder een belangrijke rol mag spelen op deze memorabele dag.
Lieve Bianca, je bent sterk in alles wat je doet en beleeft. Hoewel niet altijd alles even 
makkelijk gaat, weet je er voor een ander te zijn en ook je eigen dromen na te leven. 
Bijzonder! Geniet van het leven!
Lieve Wendelijn, ik moet altijd lachen met (en ja, ook om) jou! In jou heb ik iemand 
gevonden die nóg meer praat dan ik. Dank voor alle fijne momenten rondom de hockey, 
tijdens de wintersport en alle dagen en avonden dat we afspreken. Laat er nog vele 
volgen!
Lieve Marieke, ik bewonder je nuchtere houding en discipline in het leven. Je hebt het al 
ver geschopt, ik ben trots op je! Je komt uit een warm gezin waar ik ook altijd graag kom; 
dank aan jouw ouders voor hun eeuwige interesse in mijn leven en werkzaamheden. 
Victor, ook jij verdient hier een plekje. Hoewel je altijd wat afstandelijk overkomt, merk 
ik jouw bezorgdheid en de daaruit voortvloeiende zorgzaamheid en waardeer ik deze.
Lieve Nathalie, dank voor alle momenten dat ik weer eens dreigde te laat te komen voor 
een training en jij nooit te beroerd was om door de drukte van de stad mij op te halen. 
Dank ook voor alle lekkernijen; ik blijf erbij, je zou er iets mee moeten doen!
Lieve Hilde, wat een bewonderingswaardig doorzettingsvermogen heb je! Leuk dat je je 
levensgeluk hebt gevonden; hopelijk gaat je gezondheid ook meewerken.
Lieve Chantal, hoewel je nooit bij mij in het team hebt gezeten, behoor je hier wel toe. 
Als mijn nicht ervaar ik een speciale band met jou en koester ik deze. Fijn dat we elkaar, 
zonder elkaar vaak te zien, op deze manier kennen!
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Lieve Harvard homies, hoewel Boston inmiddels al ver achter ons ligt, werd hier de basis 
gelegd voor een vriendschap waarin het niet nodig is om elkaar vaak te zien, maar op 
de momenten dat het gebeurt, dit altijd een feest is. Lieve Denise, wat heb ik enorm 
veel respect voor jou! Jouw manier van leven waarin je niet bang bent om je kwetsbaar 
op te stellen, hard te werken, mooie reizen te maken en ultiem te genieten van het 
leven, vind ik mooi. Ik heb vertrouwen in jouw toekomst! Lot, onvoorstelbaar hoe jij je 
opleiding, promotie, verhuizing, trouwen, en het moederschap allemaal combineert of 
in elkaar laat overvloeien. De bezoekjes aan jou en Stijn voelen voor mij altijd als een 
kleine vakantie. Succes met de laatste loodjes van jouw proefschrift!
Lieve Kalynda, Gytha en Vicky, onze ontmoeting in Suriname was er één uit duizenden. 
Inmiddels 5 jaar geleden maar we zijn elkaar nadien nooit uit het oog verloren. Kalynda, 
dank dat je nooit schroomde om langs Rotterdam te rijden voor een etentje of borrel. In 
de toekomst kom ik vaker jouw kant op. Succes met al jouw plannen!
Gytha, jij weet hoe je van het leven moet genieten! Blijf dit doen; ik geniet graag mee. 
Leuk dat we binnenkort eindelijk bij elkaar in de buurt wonen,  ik kijk er naar uit!
Vicky, hoewel we elkaar niet vaak zien, voelt onze vriendschap altijd vertrouwd. Dank 
daarvoor! Succes met alles, je komt er wel!
Lieve Eefje, onze vriendschap gaat al zo ver terug. Als Knabbel en Babbel hebben we de 
basisschool doorlopen en volgens mij voldoen we nog steeds aan die beschrijving. We 
zien elkaar niet vaak maar weten beiden dat dit niet nodig is. Fijn dat je (nog steeds) in 
mijn leven bent!
Dan mijn lieve Primaatjes! Zonder jullie in mijn leven was het niet zo leuk geweest! 
Iedereen is anders, iedereen betekent veel voor me en als groep zijn we ijzersterk. Dank 
jullie wel voor onze bijzondere vriendschap! Ik geniet van al onze momenten samen: 
etentjes, thee en/of wijn en/of gin tonics drinken, alle verjaardagen en alle mooie 
momenten tijdens onze tripjes; van vakanties naar de meest foute oorden tot kamperen 
in de Schaapskooi, Ermelo of onze verblijven in een luxe villa op Curaçao of Ibiza. 
Lieve Marcella, we go way back. Inmiddels kennen we elkaar 18 jaar en is het allemaal 
begonnen op brugklaskamp. Met een soort seintaal hebben we elkaar leren kennen 
en zijn we nooit meer uit elkaar gegaan. Je hebt een hoop hindernissen genomen en ik 
vind het knap om te zien hoe je je leven inmiddels hebt georganiseerd. Succes met je 
nieuwe opleiding! 
Lieve Lianne, we go even more back! Geen idee hoe lang we elkaar precies 
kennen, maar de knutselclub was onze basis. Inmiddels knutselen we wat minder, 
maar dat mag de pret niet drukken. Wat hebben wij mooie en bizarre dingen 
beleefd! Op naar nog veel meer! Ik ben trots op jou als persoon; je doorstaat 
alle tegenslagen als geen ander en bent ondertussen huisarts geworden. 
Lieve Irene, ook wij zijn van origine van de knutselclub. Jouw nuchterheid en 
stabiliteit waardeer ik zeer en ik vind het fijn om te merken dat het niet uitmaakt 
waar we wonen of hoe vaak we elkaar zien, de basis is daar. Ik ben trots op je! 
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Lieve Kelly, dank je wel voor je vriendschap voor al zo'n lange tijd. Ik 
bewonder je relaxte houding in het leven en je inzet bij alles wat je doet. Je 
was de eerste van ons die écht carrière maakte en je doet het fantastisch! 
Lieve Nadine, de absolute sfeermaker van de groep. Met jouw aanstekelijke lach en je 
hilarische verhalen weet je me altijd vrolijk te maken (of te houden). Ik bewonder hoe je 
je levenspad bewandelt en waardeer je creatieve geest.
Lieve Samantha, jouw cynische kijk op vele dingen in het leven doet me altijd realiseren 
waar het écht om gaat in het leven. Dank voor je luisterend oor op de 
momenten dat ik het nodig heb. Ik ben trots op de stappen die je hebt gezet en 
nog gaat zetten; geniet van het leven!
Lieve Anne, als mede-promovendus heb ik je discipline altijd bewonderd (en benijd). 
Hetzelfde doe ik nu je in opleiding bent tot neurochirurg. Ik weet zeker dat jouw 
promotie er ook gaat komen! 
Lieve familie Brugman, dank voor jullie interesse in mijn leven en werkzaamheden. Dank 
ook voor alle leuke momenten samen, ik hoop dat er nog vele mogen volgen.
Lieve familie Reijm, het is fijn om uit zo’n grote familie te komen! Dank voor jullie 
interesse en gezelligheid. Zonder jullie aanwezigheid zijn de feestjes niet compleet. 
Mooi om te zien hoe de generaties zich uitbreiden met aan het hoofd oma Reijm. Oma, 
ik hoop dat u nog vele jaren de spil van de familie mag vormen!
Lieve familie van Roland, dank dat jullie mij zo snel hebben opgenomen in jullie gezin. 
Dank voor jullie interesse, waardering en warmte.
Lieve Rogier, dank voor het zijn van mijn grote broer. Je bent er altijd voor me en ik vind 
het fijn dat ik altijd bij je aan kan kloppen. Lieve Elena, dank voor het levensgeluk van 
mijn broer. Jouw zorgzaamheid is buitengewoon en ik bewonder hoe je het gezin met 
Fjodor en Jeanne draaiende houdt.
Lieve Agnes, jij bent mijn grote zus. Hoewel je dit misschien niet altijd zo voelt, is het 
toch echt zo. Ik ben trots op de stappen die je hebt gezet in je carrière en privé. Lieve 
Dennis, fijn om jou in de familie te hebben! Jij bent de rust zelve en ik waardeer je 
humor. Als trotse tante van Fenne kijk ik uit naar frequentere bezoeken in de toekomst.
Lieve pap en mam, dit boekje draag ik aan jullie op. Het is voor mij het symbool dat 
ik van jullie heb geleerd af te maken waar ik aan ben begonnen. Dank voor jullie 
onvoorwaardelijke steun en liefde. Dank ook voor jullie luisterend oor, oplossingen en 
geregel wanneer ik dit nodig heb. Jullie staan altijd voor me klaar. Kortom, dank jullie 
wel voor alles wat jullie me hebben (mee)gegeven.
Lieve Roland, ik kan niet beschrijven hoeveel je voor me betekent. Dank voor wie je 
bent, mijn liefde voor jou is intens. Jij bent mijn kompas, zowel op reis als in het leven. 
Jouw energie slaat op mij over en samen kunnen we de hele wereld aan. Je haalt het 
beste in mij naar boven, helpt me relativeren en te genieten van het leven. Dank voor je 
kracht, je steun en je liefde. Ik kijk uit naar onze toekomst samen, ik houd van je!
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- Workshop Tutoring; how to handle a group  2012  0.2
Research skills
- Basic course regulations and organization for   2012   1.5
 Clinical Researchers (Basiscursus Regelgeving en
 Organisatie Voor Klinisch onderzoekers [BROK[)
In-depth courses
- SNPs and Human Diseases    2008  2.0
- Basic and Translational Oncology   2008  1.8
- Molecular Medicine    2012  1.9
- Molecular Diagnostics VII    2012  1.0
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- Poster presentation at the Annual San Antonio Breast 2009, 2012 0.6
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- Annual Cancer Genomics Centre Scientific Meeting 2012  0.3
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- Lectures in medicine (second-year Keuze-onderwijs) 2013  0.2
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